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1. EQUINE HERPESVIRUS 1 (EHV1): general characteristics 
 
1.1 History 
 
Equine herpesvirus 1 (EHV1) was first described in the early 1930s after a 
necropsy examination of an aborted fetus (Dimock & Edwards, 1933), but virus 
isolation from such cases succeeded only decades later (Jackson & Kendrick, 1971; 
Saxegaard, 1966). The first recorded observation to indicate that major antigenic 
differences may exist among clinical isolates of EHV1, was made in 1959 (Shimizu et 
al., 1959). Thirteen years elapsed before a high correlation between antigenic subtype 
and anatomic origin of the virus isolates was described (Burrows & Goodridge, 1972). 
Until 1981, EHV1 and EHV4 were considered as two subtypes of the same virus, 
namely ‘EHV1’, causing febrile rhinopneumonitis, ataxia, abortions and neonatal foal 
disease in horses (Allen & Bryans, 1986). Unambiguous differentiation into EHV1 
and EHV4 came from viral genomic fingerprints or so-called restriction length 
polymorphisms (RLFP), but official recognition of the distinction between those two 
viruses came almost one decade later (Roizman et al., 1992; Sabine et al., 1981; 
Studdert et al., 1981; Turtinen et al., 1981). 
 
1.2 General characteristics 
 
1.2.1 Classification 
 
The revised family Herpesviridae retains the viruses of mammals, birds and 
reptiles. Members are highly disseminated in nature, with isolations from most animal 
species of at least one and frequently several diverse herpesviruses (Davison et al., 
2009; Roizman & Pellett, 2001). Assignment to the Herpesviridae family is made by 
the criterion of the characteristic herpes virion architecture. The known herpesviruses 
appear to share four significant biological properties: (1) although the exact array of 
enzymes may vary from one herpesvirus to another, all herpesviruses specify a large 
array of enzymes involved in nucleic acid metabolism, DNA synthesis and processing 
of proteins, (2) synthesis of viral DNA and capsid assembly occurs in the nucleus, (3) 
production of infectious progeny virus is always accompanied by the destruction of 
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the infected cell and (4) herpesviruses are able to remain latent in their natural hosts 
(Roizman & Pellett, 2001).  
Herpesviruses differ with respect to their biologic properties and are classified into 
three different subfamilies based on host range, length of the reproduction cycle, 
spread in cell culture, destruction of infected cells and capacity to establish latent 
infections primarily but not exclusively in sensory ganglia (Roizman & Pellett, 2001): 
(i) members of the Alphaherpesvirinae show a variable host range, short reproduction 
cycle, rapid spread in cell culture, efficient destruction of infected cells and capacity 
to establish latent infections primarily, but not exclusively, in sensory ganglia; (ii) a 
restrictive host range is rather characteristic for the members of the subfamily 
Betaherpesvirinae. They have a long reproduction cycle, with a slow infection 
progress in cell culture. Cytomegalia is frequently seen in infected cells and latency 
can be found in secretory glands, lymphoreticular cells, kidneys and other tissues. (iii) 
Finally, host range of the members of the Gammaherpesvirinae is limited to the 
family or order to which the natural host belongs. Replication is followed by a lytic 
infection and latency is frequently demonstrated in lymphoid tissue. 
Equid herpesvirus 1 (EHV1) or equine abortion virus is a member of the order 
Herpesvirales, Family Herpesviridae, subfamily Alphaherpesvirinae, genus 
Varicellovirus (Davison et al., 2009). 
  
1.2.2 Herpesviruses in equids 
 
In equids, fourteen herpesviruses have been identified so far: six belong to the 
subfamily Alphaherpesvirinae and eight to the Gammaherpesvirinae (Table 1). The 
horse is the natural host to alphaherpesvirus types 1 (EHV1), 3 (EHV3, coital 
exanthema virus), 4 (EHV4) and gammaherpesvirus types 2 (EHV2) and 5 (EHV5). 
The donkey is the host of EHV1-homologue asinine herpesvirus type 3 (AHV3), 
EHV3-homologue asinine herpesvirus type 1 (AHV1) and asinine gammaherpesvirus 
type 2 (EHV2) (Browning et al., 1988; Crabb & Studdert, 1990; 1995; Ficorilli et al., 
1995). In 2002, two new herpesviruses (AHV4 and AHV5) were isolated from the 
lungs of donkeys suffering from respiratory disease (Kleiboeker et al., 2002). The 
isolation of a new EHV1-related neurotropic virus from a gazelle (Gazelle 
herpesvirus- 1, EHV9) and an unknown herpesvirus from a donkey with neurological 
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disease, indicates that the list of presently known equid herpesviruses is likely to grow 
(Fukushi et al., 1997; Hartley et al., 1999; Vengust et al., 2008). 
 
       Table 1. Known herpesviruses of equids 
 
Virus 
 
Abbreviation Subfamily Host Clinical signs 
Equine herpesvirus 
1 
 
EHV1 α horse respiratory disease, abortion, neonatal 
foal death, neurological disorders 
Equine herpesvirus 
2 
 
EHV2 γ horse rhinitis, conjunctivitis, 
immunodepression 
Equine herpesvirus 
3 
 
EHV3 α horse coital exanthema 
Equine herpesvirus 
4 
 
EHV4 α horse respiratory disorders, (abortion) 
Equine herpesvirus 
5 
 
EHV5 γ horse respiratory tract disease, multinodular 
pulmonary fibrosis 
Asinine herpesvirus 
1 
 
AHV1 
(EHV6) 
α donkey lesions on external genitalia and udder 
Asinine herpesvirus 
2 
 
AHV2  
(EHV7) 
γ donkey ? 
Asinine herpesvirus 
3 
 
AHV3 
(EHV8) 
α donkey rhinitis? 
Asinine herpesvirus 
4 
 
AHV4 γ donkey pneumonia 
Asinine herpesvirus  
5 
 
AHV5 γ donkey pneumonia 
? 
 
 
? γ donkey neurological disease 
Zebra herpesvirus 1 
 
 
ZHV1 γ Zebra ? 
Wild ass 
herpesvirus 
 
WAHV γ wild 
ass 
? 
Gazelle herpesvirus  
9 
 
EHV9 α gazelle encephalitis 
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Of all equid herpesviruses, EHV1 and EHV4 are clinically, economically and 
epidemiologically the most relevant pathogens. EHV1 infections can result in 
respiratory disease, abortion, fatal neonatal illness and neurologic syndromes (Allen 
& Bryans, 1986). In contrast to EHV1 infections, EHV4 infection is mostly limited to 
signs of upper respiratory tract disease, while abortion and nervous system disorders 
are extremely rare (Ostlund, 1993). EHV2 is suggested to be ubiquitous in the equine 
population. EHV2 has been implicated in upper respiratory disease, pyrexia, 
inappetance, lymphoadenopathy, immuno-suppression, general malaise and poor 
performance, and a high prevalence of the virus could be found in horses with upper 
respiratory tract disease, abortion and severe ataxia. However, a correlation between 
clinical signs and EHV2 as a causative agent could not be determined (Borchers et al., 
1997; Borchers et al., 1998; Kershaw et al., 2001; Schlocker et al., 1995). EHV3 
causes an acute and self-limiting venereal disease characterized by the formation of 
papules, vesicles, ulcers, and pustules on genital mucosa and skin (Blanchard et al., 
1992; Pascoe et al., 1968). Little is known about the distribution and natural genesis 
of EHV5. A relationship with respiratory tract disease is suspected and two recent 
reports suggest an association between the development of equine multinodular 
pulmonary fibrosis and EHV5 infection (Verryken et al., 2010; Williams et al., 2007; 
Wong et al., 2008). 
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2. EQUINE HERPESVIRUS 1 and the cell 
 
2.1 Virus structure 
 
Morphologically, herpesviruses are distinct from all other viruses. They contain a 
linear double-stranded DNA genome of 125-290 kbp in the form of a torus (Furlong 
et al., 1972). The DNA is contained within a icosadeltahedral capsid, which is 
surrounded by a proteinaceous matrix, designated the tegument. The latter is 
surrounded by a lipid envelope, containing membrane-associated proteins (Davison et 
al., 2009; Roizman & Knipe, 2001; Roizman & Pellett, 2001) (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Electronmicroscopic photomicrograph (left) and schematic drawing (right) of an EHV1 
virion (picture from University of Wisconsin) 
 
Up till now, 12 different glycoproteins have been described for EHV1: gB, gC, 
gD, gE, gG, gH, gI, gK, gL, gM, gN and gp2 (Turtinen & Allen, 1982). These 
envelope proteins are involved in virus attachment, penetration, egress and cell-to-cell 
spread. 
Glycoprotein B is an essential glycoprotein of EHV1. Functional analysis of gB 
revealed that this glycoprotein is clearly involved in the penetration process. In 
common with gB homologues of herpes simplex virus and other herpesviruses, gB 
also plays a role in the cell-cell fusion process (Wellington et al., 1996b). However, 
gB-negative EHV1 retained some infectivity and the absolute requirement of gB for 
Envelope glycoproteins  
gB, gC, gD, gE, gG, gH, 
 gI, gK, gL, gM,  
gN and gp2  
Envelope 
Tegument 
Capsid 
Double  
stranded DNA 
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fusion process in EHV1 is not entirely clear (Neubauer et al., 1997). Glycoprotein D 
is the second essential protein of EHV1. Monoclonal antibodies against gD strongly 
neutralize virus infectivity and inhibit the penetration of the virus into the cell, 
suggesting an important and essential function of gD in viral cell penetration (Csellner 
et al., 2000; Van de Walle et al., 2008a; Whittaker et al., 1992). Glycoprotein D is 
also associated with spontaneous cell-cell fusion, which is consistent with a role in 
virus spread and is one of the functions attributed to gD homologues in 
alphaherpesviruses (Csellner et al., 2000; Wellington et al., 1996a). 
Glycoprotein C was shown to play an important role in the early steps of infection 
and in release of virions (Osterrieder, 1999). It also acts as a complement receptor on 
EHV1-infected cells, capable of binding the third component of complement (C3) 
(Huemer et al., 1995). Glycoprotein G is a viral chemokine-binding protein, capable 
of binding a broad range of chemokines, including CCL3 and IL8, thus modulating 
pulmonary inflammation and virus replication during an EHV1 infection (Bryant et 
al., 2003; Van de Walle et al., 2007; Van de Walle et al., 2008b). 
EHV1 glycoprotein M is involved in both virus entry and direct cell-to-cell spread 
of virus (Osterrieder et al., 1996). Processing of gM inside the infected cell depends 
on the expression of gN (Rudolph et al., 2002). Studies with an EHV1 recombinant 
virus containing deletions of glycoprotein E and I showed that these glycoproteins 
facilitate cell-to-cell spread and may be important factors in EHV1 virulence 
(Matsumura et al., 1998). Glycoprotein K is also critically involved in direct cell-to-
cell spread, as well as in secondary envelopment and/or egress. It facilitates virus 
penetration and is at least partially responsible for syncytium formation at later time 
points post infection (Neubauer & Osterrieder, 2004). 
Although the presence of gH and gL has been demonstrated in infected cells, their 
functions in the replication cycle of EHV1 remain unclear (Robertson et al., 1991; 
Stokes et al., 1996). 
Last, gp2 is a unique glycoprotein that has no positional or structural counterpart 
in herpesviruses of other species. Although its function is not fully known, it was 
shown to function in virus attachment (Sun et al., 1996) and in vivo, gp2 is proposed 
to function as an immuno-modulatory protein (Smith et al., 2005). The simultaneous 
absence of gM and gp2 had an additive negative effect on egress but not on secondary 
envelopment or cell-to-cell spread (Rudolph & Osterrieder, 2002). 
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2.2 Replication cycle 
 
The replication cycle of EHV1 is divided into several steps. A schematic 
representation of the various steps is shown in Figure 2. 
EHV1 attachment to cells is mediated via an interaction between glycoproteins 
gB, gC and cellular heparan sulphate (Osterrieder, 1999). After attachment, an 
interaction between gD and a putative entry receptor is required to complete the 
fusion between the viral envelope and the cellular membrane (Csellner et al., 2000; 
Frampton et al., 2005). Recently, it has been shown that Major Histocompatibility 
Complex Class I acts as a functional entry receptor for this glycoprotein (Kurtz et al., 
2010; Sasaki et al., 2011). EHV1 can enter cells via fusion at the plasma membrane in 
equine endothelial cells or by endocytosis/phagocytosis in peripheral blood 
mononuclear cells (Van de Walle et al., 2008a). Successful infection through either 
mechanism requires the activation of Rho-associated coiled-coil kinase 1 (ROCK1) 
(Frampton et al., 2007). Recently, it has been shown that EHV1 entry via endocytosis 
is triggered by the interaction between cellular integrins and the RSD motif present in 
gD (Van de Walle et al., 2008a). Subsequent to fusion between the two lipid 
membranes, the nucleocapsid is released into the cytoplasm of the infected cell, where 
it is transported along microtubules to the nuclear pore of the cell. Transport is both 
dependent on the integrity of the microtubule network and the minus-end microtubule 
motor protein, dynein. Integrity is in part promoted by EHV1, as it actively induces 
the acetylation of tubulin, a marker of microtubule stabilization. Also the cellular 
kinase ROCK1 has an important role in virus trafficking to the nucleus (Frampton et 
al., 2010). At the pore, the nucleocapsid releases its DNA into the nucleus, leaving an 
empty capsid at the cytoplasmic side of the complex (Roizman & Pellett, 2001). 
Transcription of the viral genome, replication of viral DNA and assembly of new 
capsids take place in the nucleus, but all viral proteins are synthesized in the 
cytoplasm. Viral DNA is transcribed throughout productive infection by host RNA 
polymerase II, but with the participation of viral factors at all stages of infection. 
EHV1 transcription is co-ordinately regulated into immediate-early (IE), early (E) and 
late (L) phases in a cascade fashion (Caughman et al., 1985). Several of the gene 
products are enzymes and DNA-binding proteins involved in viral DNA replication. 
First, the immediate early gene, IR1, is expressed (Gray et al., 1987a; Gray et al., 
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1987b). This IE gene region is transcribed into a single mRNA, but multiple species 
of the IE protein exist (Robertson et al., 1988). The major IE polypeptide (IE1) 
functions as a regulatory protein that is capable of modulating gene expression from 
both early and late promotors and also of trans-repressing its own promoter 
(Caughman et al., 1985; Gray et al., 1987a). Early genes are expressed before DNA 
replication and encode proteins required for DNA replication, e.g. DNA polymerase 
and other enzymes such as thymidine kinase. These viral proteins promote viral DNA 
replication, and in a late phase, expression of late genes is stimulated. The late genes 
are expressed after viral DNA replication has started and their expression is enhanced 
by other viral proteins. Late genes mostly encode viral structural components like 
capsid proteins and envelope glycoproteins. 
Like transcription, viral DNA replication takes place in the nucleus, resulting in 
multiple copies of the EHV1 genome. These newly synthesized DNA copies have to 
assemble with capsid proteins to form nucleocapsids. Upon translation and expression 
in the cytoplasm, capsid proteins enter the nucleus, after which assembly and 
incorporation of viral DNA molecules occur, a process called encapsidation. 
Assembly occurs in several stages. DNA is packaged into preassembled capsids, after 
which the virus matures and nucleocapsids bud at the inner leaflet of the nuclear 
membrane, resulting in enveloped particles in the perinuclear space. Egress from the 
perinuclear cisterna primarily occurs by fusion of the primary envelope with the outer 
leaflet of the nuclear membrane, resulting in intracytoplasmic naked nucleocapsids 
(Granzow et al., 2001; Mettenleiter, 2004; Mettenleiter et al., 2006). Inside the 
cytoplasm, the majority of the tegument is added to the nucleocapsids (Mettenleiter, 
2002; Mettenleiter et al., 2009). Unlike capsid proteins, viral envelope proteins are 
co-translationally transported into the endoplasmatic reticulum (ER) and subsequently 
incorporated into various cellular membranes while passing through the secretory 
pathway (Granzow et al., 2001). The intracytoplasmic naked nucleocapsids are 
enveloped at membranes of the trans-Golgi network (TGN) (Granzow et al., 2001). 
The enveloped particles are then released through secretory vesicles. Little is known 
about viral proteins involved in egress, i.e. transport of vesicles containing enveloped 
virions to the plasma membrane and subsequent virus release by fusion of vesicle and 
plasma membrane (Mettenleiter et al., 2009).   
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Figure 2. The EHV1 replication cycle (adapted from Garré, 2008). The first step in the replication of EHV1 
is the attachment of free virions to the surface of the target cell (1). After endocytosis (2a) and/or fusion of 
the viral envelope with the plasma membrane (2b), the nucleocapsid is released into the cytoplasm (3) and 
transported into the nucleus (4). DNA replication (5) and transcription (6) occur and RNA molecules are 
transported to the cytoplasm and translated to proteins (7, 9). Capsid proteins are redirected into the nucleus 
where encapsidation occurs (8). Viral envelope proteins are co-translationally transported into the 
endoplasmatic reticulum (10) and subsequently incorporated into various cellular membranes, while passing 
through the secretory pathway. The nucleocapsid leaves the nucleus via budding through the inner leaflet of 
the nuclear membrane (11) and subsequent fusion with the outer leaflet of the nuclear membrane, resulting 
in entry of naked nucleocapsids in the cytoplasm (12). The nucleocapsid acquires its secondary envelope at 
the Golgi apparatus (13) and then leaves the cell via vesicle-mediated exocytosis (14, 15, 16) 
 
 
 
 
 
2a
2b
3
4
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3. EQUINE HERPESVIRUS 1 and the horse 
 
3.1 Epidemiology and prevalence 
 
A schematic overview of the epidemiology of EHV1 is depicted in Figure 3 
 
Equine herpesvirus 1 infections are endemic in horse populations worldwide, and 
most animals are probably infected during the first year of life (Allen & Bryans, 1986; 
Allen et al., 1999; Borchers et al., 2006). However, due to antigenic similarity 
between EHV1 and EHV4, the interpretation of data from serological surveys was 
complicated by the lack of a type-specific antibody test until early 1990 (Crabb & 
Studdert, 1993). It should also be indicated that sero-epidemiological studies are 
complicated in horse populations in which EHV1 and/or EHV4 vaccination is 
practised. Retrospective testing of sera from Thoroughbred horses collected between 
1967-1974 and 1993 gave values of 9-28% for EHV1-specific antibodies (Crabb & 
Studdert, 1995). Another study found an incidence of EHV1 antibodies in mares and 
foals of 26,2% and 11,4% respectively (Gilkerson et al., 1999).   
Latency by alphaherpesviruses is an important epidemiological strategy ensuring 
survival and spread within the natural host population. When horses are first infected, 
latency is established in the lymph nodes of the respiratory tract, the trigeminal 
ganglion and CD5+/CD8+ leukocytes (Baxi et al., 1995; Chesters et al., 1997; 
Edington et al., 1994; Slater et al., 1994). Months or years after primary infection, the 
latent virus may again become manifest with renewed replication and with the 
potential for initiating new outbreaks of disease in its host as well as in susceptible 
cohorts. As EHV1 infection already occurs in the first weeks or months of life, it is 
assumed that viral reactivation in latently infected mares leads to this early foal 
infection (Gilkerson et al., 1999; Marenzoni et al., 2008). Therefore, lactating mares 
may be the primary source of EHV1 infection of foals and the latter may further 
transmit the virus to other mares and foals (Gilkerson et al., 1997). However, a recent 
study could not demonstrate infection of sentinel horses with EHV1 after direct 
contact with horses undergoing experimental corticosteroid-induced recrudescence of 
latent infection (Pusterla et al., 2010). Failure to effectively transmit EHV1 to 
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susceptible horses may have resulted from the low level and short period of viral 
shedding in these latently infected horses. 
Estimates of the prevalence of EHV1 infection based on viral detection 
technologies vary strongly. Latent EHV1 could be found by polymerase chain 
reaction (PCR) in 87.5% of examined bronchial lymph nodes and a similar level in the 
trigeminal ganglia of 40 horses examined at slaughter (Edington et al., 1994). In pools 
of tissue with peripheral blood leukocytes, nasal swabs and abattoir specimens from 
116 animals, EHV1 DNA was found in 88% of the analysed samples in Brazil 
(Carvalho et al., 2000). In a recent study, the prevalence of latent EHV1 in 
submandibular lymph nodes was 54% (Allen et al., 2008). Current estimates of the 
prevalence of latent EHV1 suggest a rate in excess of 60%, which is probably more 
limited by detection technology than by the actual infection rate. We should presume 
that the majority of horses is latently infected with EHV1 (Lunn et al., 2009). The 
establishment of latency provides a permanent reservoir for the virus and makes total 
disease eradication highly unlikely. It also diminishes the effectiveness of  antiviral 
therapy or immunotherapy and complicates vaccination protocols for control of EHV1 
infections (Allen & Bryans, 1986). 
It is thought that subclinical EHV1 infections are common in horses and play an 
important role in EHV1 epidemiology, as they result in frequent spread and a high 
risk of exposure particularly in open horse populations subjected to stress and 
introduction of new animals. However, recent reports in both horses exposed to stress 
and healthy horses demonstrated that subclinical shedding of EHV1 is infrequent and 
at a very low level (Brown et al., 2007; Wang et al., 2007). These observations 
suggest that spread of EHV1 among adult horses is typically accompanied by clinical 
disease, either respiratory disorders, abortion or equine herpes myelitis (EHM) (Lunn 
et al., 2009). 
Either after recrudescence from latency or after exogenous introduction, EHV1 
infections can spread rapidly within groups of horses. Evidence of widespread 
horizontal infection by direct or indirect contact has been reported repeatedly for 
outbreaks of EHV1 induced abortion and neurological disease (Drummer et al., 1995; 
Friday et al., 2000; McCartan et al., 1995). Aerosol transmission cannot be excluded 
and putatively depends on the amount of infectious virus released by the source, 
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climatic conditions, dilution of the aerosolized virus, and distance between horses 
(van Maanen, 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
          
 
Figure 3. Epidemiology of EHV1 infection in the horse population 
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3.2 Pathogenesis and disease 
 
3.2.1 Pathogenesis  
 
A schematic overview of the complete pathogenesis is depicted in Figure 4. 
  
Primary replication. Horses acquire an EHV1-infection through direct contact or 
inhalation of infectious secretions (Allen & Bryans, 1986). After inhalation, EHV1 
binds to and penetrates the epithelial cells of the upper and lower respiratory tract 
(Kydd et al., 1994b; Patel et al., 1982). Following a rapid replication, EHV1 
disseminates into the connective tissue, infecting local blood vessels and regional 
lymph nodes (Kydd et al., 1994b; van Maanen, 2002). How the virus penetrates the 
basement membrane and reaches the underlying connective tissue and lymphoid 
tissue remains unsolved to date. 
 
Viremia. Via a still unknown pathway, EHV1 infects mononuclear cells which 
can enter the blood circulation resulting in a cell-associated viremia lasting for 8 to 18 
days post infection (Edington et al., 1986; Gibson et al., 1992; Gleeson & Coggins, 
1980; Patel et al., 1982). The exact identity of these carrier cells still remains 
uncertain. A study from 1983 showed that T-lymphocytes, B-lymphocytes and 
monocytes are all able to harbour EHV1, but the predominant mononuclear cells 
harbouring virus were found to be T-lymphocytes (Scott et al., 1983). Remarkably, 
after disruption of these cells, no infectious EHV1 could be found during virus 
isolation, suggesting that EHV1 exists in mononuclear cells in a non-infective form, 
or is blocked at a certain replication level until activation occurs (Gleeson & Coggins, 
1980; Scott et al., 1983; van der Meulen et al., 2006). A later study confirmed the 
latter hypothesis. The majority of infected PBMC do not show viral envelope proteins 
on their surface during viremia (van der Meulen et al., 2003b). During a recent study 
using PBMC isolated from experimentally infected horses, viral genomic DNA was 
found by means of PCR techniques in all PBMC subpopulations, with CD8+ 
lymphocytes and B-lymphocytes as most frequently infected cells (Wilsterman et al., 
2010). These results indicate that different PBMC subpopulations may play different 
roles in EHV1 viremia. 
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Secondary replication. Transfer of EHV1 from viremic cells to endothelial cells 
of target organs causes infection, followed by replication of EHV1 and subsequent 
damage to these organs. Smith et al. showed that activation of adhesion molecules in 
endothelial cells of the nasal mucosa and the reproductive tract is a key step in 
transferring virus from infected leukocytes to endothelial cells. Indeed, an in vitro 
flow system using equine veins and arteries showed that EHV1 was only transferred 
to endothelial cells if both leukocytes and endothelial cells expressed these surface 
molecules (Smith et al., 2002; Smith et al., 2001). An infection model with EHV1-
infected leukocytes on the one hand and carotid artery and brain endothelial cells on 
the other hand has recently been established (Goehring et al., 2010a). In this model, 
neutralizing antibodies could only prevent infection of endothelial cells when an 
indirect contact model was used. In the case of a direct contact model between the two 
cell types, neutralizing antibodies could not prevent transfer of virus to endothelial 
cells. This further confirms the importance of the direct transfer mechanism of EHV1 
from infected leukocytes to endothelial cells. 
Transfer of EHV1 from infected leukocytes to placental maternal endothelial cells 
plays a major role in the pathogenesis of abortion. Infection of endothelial cells in the 
umbilical cord seems to be the primary route of dissemination of virus in the fetus. 
These infected cells may then act as centres for the development of focal lesions of 
parenchymal necrosis. Further spread of the virus with widespread vasculitis, 
thrombosis, cotyledonary infections and ischemic damage to the endometrium with 
replication of EHV1 in foetal tissues leads to subsequent abortion (Edington et al., 
1991). 
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Figure 4. Schematic overview of the pathogenesis of EHV1. 1) Attachment/penetration and replication 
of virus in epithelial surfaces of the upper respiratory tract; 2) spread of virus through the basement 
membrane; 3) spread to connective tissue (3a) and draining lymph nodes (3b); 4) infection of 
leukocytes; 5) leukocyte associated viremia; 6) transfer of virus from infected leukocytes to endothelial 
cells of target organs; 7) replication and spread of virus in target organs. Full arrow: known 
mechanism; striped arrow: unknown mechanism. 
 
Secondary replication of EHV1 in the nervous system of horses causes EHM. 
Different independent researchers agreed that lesions accompanying central nervous 
system disorders were characterized by a focal vasculitis with associated oedema, 
haemorrhage and thrombosis. Axonal and myelin degeneration occurred focally and 
secondary to these vascular changes (Jackson et al., 1977; Mumford & Edington, 
1980; Platt et al., 1980). As actual isolation of EHV1 from the nervous system is very 
rare, it was postulated that lesions could be induced by circulation immune 
complexes. However, in 1986, Edington et al. showed that although recovery of virus 
1
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from the central nervous system (CNS) was low, immunofluorescence indicated that 
endothelial tropism of the virus was the initiating and persisting feature. The action of 
immune complexes in EHV1 infections seems to be secondary and localized 
(Edington et al., 1986). In contrast to several other alphaherpesviruses, which can 
cause encephalitis through primary neurotropism, EHV1 seems to be non-neurotropic 
and its propensity to induce myeloencephalopathy reflects a marked 
endotheliotropism (Edington et al., 1986; Jackson et al., 1977; Whitwell & Blunden, 
1992; Wilson, 1997). Vascular lesions result in secondary hypoxic degeneration of 
nervous tissue, causing nervous system disorders due to the impairment of blood flow 
and metabolic exchange. 
  
Abortion versus nervous system disorders. For many years, it has been 
suspected that distinct isolates of EHV1 might be responsible for outbreaks of either 
abortion and neonatal foal death or neurological disease. The difference in pathogenic 
potential of EHV1 strains to induce abortion or neurological damage appears to be 
correlated with differences in the ability to establish infection at vascular endothelial 
sites, in particular within the endometrium and central nervous system (Edington et 
al., 1986; Mumford et al., 1994; Patel et al., 1982; Platt et al., 1980). Infection with 
neurovirulent strains may result in severe clinical disease, including a high frequency 
of abortion and a less frequent occurrence of paralysis, while infection with non-
neurovirulent strains is restricted to mild respiratory signs, with infrequent induction 
of abortion and no neurological disease (Mumford et al., 1994; Smith et al., 1992; 
Smith et al., 2000). It was noticed that horses inoculated with neurovirulent strains of 
EHV1 developed both a greater magnitude and duration of PBMC-associated viremia 
than animals inoculated with non-neurovirulent strains of the virus, which contributes 
to the risk for development of neurological signs (Allen & Breathnach, 2006). 
Recently, it was demonstrated that a variation of a single amino acid is strongly 
associated with neurological versus non-neurological disease outbreaks (Nugent et al., 
2006). This study compared different isolates recovered from neurological and non-
neurological outbreaks over the course of 30 years. It was found that a single 
nucleotide polymorphism (SNP) in the catalytic subunit of the viral DNA polymerase 
(pol), causing a substitution of asparagine (N) by aspartic acid (D) at amino acid 
position 752 at the ORF30 position of the DNA polymerase, was a major contributory 
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factor in determining whether a disease outbreak will include animals presenting 
neurological signs. To strengthen the finding that the single amino acid exchange by 
itself influences neurovirulence, several studies have been performed, using 
recombinant viruses of non-neurological EHV1 strains with an inserted point 
mutation for the neurological variant and vice versa, further confirming the previous 
finding (Goodman et al., 2007; Van de Walle et al., 2009). However, horses with 
neurological disease upon infection with a non-neurovirulent EHV1 isolate, as well as 
a high prevalence of neurovirulent strains in equine abortions have been reported, 
suggesting that other factors such as host and/or environmental factors will also 
contribute to the onset of neurological disease (Fritsche & Borchers, 2010; Goehring 
et al., 2006; Perkins et al., 2009; Pronost et al., 2010; Smith et al., 2010).  
In recent years, outbreaks of neurological disease due to EHV1 infections have 
been reported with increasing frequency and severity (Friday et al., 2000; Lunn et al., 
2009; McCartan et al., 1995; USDA, 2007; van Maanen et al., 2001). Unfortunately, 
despite 40 years of worldwide research, EHV1-induced neurological disease cannot 
be adequately prevented nor fully explained. 
 
3.2.2 Symptoms 
 
An overview of  different symptoms following EHV1 infection, is shown in Figure 5. 
 
Respiratory disorders. Primary replication of EHV1 in tissues of the upper 
respiratory tract is mostly accompanied with signs of a mild, self-limiting upper 
respiratory tract infection (Gibson et al., 1992). Infected horses spread large amounts 
of virus via nasal secretions, allowing the virus to spread to other susceptible animals. 
Infectious virus can be detected from day 1 till 7 to 14 days post infection (Gibson et 
al., 1992; Heldens et al., 2001; van der Meulen et al., 2006) and in some cases even 
till 21 days post infection (Garré et al., 2009; Patel et al., 1982). 
Young horses usually develop fever, serous to mucopurulent nasal discharge and 
swelling of draining lymph nodes, while older horses mainly show mild or subclinical 
disease (Coggins, 1979). Conjunctivitis, depression and anorexia can be observed in 
some cases (Edington et al., 1986; Kydd et al., 1994a; Patel et al., 1982).  
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In sporadically reported cases, EHV1 targets the pulmonary endothelium in young 
adults, which causes a severe pulmonary oedema (Del Piero & Wilkins, 2001; Del 
Piero et al., 2000). Such severely affected horses die in acute respiratory distress.  
 
Abortion and neonatal foal death. Secondary replication of EHV1 in endothelial 
cells of the pregnant uterus plays a major role in the occurrence of EHV1-induced 
abortion or neonatal death (Edington et al., 1991). The incubation period for abortion 
after respiratory infection with EHV1 varies from 6 days (Gleeson & Coggins, 1980) 
to 4 months (Mumford et al., 1987). Virologically positive foetuses, including 
placenta, are often fresh and abortion occurs suddenly and spontaneously. However, 
abortions with virological negative foetuses are also described (Gleeson & Coggins, 
1980; Smith et al., 1992). 
EHV1-induced abortion can be preceded by mild upper respiratory tract disease in 
the mare but usually no signs of disease or warning signs of impending abortion are 
noticed. Following abortion, virus is cleared rapidly from the genital tract, and future 
breeding capacity is not impaired unless some uterine damage has occurred due to 
dystocia (Smith, 1997). Although mares are not immune to subsequent infection, 
EHV1-induced abortions in successive pregnancies are rare (Doll et al., 1955; 
Ostlund, 1993). EHV1-induced abortions usually involve only 1 or 2 mares in a herd, 
although sometimes abortion storms can occur in which more than 50 % of the foals 
are lost (Mumford et al., 1987; Van Maanen et al., 2000). 
If infection occurs close to term, the mare may deliver an apparently normal or 
weak living foal. These foals usually develop jaundice and respiratory distress and 
mostly die within 7 days post partum despite of intensive treatment, due to extensive 
viral damage and secondary bacterial infection (Murray et al., 1998; Perkins et al., 
1999).  
Field studies have shown that 95% of EHV1-induced abortions occur during the 
last 4 months of gestation (Allen & Bryans, 1986; Doll, 1952; Doll & Bryans, 1963). 
EHV1-abortion has been recorded on rare occasions as early as the fourth month of 
gestation (Prickett, 1970). This apparent resistance of the early pregnant mare to 
abortion is not completely understood.  
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Nervous system disorders. 
Secondary replication of EHV1 in the endothelial cells of blood vessels of the 
nervous system is the first step in the development of nervous system disorders 
(Edington et al., 1986). Neurological disease may affect either single horses or groups 
of animals within a herd. An incubation period of 6 to 10 days between initial 
infection and the occurrence of nervous system disorders has been described (Jackson 
et al., 1977; van Maanen et al., 2001).  
Although the disorders may be preceded by signs of respiratory disease such as 
fever or nasal discharge one or two weeks earlier, they can also occur without any 
previous signs (Carroll & Westbury, 1985; Greenwood & Simson, 1980; Stierstorfer 
et al., 2002; van Maanen et al., 2001). Neurological disease is usually acute in onset 
and can display a variable set of clinical signs. Most commonly, signs vary from mild 
ataxia to complete paralysis, accompanied by bladder and/or rectal paralysis (Jackson 
et al., 1977; Stierstorfer et al., 2002). In less common cases, oedema of the hind legs, 
swollen testis, urticaria and central nervous disorders such as blindness and torticollis 
can be observed (Friday et al., 2000; Greenwood & Simson, 1980; van der Meulen et 
al., 2003a). The prognosis for horses with ataxia due to EHV1 myeloencephalitis is 
favourable, with the possibility to regain their normal performance level. However, if 
the horse becomes recumbent for more than 24 hours, the prognosis is grave and 
euthanasia is indicated (McCartan et al., 1995; van Maanen et al., 2001). 
Although animals of various age, gender and breed can be affected, a retrospective 
study of Goehring et al. (2006) indicated that certain pony breeds and females were 
more commonly affected. Although neurological problems have been reported in 
weanlings, the clinical picture in young horses seems to be less severe than in adults, 
suggesting age to be an important risk factor as well (Goehring et al., 2006; 
Greenwood & Simson, 1980). 
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Figure 5. Different EHV1-related symptoms. A: respiratory disorders; B: abortion; C: neonatal foal 
disease; D: nervous system disorders 
 
3.2.3 Treatment 
 
Antiviral therapy. Treatment of EHV1 infections is limited to symptomatic care 
since no specific antiviral drugs are available for treatment of EHV1 infections in 
horses to date. Experimental antiviral drugs have yet to prove clinical efficacy and 
several of them have been tested in field as well as under experimental conditions.  
During several natural outbreaks of EHV1, treatment with the antiviral drug 
acyclovir has been reported with conflicting results (Friday et al., 2000; Henninger et 
al., 2007; van der Meulen et al., 2003a). However, since therapeutic evaluations in 
case-control studies under field conditions are difficult due to a lack of good control 
animals, great care should be taken in interpreting these results. Acyclovir was also 
shown to have serious limitations due to poor oral bioavailability. Therefore, high 
therapeutic concentrations are needed in order to reach the desired effect, making this 
drug a costly medication with questionable efficacy (Garré et al., 2009; Garré et al., 
A 
C 
B 
D 
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2007; Maxwell et al., 2008a). When using the pro-drug valacyclovir, sufficiently high 
acyclovir levels could be reached in plasma and nasal mucus after oral treatment, but 
no effect of this treatment was seen on clinical signs, viral shedding and viremia of 
EHV1-infected ponies (Garré et al., 2009). The latter was in contrast to the results of 
another study, showing that oral treatment with valacyclovir significantly decreased 
signs of EHV1 disease (Maxwell et al., 2008b). The protective effect was greatest 
when therapy was initiated before viral infection and continued for two weeks. 
However, initiation of therapy at the onset of fever also decreased sings of disease as 
compared to control horses. These encouraging results should be viewed cautiously in 
light of the small number of horses studied. 
Recently, synthetic siRNAs against envelope glycoprotein B and the origin-
binding protein helicase were designed, and their efficacy to limit and prevent EHV1 
infection was tested in vitro and in a murine model. The results obtained during this 
study, indicated that siRNA treatment could be of great importance during an 
outbreak of EHV1 in a horse population, as not only the severity of clinical disease 
but also the number of affected animals and the magnitude of nasal shedding could be 
reduced (Fulton et al., 2009). Although there was no significant difference in viral 
shedding and viremia between treated and control groups during an in vivo 
experiment with EHV1-infected horses, euthanasia necessitated in case of 
neurological disease was significantly reduced after application of EHV1 specific 
siRNA (Brosnahan et al., 2009). 
 
Supportive therapy. Despite many experimental approaches, no systemic 
antiviral therapeutic agents are approved for the use in horses or have a proven 
efficacy. Therefore, supportive therapy is of paramount importance in the field. 
Treatment strategies are aimed at easing clinical signs and preventing secondary 
complications. The level of care necessary is dependent on the severity of clinical 
signs. 
Respiratory infections of immunocompetent animals are generally self-limiting 
and require only good nursing care. Broad-spectrum antibiotics can be administered to 
assist in combating secondary bacterial infections and high fever can be treated with 
antipyretics. Stress avoidance is paramount and horses in training should receive 
adequate rest before resuming work (Ostlund, 1993; van Maanen, 2002).  
Review of the literature 
 
 34 
Abortion occurs suddenly with complete expulsion of fetus and placenta and 
complications are seldom. Therefore, after an uncomplicated partus, usually no 
therapy for the aborting mare is required (Ostlund, 1993; van Maanen, 2002). 
However, it is advisable to wash tail and hind quarters with disinfectants to avoid 
further viral contamination of the environment and/or other animals (Goulden et al., 
1989).  
Weak, but live born affected foals or, less frequently, foals that initially appear 
healthy but rapidly deteriorate due to intractable bacterial infections should be treated 
with intensive therapy like provision of warmth, oxygen, cardiovascular and 
nutritional support and appropriate drugs (Murray et al., 1998; van Maanen, 2002). 
However, these measures are almost always unsuccessful, as these foals are almost 
always bound to die within a few days due to extensive damage in parenchymal and 
lymphoreticular organs and subsequent bacterial infections (Allen & Bryans, 1986; 
Goulden et al., 1989).  
Animals showing nervous system disorders should receive appropriate intensive 
care. Non-recumbent animals should be housed in a deeply bedded box, until 
coordination improves. Severely ataxic horses may be temporarily assisted by a sling 
to prevent secondary complications associated with recumbency. Regular urinary 
catheterization and rectum evacuation may be required in case of bladder or rectum 
paralysis (Friday et al., 2000; McCartan et al., 1995). Horses which are able to stand, 
should be turned out or hand walked as soon as possible (Greenwood & Simson, 
1980; McCartan et al., 1995; van Maanen et al., 2001). Recumbent animals not able 
to be supported by a sling should be maintained in a sternal position in a well-bedded 
stable if possible. They should have easy access to food and water. Intravenous 
rehydratation may be necessary for horses unable to remain in sternal position. Horses 
in lateral recumbency should be manually rotated every few hours. Antibiotics are 
indicated because of the higher risk of developing aspiration pneumonia and/or 
decubital ulcers. Horses can also be treated with corticosteroids in order to reduce the 
inflammatory response in the nervous system. However, considerable care should be 
taken when treating horses with such drugs during an outbreak, as they induce 
immunosuppression and may stimulate a longer and higher spread of virus which can 
make them even contra-indicated (Edington et al., 1985; Goehring & Sloet van 
Oldruitenborgh-Oosterbaan, 2001; Slater et al., 1994). Therefore, only short-acting 
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corticosteroids, if at all, should be used, for a limited period (McCartan et al., 1995; 
Reed & Toribio, 2004). Other anti-inflammatory drugs such as dimethyl sulfoxide 
(DMSO) and non-steroidal anti-inflammatory drugs can be used, although their 
capacity to inhibit the development of the lesions of EHM is unknown. Recovery of 
non-recumbent animals is usually complete, although improvement is gradual and 
several months may elapse before maximal improvement (Ostlund, 1993). However, 
when a horse is recumbent for more then 24 hours, the prognosis is grave and 
euthanasia may be indicated (van Maanen et al., 2001). 
 
3.3 Diagnosis 
 
Virus culture and isolation are considered the gold standard test for the laboratory 
diagnosis of EHV1 (Lunn et al., 2009). Virus culture, isolation and identification of 
EHV1 is strongly supportive of a diagnosis of EHV1-induced disease in a horse with 
compatible clinical signs. The choice of sample depends on the disease syndrome 
encountered (Ostlund, 1993). Both nasal and nasopharyngeal swabs can be collected 
during the first phase of infection or in case of respiratory symptoms. A recent study 
showed that nasal swabbing represents a viable alternative to the less well tolerated 
nasopharyngeal swabbing technique for the molecular detection of EHV1 in horses 
(Pusterla et al., 2008a). Heparinized whole blood can also be collected at this stage, as 
viremia, associated with the buffy coat fraction, often coincides with clinical signs of 
respiratory disease, abortion and neurologic disease. In case of abortion, virus can be 
isolated from different foetal tissues. Viral culture and positive identification can be 
accomplished in as little as 2-3 days in a laboratory when the sample contains a high 
viral load. However, virus isolation is often unsuccessful during outbreaks, because 
the peak of virus shedding may already have passed and local antibodies may interfere 
(Mumford, 1984; van Maanen et al., 2001). The likelihood of detecting EHV1 during 
outbreaks of disease can be increased by testing in-contact horses, especially during 
episodes of fever.  
Recently, PCR techniques have become more and more common as a diagnostic 
test because of their high analytical sensitivity and specificity in case of low viral load 
(Sharma et al., 1992; van Maanen et al., 2001; Varrasso et al., 2001). Conventional 
PCR, however, is limited in its sensitivity, because no distinction between the 
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presence of infectious virus and latent infection can be made. The random testing or 
screening of healthy horses for EHV1 by conventional PCR should therefore be 
avoided (Lunn et al., 2009). The use of novel EHV1 PCR platforms, such as real time 
PCR, allows for a more sensitive detection, a greater specificity and calculation of 
viral loads (Elia et al., 2006; Hussey et al., 2006). Determination of viral load can 
offer important advantages as it can allow for better characterization of disease stage, 
assessment of risk of exposure to other horses and monitoring of response to treatment 
(Pusterla et al., 2009b; Pusterla et al., 2008b; Pusterla et al., 2009c). Concerning the 
circulation of neurovirulent and non-neurovirulent strains of EHV1 in the field, real-
time PCR tests have been developed that distinguish between these two biovars 
(Allen, 2007; Pusterla et al., 2009c). 
Serologic testing demonstrating a 4-fold or greater increase in serum antibody titre 
by serum-neutralizing (SN) or complement-fixation tests on acute and convalescent 
samples collected 3 weeks apart, provides presumptive evidence of EHV1 infection 
(Kydd et al., 2006). Although serologic testing has limitations in confirming a 
diagnosis of EHV1 infection in an individual horse, testing of paired serum samples 
from in-contact horses is recommended. However, serologic testing is limited due to 
cross-reactivity between EHV1 and EHV4, and most laboratories cannot distinguish 
these two viruses (Hartley et al., 2005). Therefore, a specific ELISA test based on the 
C-terminal portion of glycoprotein G of both viruses has been developed (Drummer et 
al., 1995).  
Cerebrospinal fluid analysis with the presence of xanthochromia, a yellowish 
appearance of cerebrospinal fluid, is often supportive of an EHM diagnosis. In 
addition, increased protein concentrations with or without a monocytic pleocytosis are 
typical findings. Histopathology on brain and spinal cord, with typical vasculitis and 
thrombosis of small blood vessels, is an essential method for confirming EHV1 
infection in a horse with suspected EHM post mortem (Schultheiss et al., 1997).  
 
3.4 Disease control 
 
Vaccination. EHV1 remains a leading cause of upper respiratory tract infection, 
viral abortion and nervous system disorders in horses worldwide, despite the 
customary use of commercial vaccines (Allen et al., 1999; Kydd et al., 2006). 
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Following natural infection, EHV1 efficiently induces a local mucosal humoral 
response, which offers the potential for immune exclusion of virus at the respiratory 
tract epithelium portal of entry. However, neither inactivated, nor attenuated vaccines 
are able to induce detectable mucosal antibodies (Breathnach et al., 2001). The 
currently available vaccines are not able to induce a significant level of protection 
against EHV1-induced viremia. However, several vaccines are able to induce a 
significant level of protection against either abortion or nervous system disorders (van 
der Meulen et al., 2007).  
The purpose of vaccination is twofold. First, vaccination is meant to minimize 
virus replication in the respiratory tract upon infection, thus limiting nasal shedding 
and the occurrence of respiratory disorders. Second, vaccination should prevent the 
occurrence of abortion and/or nervous system disorders. The first purpose of 
vaccination seems to be fulfilled by the available vaccines, as demonstrated by 
reduced nasal virus titres and the reduced severity of respiratory disease upon 
challenge infection of vaccinated horses (Burrows et al., 1984; Goodman et al., 2006; 
Heldens et al., 2001). However, the second purpose to protect horses against EHV1-
induced viremia and subsequent abortion or neurological disorders is highly variable 
and none of them can guarantee 100% protection. In view of this, we will briefly 
review several vaccination/challenge studies performed with commercially available 
vaccines. 
Many studies have addressed the potential of inactivated vaccines in the battle 
against EHV1. Inactivated virus vaccines can stimulate high titres of serum virus 
neutralizing (VN) antibody, which cannot only reduce the amount and duration of 
virus shedding but also prime the mucosal compartment (Breathnach et al., 2001). 
However, they fail to induce cytotoxic T-leukocyte (CTL) responses which have 
proven to be of paramount importance to limit EHV1 infection (Kydd et al., 2003; 
Minke et al., 2004). Several case-control studies have been performed with the 
commercially available vaccine Duvaxyn EHV1,4® (Foote et al., 2002; Heldens et al., 
2001). This inactivated vaccine clearly reduced clinical symptoms, the duration of 
virus shedding and the quantity of virus shed. Additionally, a significant reduction in 
the occurrence of abortion was noticed. However, vaccination under field conditions 
could not prevent continuous circulation of both EHV1 and EHV4 in vaccinated 
populations (Foote et al., 2006). Two other studies were performed with another 
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inactivated and oil-adjuvanted vaccine Pneumabort K®. Neither of these studies could 
demonstrate a difference in febrile responses, clinical signs and subsequent abortion 
rates between vaccinated and control mares (Bürki et al., 1990; Burrows et al., 1984). 
However, a recent study with the latter vaccine did not only show a significant 
reduction of clinical signs and nasal shedding after three vaccinations, but also 
demonstrated a significant reduction in the number of days of viremia (Goehring et 
al., 2010c). A possible influence on abortion or nervous system disorders was not 
evaluated during this study. 
Modified-live vaccines (MLV) probably stimulate CTL responses and prime the 
animals for mucosal antibodies, making them valuable candidates to limit EHV1 
infections. They induce a rapid onset of immunity which is both broad and long 
lasting. However, care should be taken when using these vaccines as reversion to 
virulence remains a possible risk (Minke et al., 2004). A study of Bürki et al. (1990) 
showed that all horses became infected and developed viremia upon challenge after 
vaccination with the MLV Prevaccinol® (Bürki et al., 1990). Two out of 4 mares 
aborted, but the study lacked a control group of non-vaccinated mares. Another study 
compared a commercially available inactivated vaccine (Flu-vac Innovator 6®) and a 
commercially available modified-live vaccine (Rhinomune®) (Goodman et al., 2006). 
The modified-live vaccine induced significantly lower VN antibodies, suggesting a 
bias towards a cytotoxic immune response and virus shedding was significantly lower. 
Although the lymphocyte viral gene copies were similar, viremia lasted for a shorter 
period after vaccination with Rhinomune®. Upon challenge, none of the horses 
showed nervous system disorders, in contrast to the horses vaccinated with Flu-vac 
Innovator 6® (3/5) and the control group (3/5). Also a recent study showed a great 
decrease in clinical symptoms and nasal shedding after vaccination with Rhinomune®. 
However a decrease in duration of viremia could not be noticed (Goehring et al., 
2010c). 
Other alternative approaches for potential vaccination against EHV1-induced 
disease such as DNA vaccines, live-vectored vaccines and gene-deleted mutants are 
not yet commercially available, but have undergone pilot studies. A study of Soboll et 
al. (2006) could demonstrate a limited immune response and protection following 
DNA vaccination with plasmids encoding gB, gC, gD, IE and early proteins of EHV1 
(Soboll et al., 2006). A recent study showed that a vaccine with the IE gene of EHV1 
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in a recombinant modified-live vaccinia vector provides not only a reduction in 
clinical disease, but also a reduction of cell-associated viremia (Soboll et al., 2010). 
Unfortunately, until now, the currently available vaccines do not provide complete 
protection as they especially stimulate high titres of circulating antibodies and are 
unlikely to stimulate cytotoxic effector lymphocytes. As EHV1-induced protective 
immunity is only short-lived, vaccination has to be repeated every 6 months (Kydd et 
al., 2006). Future vaccination strategies should be aimed at stimulating both CD8+ and 
CD4+ elements of cell-mediated immunity, in particular CTLs, but at the same time 
maximise stimulation of mucosal and plasma VN antibody (Kydd et al., 2006). 
 
Routine management. The overall goals in management of EHV1 infections are 
to minimize exposure of horses to exogenous virus, to maximize immune 
preparedness to forestall disease in the event of exposure, and to decrease the 
likelyhood of latent virus recrudescence under influence of stress (Ostlund, 1993; van 
der Meulen et al., 2007). Management has to be concentrated mainly on prevention of 
the more serious sequelae of an EHV1 infection like abortion storms and outbreaks of 
neurological disease (van Maanen, 2002). 
Retrospective analysis of equine herpesviral disease outbreaks often can be linked 
to a source of exogenous virus. Age segregation of horses on a farm is one of the best 
tactics to limit spread of herpesviruses. In particular, pregnant mares should be 
separated from young stock and transient horses. Ideally, the pregnant mare 
population should be routinely subdivided into small groups according to expected 
delivery dates (Ostlund, 1993). Personnel should handle pregnant mares before 
contacting other horses on the premises. New horses should be isolated for a period of 
3 weeks, with daily monitoring of rectal temperature and general health, before 
mixing with the resident population (Allen & Bryans, 1986; Ostlund, 1993). 
Vaccination programs should be instituted on a farm-wide basis and should 
include adult horses and non-breeding animals as well as young stock and pregnant 
mares (Ostlund, 1993) (see chapter 3.4 Disease control, vaccination).  
Although some stress is unavoidable, efforts can be made to avoid unnecessary 
stress and to be diligent in routine disease surveillance among animals known to be 
recently subjected to stress (Ostlund, 1993). Stress factors such as poor feeding 
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conditions, overcrowding, travelling in late pregnancy and separation from mates 
should be minimized (van Maanen, 2002). 
 
Management in case of an outbreak. The three priorities for management in case 
of an outbreak of EHV1 are an early diagnosis, prevention of further spread and 
thorough management of clinical cases (Allen, 2002; Pusterla et al., 2009a).  
The importance of an early diagnosis of EHV1 is crucial, as several specific 
interventions may be implemented in case of an EHV1-induced outbreak. Measures 
designed to contain potential EHV1 spread are necessary until EHV1 is either 
confirmed or excluded (Lunn et al., 2009). A good understanding of the appropriate 
diagnostical methods and understanding what samples to take is vital for outbreak 
management (see chapter 3.3 Diagnosis). 
To prevent further spread of virus to other horses or facilities, quarantine 
measurements of the whole facility are necessary for at least 4 weeks after the last 
clinical case. A recent paper even describes the necessity of isolating actively EHV1-
shedding horses in a separate airspace under strict biosecurity and isolation 
procedures (Goehring et al., 2010b). All affected animals should be kept isolated and 
no horses should be allowed to enter or leave the property until quarantine is lifted 
(Allen & Bryans, 1986; Pusterla et al., 2009a; van Maanen, 2002). Areas 
contaminated by virus should be carefully cleaned with detergents. In the face of an 
EHV1 outbreak, vaccination can be used for horses at increased risk of exposure and 
to reduce the spread of infectious virus. There is some controversy associated with 
this practice, because of the concern that EHM might be associated with a history of 
frequent vaccination (Henninger et al., 2007). However, the latter statement should be 
interpreted with care, as the majority of horses that was vaccinated 3-4 times a year 
were older than 5 years. The latter has been described as a risk factor for the 
development of neurologic disease (Goehring et al., 2006). 
Clinical cases should be handled as described in chapter 3.2.3 Treatment. 
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AIMS OF THE THESIS 
 
Equine herpesvirus 1 (EHV1) is the most important cause of infectious abortion in 
horses worldwide and can also lead to severe nervous system disorders with frequent fatal 
outcome. Infection occurs via respiratory route and after local replication in tissues of the 
upper respiratory tract, the virus spreads via a cell-associated viremia to target internal 
organs such as the uterus or the nervous system. Secondary replication of EHV1 in 
endothelial cells of these organs can result in late term abortion or nervous system 
disorders. 
Vaccination with the currently available vaccines cannot prevent clinical symptoms 
such as abortion or nervous system disorders. Moreover, treatment of these symptoms is 
only supportive and specific medication is not available. Therefore, an improvement of 
existing vaccines and/or the development of therapies are necessary. Unfortunately, at the 
start of this thesis, several important steps in the pathogenesis of this disease were still not 
fully clarified, making it difficult to find new directions in the strategy to develop better 
vaccines and to create drugs that inhibit steps of the pathogenesis. In order to achieve this 
goal, studies in the natural host of EHV1, the horse, under both experimental and field 
conditions, are of paramount importance to obtain relevant and correct information about 
the pathogenesis of this disease. 
 
 Firstly, a thorough knowledge of the complete pathogenesis from primary replication 
and invasion via cell-associated viremia to the target organs is urgent. Therefore, the first 
aim of this thesis was to gain a more detailed insight in the invasion of neurologic and 
non-neurologic strains of EHV1 from the upper respiratory tract to the carrier cells in the 
blood stream by means of experimental infection studies in horses (Chapter III). The 
second aim was to examine how individual EHV1-infected cells escape from immune 
effector mechanisms at the primary site of replication (Chapter IV).  
Secondly, to develop suitable vaccination and treatment strategies during natural 
occurring outbreaks of disease, field information about the epidemiology of the virus is 
needed. The third and last aim was therefore to gain more information about naturally 
occurring outbreaks in Belgium in terms of risk factors, protective properties of 
vaccination, the effect of experimental therapies and diagnosis (Chapter V). 
 
  
 
Replication kinetics of EHV1 
 
 57 
 
 
 
 
 
CHAPTER III 
 
DIFFERENCES IN REPLICATION KINETICS 
AND CELL TROPISM BETWEEN 
NEUROVIRULENT AND NON-NEUROVIRULENT 
EHV1 STRAINS DURING THE ACUTE PHASE OF 
INFECTION IN HORSES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Veterinary microbiology 142 (2010), 242-253 
 
Annick C. Gryspeerdt, A.P. Vandekerckhove, B. Garré, F. Barbé, G.R. Van de Walle, H.J. 
Nauwynck
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Replication kinetics of EHV1 
 
 59 
 
 
 
SUMMARY 
 
Equine herpesvirus 1 (EHV1) replicates in the respiratory tract of horses, after which 
infected leukocytes transport virus throughout the body, resulting in abortion or nervous 
system disorders. Two EHV1 strains circulate in the field: neurovirulent and non-
neurovirulent. To investigate differences in replication in the upper respiratory tract 
(URT), an experimental inoculation study in ponies was performed with both strains. Two 
groups of six ponies, were inoculated intranasally with 106.5  TCID50 of either strain. 
Clinical signs, nasal shedding and viremia were evaluated. At early time points post 
inoculation (pi), one pony of each group was euthanized. Tissues were collected for 
titration and immunostainings. Number and size of EHV1-induced plaques were 
calculated, and individual EHV1-infected cells were quantified and characterized. 
Inoculation with either strain resulted in nasal shedding and replication in several tissues 
of the URT. Both strains replicated in a plaquewise manner in epithelium of the nasal 
mucosa, but replication in epithelium of the nasopharynx was largely limited to non-
neurovirulent EHV1. Plaques were never able to cross the basement membrane, but 
individual infected cells were noticed in the connective tissue of all examined tissues for 
both strains. The total number of these cells however, was 3-7 times lower with non-
neurovirulent EHV1 compared to neurovirulent EHV1. CD172a+ cells and CD5+ 
lymphocytes were important target cells for both strains. Interestingly, in lymph nodes, B-
lymphocytes were also important target cells for EHV1, irrespective of the strain. Viremia 
was detected very early pi and infected cells were mainly CD172a+ for both strains. In 
summary, these results are valuable for understanding EHV1 pathogenesis at the port of 
entry, the URT. 
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1 INTRODUCTION 
 
Infectious respiratory tract disease has been recognized as the cause of major health 
problems in horses. The most important respiratory pathogen is equine herpesvirus 1 
(EHV1) and infections with this virus cause serious economic losses in the horse industry 
worldwide (Allen & Bryans, 1986; Ostlund, 1993; van Maanen, 2002). The upper 
respiratory tract is the first line of defence against respiratory pathogens and is also the 
primary replication site of EHV1, where it causes upper respiratory disorders (Kydd et 
al., 1994a; b). In addition, EHV1 can spread via infected blood leukocytes to internal 
organs, for example the pregnant uterus, causing symptoms such as abortion and neonatal 
foal death (Allen & Bryans, 1986). EHV1 can also reach the central nervous system, 
where replication in endothelial cells results in severe nervous system disorders with 
frequent fatal outcome. Neurological disease in horses caused by infection with certain 
isolates of EHV1 is a severe condition which is poorly understood (McCartan et al., 1995; 
Stierstorfer et al., 2002; van der Meulen et al., 2003a). The pathogenesis for developing 
this devastating condition is largely unknown and full protection against these secondary 
and severe symptoms can not be obtained by vaccination with the currently available 
vaccines (Goodman et al., 2006; Heldens et al., 2001; van der Meulen et al., 2007). 
Therefore, an improvement of the existing vaccines and/or the development of alternative 
strategies for the prevention and treatment of EHV1-induced infections are necessary. 
Importantly, this implies a good understanding of the pathogenesis of EHV1 during the 
acute phase of infection.  
It has been suggested that distinct isolates of EHV1, differing in pathogenic capacity, 
circulate in the field. Nugent et al. (2006) indicated that a single nucleotide polymorphism 
(SNP) in the DNA polymerase is strongly associated with neurological versus non-
neurological disease outbreaks. Studies in naturally infected horses with nervous system 
disorders have revealed a more robust cell-associated viremia in horses infected with 
neurovirulent isolates of EHV1, in contrast to horses infected with non-neurovirulent 
isolates (Allen & Breathnach, 2006). This was further confirmed by reverse genetic 
experiments of EHV1 strains with a sole mutation of the DNA polymerase SNP, where 
experimental inoculation with such strains altered neurologic disease in horses (Goodman 
et al., 2007; Van de Walle et al., 2009). Moreover, in vitro experiments with these strains 
revealed differences in leukocyte tropism which could explain the difference in clinical 
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outcome (Goodman et al., 2007). Still, the exact identity of carrier cells susceptible to 
EHV1 infection and hereby responsible for dissemination of infectious virus to sites of 
secondary replication, is a matter of debate. Blood samples from experimentally infected 
ponies were collected and examined for the presence of neurovirulent EHV1 (Scott et al., 
1983). T-lymphocytes were found to be the most important cell fraction to harbour virus 
in vivo. However, no full characterization of these cells was performed. Different studies 
with in vitro EHV1-infected leukocytes have also been performed to determine the 
identity of these cells. Hereby, mainly monocytes were susceptible to infection with non-
neurovirulent EHV1 (van der Meulen et al., 2000). After stimulation with mitogens, T-
lymphocytes became more susceptible, followed by B-lymphocytes (van der Meulen et 
al., 2001). Despite these studies, information on possible differences between 
neurovirulent and non-neurovirulent EHV1 strains at the port of entry, and identity of 
carrier cells during viremia remains limited. 
To investigate this, six Shetland ponies were experimentally inoculated with a 
neurovirulent EHV1 strain and six with a non-neurovirulent EHV1 strain. These animals 
were subsequently euthanized to collect different tissues of the upper respiratory tract. 
Tissues that were positive for EHV1 on titration were stained with markers for different 
cell types to determine and quantify the carrier cells of EHV1 in the upper respiratory 
tract. In addition, peripheral blood mononuclear cells (PBMC) were also collected to 
quantify and identify the infected cell type during cell-associated viremia.  
 
2 MATERIALS AND METHODS 
 
2.1 Horses 
 
Twelve male Shetland ponies, between the age of 6 months and 2 years, were used in 
this study. They were housed inside isolated stables. They were fed daily with a 
commercial, complete feed. Drinking water and hay were supplied ad libitum. 
Prior to the experiment, ponies were monitored for 4 weeks. Rectal temperatures were 
measured daily and complement-dependent seroneutralization (SN)-tests and 
immunoperoxidase monolayer assays (IPMA) were performed weekly to determine EHV-
specific antibody titres.  
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2.2 Virus and inoculation 
 
Ponies were divided into two groups of 6. For the first group the Belgian EHV1 strain 
03P37, isolated from the blood of a paralytic horse in 2003, was used for inoculation 
(Garré et al., 2009; van der Meulen et al., 2003a). The second group was inoculated with 
the Belgian strain 97P70, which was isolated from an aborted fetus (van der Meulen et 
al., 2006). The strains were typed in the DNA polymerase as D752 and N752 respectively in 
cooperation with the Animal Health Trust in the United Kingdom (Nugent et al., 2006). 
Based on their origin and genotyping, these strains will be referred as neurovirulent and 
non-neurovirulent in this paper. Virus stocks used for inoculation were at the 6th passage; 
2 passages in rabbit kidney cells (RK13) and 4 subsequent passages in equine embryonic 
lung cells (EEL). Both viruses had virtually identical single-step growth properties in 
RK13 cells for intra- and extracellular virus yields at all tested time points post infection 
(data not shown). 
Ponies were inoculated oronasally with a total amount of 20ml virus suspension 
containing 106.5 tissue culture infectious dose 50 (TCID50). Ten ml of the virus suspension 
was administered intranasally (5 ml per nostril) using a thin probe and 10 ml was 
inoculated orally with a syringe. The virus titre was confirmed by titration of the 
inoculum on RK13 cells. 
 
2.3 Serological examination 
 
For the seroneutralization (SN)-test, two-fold dilution series of the sera were prepared 
in minimum essential medium (MEM). Fifty micro litre of these serial dilutions were 
incubated for 23 hours (h) at 37°C with a fixed number of infectious virus (300 TCID50 of 
EHV1 strain Arabica in 50 µl). Hereafter, 25 µl of guinea pig complement was added. 
After 1 h of incubation, the mixture of serum, virus and complement was added to RK13 
cells. Inoculated cultures were further incubated at 37°C in an atmosphere containing 5% 
CO2. After 7 days of incubation, the cultures were analysed for the presence of cytopathic 
effect. The neutralization titre was calculated as the reciprocal of the highest dilution of 
the serum that was able to completely block EHV1 infection in RK13 cells.  
 For the immunoperoxidase monolayer assay (IPMA), RK13 cells were inoculated with 
103 TCID50 of the EHV1 strain 97P70. After 28 h, cells were washed, dried at 37°C for 1 
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h and stored at -20°C until use. Plates were thawed and subsequently fixed with 4% 
paraformaldehyde and a solution containing 1% hydrogen peroxide in methanol. 
Following extensive washing, serial 2-fold dilutions of the sera were added and cells were 
incubated for 1 h at 37°C. Cells were incubated with peroxidase-labeled goat anti-horse Ig 
(Jackson ImmunoResearch Laboratories Inc., PA, USA) and after 1 h, a substrate solution 
of 3-amino-9-ethylcarbazole in 0.05 M acetate buffer with 0.05% hydrogen was added to 
each well. Following 20 minutes of incubation at 37°C, substrate solution was replaced 
with acetate buffer to block the enzymatic staining reaction. The IPMA titre was 
calculated as the reciprocal value of the highest serum dilution that induced visual 
staining of infected RK13 cells as determined by light microscopy. 
 
2.4 Clinical examination 
 
Horses were monitored daily for clinical signs by physical examination and 
measurement of rectal temperatures. Fever was defined as a rectal temperature ≥ 38.5°C. 
During clinical examination, nasal discharge (serous, mucous or purulent), lymph node 
swelling, tachypnea and coughing were evaluated. In addition, neurological exams were 
performed: walking the horse in a straight line, walking on and of a step, walking the 
horse in tight circles, pulling the horse’s tail and backing the horse. 
 
2.5 Virological examination 
 
Nasopharyngeal mucus samples were taken daily until euthanasia. Immediately after 
collection, swabs were immersed in transport medium containing phosphate-buffered 
saline (PBS) supplemented with 10% fetal calf serum (FCS), 1000 U/ml penicillin, 1 
mg/ml streptomycin and 0.5 mg/ml kanamycin. EHV1 in nasopharyngeal secretions was 
titrated on monolayers of RK13 cells, exactly as described previously (van der Meulen et 
al., 2003b). 
On 1, 2, 3, 4, 5 and 7 days post inoculation, one pony of each group was euthanized 
with an overdose of Natriumpentobarbital® (Kela, Hoogstraten, Belgium). After 
euthanasia, different tissue samples were collected from the upper respiratory tract. 
Tissues from slaughterhouse horses were collected and served as uninfected control 
samples. Per tissue, two equal squares of 1 cm2 were collected from both left and right 
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side of the head. From each side, one square was frozen immediately with 
(immunofluorescence) or without (virus titration) methylcellulose medium 
(Methocel®MC, Sigma-Aldrich, St. Louis, MO, USA) at -70°C. To determine viral 
replication, 20% suspensions of collected tissues were made and titrated on RK13 cells. 
Titres of infected tissues were determined after 7 days by means of Reed and Muench’s 
formula (Reed & Muench, 1938).  
The experimental design was approved by the local ethical committee of the Faculty 
of Veterinary Medicine. 
 
2.6 Quantification and characterization of individual infected cells in tissues of the 
upper respiratory tract 
 
Immunofluorescent double stainings were used to quantify and characterize individual 
infected cells in tissues that were EHV1-positive after titration on RK13 cells. First, 
cryosections (16 µm) were incubated with either monoclonal antibody (mAb) HT23A, 
DH59B or 1.9/3.2 (VMRD Inc, Pullman, WA, USA) against CD5 (T-lymphocytes), 
CD172a (cells from the monocyte lineage, CML) or IgM (B-lymphocytes) respectively, 
and subsequently incubated with Texas Red®-labelled goat anti-mouse Abs (Molecular 
Probes, Eugene, OR, USA). Epithelial cells were identified based on the pancytokeratin 
marker MNF116 (Abcam, Cambridge, UK) and/or morphological features. Second, viral 
EHV1 proteins were stained by incubation with biotinylated polyclonal horse anti-EHV1 
IgG (van der Meulen et al., 2000), followed by streptavidin-FITC® (Molecular Probes, 
Eugene, OR, USA). As controls, (i) stainings were performed on uninfected tissue and (ii) 
isotype control antibodies were included. All cryosections were analyzed using confocal 
microscopy (Leica TCS SP2 Laser scanning spectral confocal system, Leica 
Microsystems GmbH, Wetzlar, Germany). Number and latitude of EHV1-induced 
plaques were calculated using the software program ImageJ. Latitude was used to 
evaluate plaque size and therefore the degree of cell-to-cell spread. In order to quantify 
infected cells in nasal septum, two main regions were taken into account, on the one hand 
regions with and on the other hand regions without plaques in the epithelium. These 
regions were then subdivided into three equal regions underneath the epithelium: A, B 
and C for regions with epithelial plaques and D, E and F for regions without epithelial 
plaques (Fig 4). For nasopharynx, tubal/nasopharyngeal tonsils and lymph nodes, 
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subdivisions into different zones of functional importance were made (Fig 5, 6 and 7 
respectively). All regions were evaluated for the presence of plaques and/or individual 
infected cells. In addition, the total number of infected cells (positive for staining with 
anti-EHV1 Abs), equine immune cells (positive for staining with the mAbs against 
immune cell markers) and infected equine immune cells (double positive) were 
determined. 
 
2.7 Quantification and characterization of viremia 
 
Heparinized blood samples were taken daily until euthanasia and peripheral blood 
mononuclear cells (PBMC) were isolated by density centrifugation on Ficoll-Paque, 
according to manufacturer’s instructions (Pharmacia Biotech AB, Uppsala, Sweden). To 
determine the magnitude of viremia, co-cultivation of PBMC on RK13 cells was 
performed as previously described (van der Meulen et al., 2003b). Remaining PBMC 
were resuspended in RPMI supplemented with 30% FCS and 20% Dimethyl Sulfoxide 
(DMSO) and frozen in liquid nitrogen for later examination to identify the nature of 
infected cells. Hereby, a double immunofluorescence staining was performed on acetone-
fixed cell smears of PBMC. EHV1 expression was detected using a biotinylated 
polyclonal horse anti-EHV1 IgG (van der Meulen et al., 2003b), followed by streptavidin-
FITC®. The identity of infected cells was determined using the mAbs HT23A, DH59B or 
1.9/3.2, as described above, followed by the incubation with Texas Red®-labelled goat 
anti-mouse Abs. Samples were analyzed using confocal laser scanning microscopy.  
 
3 RESULTS 
 
3.1 EHV-status of the ponies before inoculation 
 
The inclusion criterium for ponies used in this study was a complete absence of EHV-
specific antibodies by either SN-test (<2) or IPMA (<10). In addition, during the 4-week 
observation period prior to the experiment, (i) no raise in temperature was noted, (ii) no 
EHV-specific antibodies were detected, and (iii) no virus was isolated from 
nasopharyngeal swabs. The use of naïve horses is an important tool to minimize variation 
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in clinical and virological outcome due to differences in immunological status (Cornick et 
al., 1990; Heldens et al., 2001; Matsumura et al., 1996). 
 
3.2 Experimental inoculation with either strain induces fever and upper respiratory 
tract disease in ponies 
 
All ponies developed fever upon EHV1 inoculation with exception of the two ponies 
that were euthanized 24 hours post inoculation (hpi). Fever started at 48 hpi for the 
neurovirulent strain (5/5 animals) and at 36 (3/5 animals) or 48 hpi (2/5 animals) for the 
non-neurovirulent strain. High temperatures lasted for the complete observation period, 
with peak temperatures of 40.7°C for the neurovirulent strain and 40.1°C for the non-
neurovirulent strain. Serous nasal discharge was noted after inoculation with both strains, 
starting at 1 day post inoculation (dpi). A transition to purulent nasal discharge was seen 
in both groups from 3 dpi. Breathing problems, consisting of tachypnea or coughing, were 
observed in two ponies of each group. Swelling of mandibular lymph nodes was observed 
in the majority of the ponies and occurred from 1 dpi in 2/6 animals inoculated with a 
neurovirulent strain and in 4/6 animals inoculated with a non-neurovirulent strain. Painful 
retropharyngeal lymph nodes were noted in 5/6 ponies inoculated with a non-
neurovirulent strain, in contrast to only 2 ponies inoculated with a neurovirulent strain. 
None of the ponies showed neurological signs, irrespective of the strain used for 
inoculation. The latter is not too unexpected, as the incubation period of EHV1-induced 
neurological disorders is normally 6 to 10 days (Edington et al., 1986; Jackson et al., 
1977; Mumford & Edington, 1980). Moreover, nervous system disorders have been 
described to occur more frequently in older horses and certain breeds (Garré et al., 2009; 
Goehring et al., 2006; Greenwood & Simson, 1980; Jackson et al., 1977; McCartan et al., 
1995).  
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3.3 Experimental inoculation with either strain results in nasal shedding and viral 
replication in the upper respiratory tract, but differences were observed in the 
preferential epithelial replication site between strains 
 
When evaluating nasal shedding, by titrations of nasal swab samples, five out of six 
ponies inoculated with the neurovirulent strain shed virus from 1 dpi, with a peak 
excretion at 2 dpi (Fig 1). Nasal shedding then slowly decreased until 7 dpi. For the non-
neurovirulent strain, 6 out of 6 ponies shed virus at 1 dpi, reaching a peak at 2 dpi with 
remaining high titres until 7 dpi (Fig 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Nasal viral shedding. Ponies were inoculated with a neurovirulent or a non-neurovirulent strain 
of EHV1. At 0, 1, 2, 3, 4, 5 and 7 days post inoculation (dpi), nasopharyngeal swabs were collected and 
titrated as described in materials and methods. - : mean values 
 
Next, different tissue samples were collected from the upper respiratory tract of one 
pony per group per day for viral titrations. Virus was never isolated in negative control 
tissues and could not be detected in any tissue at 1 dpi for the neurovirulent strain, but 
was found in the nasopharynx of ponies inoculated with the non-neurovirulent strain (Fig 
2). From 2 dpi, virus was mainly recovered from different parts of the nasal septum and 
the nasopharynx for both strains (Fig 2). Septum and nasopharynx remained positive for 
EHV1 until 7 dpi, with the exception of day 5 for the neurovirulent strain where no virus 
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was detected in the nasopharynx (Fig 2) and day 4 for the non-neurovirulent strain where 
the distal nasal septum was negative (Fig 2). No difference in virus titres could be noticed 
in the nasal septum, but titres found in the nasopharynx seemed to be higher after 
inoculation with the non-neurovirulent strain of EHV1 compared to the neurovirulent 
strain (Fig 2). However, because of the limited number of animals used, we should be 
careful to draw any conclusions based on these results. Virus was also found in lymphoid 
tissues such as the tubal and nasopharyngeal tonsils and mandibular lymph nodes (Fig 2). 
In general, titres found in tubal and nasopharyngeal tonsils (Fig 2) were higher for the 
non-neurovirulent strain. Titres detected in mandibular lymph nodes started rising from 3 
dpi (neurovirulent strain) or 4 dpi (non-neurovirulent strain), and at 7 dpi, mandibular 
lymph nodes were positive for the non-neurovirulent strain only (Fig 2). EHV1 could also 
be isolated for both strains at different time points pi from the ethmoid, the cranial part of 
the trachea and 3 different tonsils (data not shown). 
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Figure 2. Viral replication in different tissues of the upper respiratory tract. Ponies were inoculated 
with either neurovirulent or non-neurovirulent EHV1 and euthanized at 0, 1, 2, 3, 4, 5 and 7 days post 
inoculation (dpi). Different tissues were collected and titrated as described in materials and methods.  
 
Finally, replication of EHV1 was evaluated in the epithelium of different tissues of 
the upper respiratory tract by immunofluorescence. Hereby, EHV1-induced plaques were 
analyzed and plaque latitudes measured. In the epithelium of the entire nasal septum, 
EHV1-induced plaques were seen at different time points pi for both strains (Fig 3A). 
These plaques were defined as groups of infected epithelial cells. Since results for 
proximal, intermedial and distal nasal septum were virtually identical, only results for the 
intermedial nasal septum are shown. Plaques were not present in the epithelium at 0 and 1 
dpi (Fig 3A). However, individual infected cells were observed at 1 dpi, which were 
identified as CD172a+ cells, as determined by the marker DH59B, or epithelial cells, as 
determined by the pancytokeratin marker (data not shown). For the neurovirulent strain, 
0
2
4
6
0 1 2 3 4 5 7
0
2
4
6
0 1 2 3 4 5 7
V
iru
s 
tit
er
 
(lo
g 1
0
TC
ID
50
/g
ra
m
 
tis
su
e)
Days post inoculation
0
2
4
6
0 1 2 3 4 5 7
Intermedial nasal septum
Tubal and nasopharyngeal tonsils
0
2
4
6
0 1 2 3 4 5 7
Distal nasal septum
0
2
4
6
0 1 2 3 4 5 7
Proximal nasal septum
Mandibular lymph nodes
0
2
4
6
0 1 2 3 4 5 7
Nasopharynx
neurovirulent
non-neurovirulent
Replication kinetics of EHV1 
 
 70 
EHV1-induced plaques were observed in the epithelium of the nasal mucosa starting from 
2 till 7 dpi (Fig 3A). At 2, 3 and 4 dpi, these plaques consisted of epithelial cells and 
rarely one or two CD172a+ cells. From 5 dpi, EHV1-positive cells became separated from 
the basement membrane (BM) and these cells were exclusively positive for the DH59B 
marker which identifies cells of the monocytic lineage (CML) (Fig 3A). This observation 
was not seen in ponies inoculated with a non-neurovirulent strain. There, plaques were 
present in the epithelium of the nasal mucosa and nasopharynx from 2 till 7 dpi (Fig 3A & 
B). These plaques consisted of epithelial cells and rarely some CD172a+ cells, but no 
separation of EHV1-positive cells was observed (Fig 3A). No differences were observed 
in both number (data not shown) and size (Fig 3A) of EHV1-induced plaques in the 
intermedial nasal mucosa at different time points pi for both strains. In the epithelium of 
the nasopharynx, plaques could be found for the non-neurovirulent strain from 2 till 7 dpi, 
with the exception of 4 dpi (Fig 3B). In contrast, no plaques were found for the 
neurovirulent strain in the nasopharyngeal epithelium, with the exception of one small 
plaque at 3 dpi (Fig 3B). Interestingly, plaques were not able to cross the BM at any time 
point pi, but single EHV1-infected cells could be noticed in the connective tissue from 1 
dpi. Plaques or individual cells could never be visualised in uninfected control tissues or 
in tissues stained with isotype control antibodies. 
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Figure 3. Plaque formation in epithelium of intermedial nasal septum and nasopharynx. Tissues of the 
intermedial part of the nasal septum (A) and nasopharynx (B) were collected and latitude of plaques were 
determined. For each tissue, ten consecutive sections were made and the total number of individual plaques 
was determined. This number is presented above the relevant histogram. The largest measurement of 
latitude of each individual plaque was used to determine plaque latitude. The sum was used to calculate the 
mean plaque latitude ± SEM. Representative immunofluorescence pictures of EHV1-induced plaques in the 
intermedial nasal septum are shown for neurovirulent or non-neurovirulent EHV1 for each dpi. BM: 
basement membrane, objective 20x, NI: non-infected epithelial cells. 
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Taken together, these results show that EHV1 infection results in nasal shedding and 
replication in several tissues of the upper respiratory tract, irrespective of its neurovirulent 
potential. However, whereas both types of EHV1 replicate equally in the epithelium of 
the nasal mucosa, replication in the nasopharynx was limited to non-neurovirulent EHV1. 
 
3.4 Neurovirulent EHV1 uses mainly CD172a+ cells as carrier cells in tissues of the 
upper respiratory tract, whereas non-neurovirulent EHV1 shows a tropism for 
both CD172a+ cells and CD5+ cells 
 
As mentioned before, EHV1-induced plaques never crossed the BM, irrespective of 
the strain used. However, individual infected cells were observed in the underlying 
connective tissue and the total number was 3-7 times lower with non-neurovirulent EHV1 
compared to neurovirulent EHV1. Individual infected cells were never observed in 
uninfected control tissues or in tissues stained with isotype control antibodies. 
To identify the nature of these cells, cryosections of tissues were made and double 
immunofluorescence stainings were performed. 
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Nasal septum. In the connective tissue of the nasal septum, no differences were  
observed in the total amount of infected cells present beneath epithelium with plaques or 
without plaques, with the exception of 5 and 7 dpi for the neurovirulent strain, where a 
marked increase in infected cells was observed in region A (Fig 4). Such increase was not 
seen in the regions located underneath epithelium without plaques (Fig 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Quantification and identification of single EHV1-infected cells in different zones of the 
intermedial nasal septum for neurovirulent and non-neurovirulent strains. Every tenth section of a 
serially sectioned block of tissue was collected. Ten sections were analysed for each cell marker separately, 
giving a total number of 30 sections. The total number of infected cells present in the intermedial nasal 
septum per zone and per day, is shown in the upper right table. The results for the identification of single 
infected cells are shown in the lower graphs and are represented as the mean of ten sections ± SEM. ROI: 
region of interest.  
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Nasopharynx. EHV1-infected cells were present in the connective tissue of the 
nasopharynx from 1 till 7 dpi, irrespective of the strain used, however, the localization of 
these cells appeared to be strain-dependent (Fig 5). Whereas for the neurovirulent strain, 
single infected cells were mainly found in epithelium (region a) and connective tissue 
(region b), single infected cells were located in connective tissue (region b) and 
lymphocyte aggregates (region c) for the non-neurovirulent strain (Fig 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Quantification and identification of single EHV1-infected cells in different zones of the 
nasopharynx for neurovirulent and non-neurovirulent strains. Every tenth section of a serially 
sectioned block of tissue was collected. Ten sections were analysed for each cell marker separately, giving a 
total number of 30 sections. The total number of infected cells present in the nasopharynx per zone and per 
day, is shown in the upper right table. The results for the identification of single infected cells are shown in 
the lower graphs and are represented as the mean of ten sections ± SEM. ROI: region of interest. 
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Tubal and nasopharyngeal tonsils. For both EHV1 strains, single infected cells were 
observed starting from 2 dpi (Fig 6). They were mostly present in the connective tissue 
underneath the epithelium (region b) and lymphocyte aggregates (region c, Fig 6), but 
single infected cells could also be observed in epithelium/fundus (region a), deeper 
connective tissue (region d), blood vessels (region e) and glands (region f) (Fig 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Quantification and identification of single EHV1-infected cells in different zones of the tubal 
and nasopharyngeal tonsils for neurovirulent and non-neurovirulent strains. Every tenth section of a 
serially sectioned block of tissue was collected. Ten sections were analysed for each cell marker separately, 
giving a total number of 30 sections. The total number of infected cells present in the tubal and 
nasopharyngeal tonsils per zone and per day, is shown in the upper right table. The results for the 
identification of single infected cells are shown in the lower graphs and are represented as the mean of ten 
sections ± SEM. ROI: region of interest. 
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Mandibular lymph nodes. For the neurovirulent strain, most of the infected cells  
were found in the marginal sinus of the mandibular lymph nodes (region c, Fig 7). Their 
number increased until 4 dpi and rapidly decreased afterwards, with rarely any infected 
cells left at 7 dpi. Furthermore, infected cells were also observed in the capsule and 
trabecula (region a), the medulla (region f) and in fewer amounts in vessels of the capsule 
and the cortical nodules (regions b and d, Fig 7). In these regions a peak number of 
infected cells was observed at 4 and 5 dpi (Fig 7). For the non-neurovirulent strain, single 
cells were only found from 4 till 7 dpi and were mostly found in the marginal sinus 
(region c) and medulla (region f) (Fig 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Quantification and identification of single EHV1-infected cells in different zones of the 
mandibular lymph node for neurovirulent and non-neurovirulent strains. Every tenth section of a 
serially sectioned block of tissue was collected. Ten sections were analysed for each cell marker separately, 
giving a total number of 30 sections. The total number of infected cells present in the mandibular lymph 
node per zone and per day, is shown in the upper right table. The results for the identification of single 
infected cells are shown in the lower graphs and are represented as the mean of ten sections ± SEM. ROI: 
region of interest. 
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Immunofluorescence stainings, using mAbs against immune cell surface markers 
showed that in all tissues of the upper respiratory tract, infected cells were largely 
CD172a+ CML, followed by a slightly lower amount of infected CD5+ lymphocytes when 
the neurovirulent EHV1 strain was used for inoculation (Table I). These results were very 
similar to what was observed with the non-neurovirulent strain, although a more 
substantial amount of infected CD5+ lymphocytes was observed in these different tissues 
of the upper respiratory tract (Table I). IgM+ lymphocytes were always present, but rarely 
infected with the exception of the mandibular (Table I) and retropharyngeal (data not 
shown) lymph nodes, were these cells were an important target cell type for both strains. 
 
Table I. Percentage of marker positive EHV1-infected individual cells in different tissues of the upper 
respiratory tract 
 
Percentage of marker positive EHV1-infected individual cells 
Neurovirulent strain Non-neurovirulent strain 
Region of interest 
CD172a+ CD5+ IgM+ CD172a+ CD5+ IgM+ 
Nasal septum 53.4 ± 22,8 16.2 ± 11.7 0.3 ± 0.8 43.9 ± 12.8 23.6 ± 8.6 0 
Nasopharynx 69.5 ± 20.7 0 8.3 ± 20.4 37.9 ± 35.5 13.6 ± 5.7 1.1 ± 2.7 
Tubal and 
nasopharyngeal tonsils 
66.4 ± 20.7 11.2 ± 12.8 4.8 ± 5.6 28.7 ± 3.6 21.2 ± 5.9 0.5 ± 1.0 
Mandibular lymph 
nodes 
71.3 ± 17.9 7.3 ± 9.5 8.3 ± 8.8 42.6 ± 21 26.7 ± 5.7 7.7 ± 10.8 
 
 
3.5 Ponies became viremic upon experimental inoculation with either strain, and 
CD172a+ cells were the most important carrier cells in the blood 
 
Transmission of EHV1 from PBMC to susceptible RK13 cells, as determined by co-
cultivation, was observed in 5 out of 6 ponies upon experimental inoculation with 
neurovirulent EHV1 (Fig 8). No differences in the amount of infected PBMC was noted, 
except for one pony, which showed a higher level of viremia at 4 and 5 dpi compared to 
the other infected ponies (Fig 8). For the non-neurovirulent strain, viremia was observed 
in all six infected ponies, with no differences in magnitude for the first 4 dpi (Fig A). 
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However, at day 5 and 7 pi, the non-neurovirulent strain seemed to retain a higher viremia 
level then the neurovirulent strain, but due to the low amount of animals left at those 
days, no conclusions could be drawn (Fig 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Quantification of viremia for neurovirulent and non-neurovirulent strains. Ponies were 
inoculated with a neurovirulent or a non-neurovirulent strain of EHV1. At 0, 1, 2, 3, 4, 5 and 7 days post 
inoculation (dpi), blood samples were collected and cocultivation of PBMC was performed as mentioned in 
materials and methods. 
 
In addition, around 2 x 107 mononuclear cells for each strain were analyzed by 
confocal microscopy to detect infected cells and further characterize their nature. These 
cells were a mixture of PBMC from three ponies collected at 2, 3 and 4 dpi. For the 
neurovirulent strain, fourteen EHV1-infected cells were found and eleven were 
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characterized as CD172a+ cells (78.5%), whereas three were CD5+ (21.5%). No infected 
B-lymphocytes were found. For the non-neurovirulent strain, nine EHV1-infected cells 
were identified, consisting of seven CD172a+ cells (77.8%), one CD5+ T-lymphocyte 
(11.0%) and one cell remained unidentified. Also here, no infected B-lymphocytes were 
found. 
These data indicate that CD172a+ cells appear to be the main target cell during EHV1-
induced viremia, irrespective of the neurovirulency of EHV1. 
 
4 DISCUSSION 
 
Despite several studies conducted on the pathogenesis of equine herpesvirus 1 
(EHV1), it still remains unclear how this virus invades the tissues of the upper respiratory 
tract and invades the deeper tissues to initiate a cell-associated viremia. Furthermore, two 
strains of EHV1 circulate in the field, namely non-neurovirulent and neurovirulent strains, 
the latter causing neurological disease, a severe condition which is poorly understood. In 
the present study, we used the two strains of EHV1 to gain more insight into the 
pathogenesis of these strains during the acute phase of infection in the upper respiratory 
tract in vivo. To this end, Shetland ponies were experimentally inoculated with either a 
non-neurovirulent or a neurovirulent EHV1 strain and upon euthanasia, several tissues 
from the upper respiratory tract were collected and analyzed. 
It was found that EHV1 has different approaches to successfully establish an infection 
in the upper respiratory tract. Firstly, we observed that EHV1, irrespective of the strain, 
can replicate in the epithelium of the nasal septum and/or nasopharynx by means of virus-
induced plaques. This replication appears to occur in a restricted way, as no increase in 
number or size of plaques was observed over time. In addition, a repulsion of EHV1-
induced plaques was observed from 5 dpi onwards for the neurovirulent strain, and a 
decrease in plaque latitude was seen for the non-neurovirulent strain starting at day 3 pi. 
This reduction in replication might be attributed to the production of interferon (IFN), as 
(i) the presence of interferon in nasal secretions after experimental inoculation of horses 
with EHV1 has previously been described and (ii) peak concentrations of IFN-α were 
noted at day 4 and day 7 pi (Bridges & Edington, 1986; Edington et al., 1989). In the 
present study, IFN-α was also found in nasal swabs of experimentally infected ponies 
(data not shown), which further points towards the importance of IFN to limit EHV1 
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replication in the epithelium of the upper respiratory tract. Interestingly, even though the 
non-neurovirulent strain was able to replicate in a plaquewise manner in the epithelium of 
the nasopharynx, no plaques could be observed at any time point pi in the nasopharynx 
after inoculation with the neurovirulent strain. As the epithelial structure of both tissues is 
identical, with the exception of the presence of lymphoid aggregates in the nasopharynx, 
the reason for this observation remains elusive.  
Another interesting observation for both EHV1 strains was that we were unable to 
observe EHV1-infected plaques under the basement membrane (BM) at any time point pi, 
indicating that EHV1 does not reach the underlying tissue by breaking down the BM. 
This is in striking contrast to previous findings with another and closely related 
alphaherpesvirus, pseudorabies virus (PRV), which has been shown to cross the BM in a 
plaque wise manner between 12 and 24 hpi in a porcine respiratory explant model 
(Glorieux et al., 2009). This indicates that different alphaherpesviruses may use different 
mechanisms to invade the underlying connective tissue. Indeed, whereas PRV was shown 
to break down the BM and replicates further in the underlying tissue in a plaquewise 
manner, our study with EHV1 demonstrated only single infected cells below the BM. 
This is in agreement with previous studies on EHV1, where the presence of single 
infected cells in tissues of the upper respiratory tract has been reported (Edington et al., 
1986; Kydd et al., 1994b). We could further demonstrate that these infected cells in the 
underlying tissue were immune cells (as discussed in more detail below), which makes it 
tempting to speculate that immune cells in the epithelium become infected with EHV1 
and are responsible for transporting the virus to deeper connective tissue. Indeed, we did 
found EHV1-infected cells in the epithelium of nasal septum and/or nasopharynx, which 
were further characterized to belong to the monocytic lineage (CML) by using the cell 
surface maker CD172a.  
Not only differences concerning the identity of the EHV1-infected immune cells 
present in the underlying tissues were noticed between both strains, moreover, differences 
concerning their localization were also observed. When analyzing the identity of the 
single EHV1-infected cells in the connective tissue of nasal septum and nasopharynx, 
several differences could be observed between the two EHV1 strains. Firstly, the total 
number of infected cells in the nasal septum was 10 to 20 times higher for the 
neurovirulent strain compared to the non-neurovirulent strain. Secondly, while individual 
infected cells in the nasopharynx were mainly present in the connective tissue upon 
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neurovirulent EHV1 inoculation, individual cells infected with the non-neurovirulent 
EHV1 seemed to migrate deeper into the lymphoid follicles of the nasopharynx in a time 
wise manner. Thirdly, CD172a+ CML were the most important carrier cells for both 
neurovirulent and non-neurovirulent EHV1, although these cells seemed to be more 
important for the neurovirulent strain. In addition, both strains were able to infect CD5+ 
T-lymphocytes, with a higher amount of infected cells for the non-neurovirulent strain 
(Table I). When analyzing the data on the identity of infected cells in lymphoid tissues of 
the upper respiratory tract, we again observed that the most prominent target cells for 
EHV1 were CD172a+ CML, irrespective of the strain used. This is in line with previous 
studies, where EHV1-infected macrophages and lymphoblasts were detected in lymph 
nodes after inoculation with EHV1 isolates from both an aborted fetus and a paralyzed 
mare (Patel et al., 1982). Moreover, another EHV1 experimental inoculation study 
showed that lymphocytes, monocytes, macrophages and plasma cells in interstitium and 
lymph nodes all expressed EHV1 antigens, as determined by immunohistochemical 
staining using anti-EHV1 polyclonal Abs (Kydd et al., 1994b). In the present study, the 
majority of EHV1-positive cells was found in the marginal sinus of lymph nodes. At 
those sites, transport is possible to extra follicular interdigitating cells in the lymph node 
where both mature and virgin lymphocytes have access to antigen, hereby initiating 
humoral immune responses (Tew et al., 1990). Surprisingly, and in contrast to what was 
observed in nasal septum and nasopharynx, IgM+ B-lymphocytes were also an important 
target cell for EHV1. In vitro it has been previously shown that a 6- to 14-fold increase of 
EHV1-infected peripheral blood mononuclear cells (PBMC) could be obtained after in 
vitro stimulation with proliferating drugs such as pokeweed mitogen (PWM), 
concanavalin A (ConA), phytohaemagglutinin (PHA), or ionomycin and phorbol 
dibutyrate (IONO/PDB) (van der Meulen et al., 2001). Together with the fact that B-
lymphocytes are known to undergo extensive proliferation in lymphoid follicles (Fu & 
Chaplin, 1999), we would like to reason that the elevated percentage of EHV1-infected B-
lymphocytes observed in lymphoid tissues, is due to the proliferation stage of these 
immune cells.  
The onset of a cell-associated viremia could be detected as early as one day after 
experimental inoculation with EHV1, indicating that EHV1-infected cells can enter the 
blood stream very rapidly. Moreover, we identified these EHV1-positive cells as mainly 
CD172a+ CML. Despite the fact that only 14 infected cells were found, we strongly feel 
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that this low number is of relevance, as it is known that EHV1-induced viremia is 
generally very low with numbers ranging from 1 to 10 positive cells/0.8 x 107 PBMC 
(van der Meulen et al., 2006). Combining the results on the identity of EHV1-infected 
cells in the connective tissues of the primary port of entry, the upper respiratory tract, 
with the results on the identity of the EHV1-infected cells in the blood, we would like to 
hypothesize that the CD172a+ cells we observed could be dendritic cells (DCs). The 
reasoning behind such hypothesis is as follows. The marker DH59B that was used in the 
present study to identify CD172a+ cells is a pan granulocyte/monocyte marker which has 
been used in several studies as a DC marker (Ahn et al., 2002; Tumas et al., 1994). In 
addition, there is evidence indicating that local tissue DCs are able to re-enter the 
bloodstream, which might facilitate the spread of pathogens from tissue to tissue, carried 
by DCs serving as Trojan horses (Randolph et al., 2008). Finally, DCs have been shown 
to play an important role during the pathogenesis of alphaherpesviruses in general 
(Bosnjak et al., 2005; Novak & Peng, 2005; Pollara et al., 2005), and for EHV1 in 
specific, both murine and equine blood-derived DCs are susceptible to EHV1 in vitro 
(Siedek et al., 1999; Steinbach et al., 1998). Unfortunately, little is known about equine 
DCs in general and mucosal DCs in specific in this species, and more research is needed 
to elucidate the role of DCs in EHV1 infection and/or other viral infections in equines. 
Regardless, the results presented here are in striking contrast to another in vivo study, 
where mainly blood T-lymphocytes were found to harbour EHV1 (Scott et al., 1983). 
However, in the latter study, leukocyte populations were solely separated by glass-bead 
columns and no direct characterization was performed. A possible explanation for the 
discrepancy between cell types infected during cell-associated viremia could be the strain 
used. In a previous study an American strain, isolated from an aborted fetus, was used 
(Scott et al., 1983) whereas in the present study, we used two Belgian EHV1 strains. 
Surprisingly, we observed CD172a+ cells as the main carrier cell type for both the 
neurovirulent and the non-neurovirulent strain, indicating that the EHV1 strain does not 
seem to correlate with a difference in cell tropism during viremia. This is again in contrast 
to another study, where a difference in leukocyte tropism between neuro- and non-
neurovirulent EHV1 strains has been demonstrated (Goodman et al., 2007). Hereby it was 
observed that the EHV1 strain Ab4, which has the neurovirulent genotype, mainly 
infected CD4+ lymphocytes, whereas mutating this strain into the non-neurovirulent 
genotype resulted in a preferential infection of monocytes and B-cells. However, these 
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experiments were performed with in vitro infected PBMC, which most likely explains the 
discrepancy with our in vivo data.  
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SUMMARY 
 
 Equine herpesvirus 1 (EHV1) starts its replication by infection in the epithelial cells of 
the upper respiratory tract (URT), where after the virus invades the lamina propria of the 
URT using single mononuclear cells, hereby reaching the bloodstream which allows 
further spread of this virus throughout the body. In addition, EHV1 has developed various 
strategies to escape from immune effector mechanisms. One of these strategies is to 
interfere with antibody-dependent cell lysis by hampering proper viral protein expression 
on the cell surface.  
 Because epithelial and mononuclear cells are crucial cell populations in the early 
pathogenesis of EHV1, the present study aimed to evaluate the expression of the late viral 
proteins gB, gC, gD and gM in these type of cells, using several experimental systems. 
Firstly, epithelial-like rabbit kidney (RK13) cells and peripheral blood mononuclear cells 
(PBMC) were infected with EHV1 in vitro. Secondly, the recently established ex vivo 
system of equine nasal mucosal explants was used and thirdly, an in vivo evaluation was 
performed by means of nasal mucosa tissues of experimentally EHV1-infected ponies. 
Our salient findings were that the late proteins gB, gC, gD and gM were clearly expressed 
in almost all late-infected epithelial cells, whereas the expression pattern was totally 
different in infected mononuclear cells: gB and gM were expressed in 60 to 90% of these 
cells, gC and gD in only 20%. 
 These results show that the expression of late viral proteins during the early 
pathogenesis of EHV1 depends upon the cell type infected. Furthermore, this study 
underlines the use of nasal mucosal explants as a valuable alternative to experimental in 
vivo studies in the horse. 
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1 INTRODUCTION 
 
 Equine herpesvirus 1 (EHV1), a member of the Alphaherpesvirinae, is an ubiquitous 
equine respiratory pathogen, affecting horses worldwide (Allen & Bryans, 1986; 
Brosnahan & Osterrieder, 2009). After an initial replication in the epithelial cells of the 
upper respiratory tract (URT), EHV1 can spread through the basement membrane (BM) 
carried by single infected mononuclear immune cells, hereby reaching the underlying 
connective tissue (Vandekerckhove et al., 2010). Via a cell-associated viremia in 
peripheral blood mononuclear cells (PBMC), EHV1 is then transported to its internal 
target organs, the pregnant uterus and the central nervous system, where viral replication 
in endothelial cells can cause abortion, neonatal foal death and nervous system disorders 
through vascular damage (Smith & Borchers, 2001; Smith et al., 1996). As a result of the 
short-lived immunity following an EHV1 infection, viral replication in the respiratory 
tract can re-occur as soon as two months and viremia can be detected as early as six 
months after primary infection (Edington & Bridges, 1990; Gibson et al., 1992). High 
levels of circulating EHV1-specific antibodies are still present when re-infection with 
EHV1 occurs, suggesting that EHV1 recognition by the immune system is seriously 
hampered (Burrows et al., 1984; Gleeson & Coggins, 1980; Heldens et al., 2001; 
Mumford et al., 1987). 
 The genome of EHV1 encodes at least 12 known glycoproteins, designated 
glycoprotein B (gB), gC, gD, gE, gG, gH, gI, gK, gL, gM, gN and gp2. Herpesviral 
glycoproteins are present in the viral envelope as distinct, projected spikes and because 
they are involved in various steps of the virus infection cycle, such as attachment, 
penetration, egress and cell to cell spread, they represent major determinants of 
pathogenicity, virulence and host cell tropism (Spear & Longnecker, 2003). For example, 
glycoprotein C and gM are non-essential glycoproteins, with gC being involved in the 
first unstable binding of the virus to glycosaminoglycan moieties of cell surface heparin 
sulphate and in the process of egress (Osterrieder, 1999; Sugahara et al., 1997), and gM 
contributing to virus penetration and cell-to-cell spread of the virus (Osterrieder et al., 
1996). The essential protein gD interacts with a putative entry receptor to attain a stable 
binding (Csellner et al., 2000; Frampton et al., 2005) and is furthermore also involved in 
cell-to-cell spread of the virus (Csellner et al., 2000; Wellington et al., 1996a). The 
essential protein gB is involved in the penetration of the virus into the host cell and cell-
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associated spread of the virus to uninfected neighbouring cells (Neubauer et al., 1997; 
Wellington et al., 1996b). 
 In general, upon infection of a cell with an alphaherpesvirus, these viral envelope 
proteins are synthesised and incorporated into various cellular membranes (Mettenleiter, 
2002). The presence of viral proteins in the plasma membrane of infected cells renders 
them susceptible to antibody (Ab)-dependent cell lysis, through binding of virus-specific 
Abs on viral proteins. Subsequently, infected cells are destructed by phagocytic cells and 
natural killer cells or via activation of the complement cascade (Hansch et al., 1997; 
Hirsch, 1982; Janeway et al., 2001). Several herpesviruses have developed strategies to 
interfere with immune effector mechanisms and EHV1 is no exception in this regard (van 
der Meulen et al., 2006b). One strategy of EHV1 is to interfere with Ab-dependent cell 
lysis by hampering envelope protein expression on the cell surface. An in vitro study by 
van der Meulen et al. (2003b) demonstrated that approximately 70% of all EHV1-infected 
PBMC did not express viral envelope proteins on their surface, despite a clear 
intracellular expression (van der Meulen et al., 2003b). This absence of viral proteins on 
the surface of these infected PBMC was shown to render them insensitive to Ab-
dependent complement-mediated lysis and Ab-dependent cell-mediated cytotoxicity (van 
der Meulen et al., 2003b). Importantly, in an in vivo study of experimentally inoculated 
ponies, 98% of the infected PBMC collected during cell-associated viremia did not show 
viral envelope proteins on their plasma membrane, nor were they found intracellularly, 
and only immediate early and at least some early proteins were present (van der Meulen 
et al., 2006a). Based on these results, it was hypothesized that EHV1-infected PBMC are 
at an early stage of infection during viremia and that further replication steps, including 
proper expression of late proteins, only occurs upon adhesion to endothelial cells at the 
target organs (van der Meulen et al., 2006b). 
 The main purpose of the present study was to evaluate the expression of several late 
viral envelope proteins, including gB, gC, gD and gM in the different cell types which 
become infected in the URT, a first step during the early pathogenesis. Two important 
cell types during early pathogenesis were analysed in three different model systems: in 
vitro with the standard epithelial RK13 cell line and PBMC, ex vivo by means of the 
recently established equine nasal mucosal explant system and finally in vivo, with tissues 
collected from experimentally infected ponies. 
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2 MATERIALS AND METHODS 
 
2.1 Virus 
 
 Two different strains were used in this study to take into account a possible influence 
of the neurovirulent/non-neurovirulent nature of EHV1. On the one hand the Belgian 
EHV1 strain 03P37 was used, isolated from the blood of a paralytic horse (Garré et al., 
2009; van der Meulen et al., 2003a), and on the other hand the Belgian strain 97P70, 
isolated from an aborted fetus (van der Meulen et al., 2006a). These strains were typed in 
their DNA polymerase in cooperation with the Animal Health Trust in the United 
Kingdom (Nugent et al., 2006) and based on their origin and genotyping, these strains are 
referred to in this paper as neurovirulent (D752) and non-neurovirulent (N752) respectively. 
Virus stocks used for inoculation were at the 6th passage; 2 passages in rabbit kidney cells 
(RK13) and 4 subsequent passages in equine embryonic lung cells (EEL). Both viruses 
have previously been shown to display virtually identical in vitro single-step growth 
properties (Gryspeerdt et al., 2010). 
 
2.2 Antibodies 
 
For the detection of the late proteins gB, gC, gD and gM, specific antibodies were 
used: mouse monoclonal antibodies (mAbs) 4B6 against gB (Osterrieder et al., 1995), 
1B6 against gC (Huemer et al., 1995), 107D1D against gD (a kind gift from Merial, 
France), and the monospecific anti-gM mouse antiserum F6 against gM (Osterrieder et 
al., 1996). 
To identify EHV1-infected cells, two antibodies were used: either rabbit polyclonal 
antibodies against the immediate early (IE) protein (Caughman et al., 1988), or horse 
polyclonal anti-EHV1 antibodies. The latter antibodies were obtained by 
hyperimmunisation of a horse (van der Meulen et al., 2003b). The polyclonal antibodies 
were purified on a protein G column and subsequently biotinylated (Amersham 
International, Buckinghamshire, UK). To ensure that these antibodies could recognise the 
late proteins of EHV1, transfection studies were performed. To this end, RK13 cells were 
transfected with 1 µg of plasmid DNA expressing gB, gC, gD or gM (a kind gift from 
Prof. Osterrieder, Freie Universitaet Berlin), using lipofectamin (Invitrogen). After 48h, 
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RK13 cells were fixed and stained by double immunofluorescence stainings as described 
below. All transfected cells, as identified by a positive staining for each late protein 
respectively, were also positive for the anti-EHV1 polyclonal antibodies, indicating that 
these EHV1-specific antibodies are able to recognise all late proteins evaluated in the 
present study. In addition, kinetic infection studies in RK13 cells showed that these 
polyclonal antibodies stain all infected cells from 24 hpi onwards when the late 
glycoproteins are fully expressed, indicating that these antibodies are a useful tool to 
detect cells in a late stage of infection. These horse polyclonal anti-EHV1 antibodies are 
especially advantageous to evaluate infected cells in the nasal mucosa because these cells 
are at different stages of infection and they always identify cells in the late stage of 
infection. Rabbit polyclonal antibodies against the IE protein cannot discriminate between 
cells early in infection from cells late in infection with an abortive infection.  
 
2.3 Expression of late proteins 
 
(i) In RK13 cells and PBMC.  
Cells of the epithelial-like rabbit kidney (RK13) cell line were seeded on glass inserts 
in 24-well culture plates (Nunc A/S) at a density of 300 000 cells/well and were further 
cultured in growth medium (MEM supplemented with 100 U/ml penicillin, 0.1 mg/ml 
streptomycin, 0.1 mg/ml kanamycin, 0.3 mg/ml glutamine and 5% foetal calf serum) at 
37°C for 24 hours . Then, cultures were infected with either neurovirulent strain 03P37 or 
non-neurovirulent strain 97P70 at a multiplicity of infection (MOI) of 10. After 1 hour, 
virus was removed by rinsing the cells twice with culture medium and after 0, 4, 8, 13 and 
24 subsequent hours of incubation, the cells were fixed with methanol for 20 minutes at -
20°C and stored at -70°C. Infected cells were stained as described below and were 
analyzed by confocal laser scanning microscopy (Leica TCS SP2 laser scanning spectral 
confocal system, Leica Microsystems GmbH, Wetzlar) and the Leica confocal software. 
Hereby, individual cells were counted from their appearance (3 hpi) until the appearance 
of plaques (8hpi). Newly infected individual cells present after 13 hpi were not taken into 
account as they represent a second replication cycle.  
Blood samples were collected from three different, healthy adult horses by jugular 
venipuncture and collected on heparin (Leo). PBMC were isolated by density 
centrifugation on Ficoll-Paque (Pharmacia Biotech AB), washed 3 times with PBS and 
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resuspended in complete medium containing 2/1 MEM/RPMI 1640, supplemented with 
10% fetal calf serum (Grainer), 0.05 mM 2-mercapto-ethanol (Gibco), 100 U/ml 
penicillin (Continental Pharma), 0.1 mg/ml streptomycin (Certa), 0.1 mg/ml kanamycin 
(Kela), 0.3 mg/ml glutamin (BDH Biochemical), 1% non-essential amino-acids 100x 
(Gibco) and 1 mM sodium pyruvate (Gibco). After 24 hours of cultivation, PBMC were 
inoculated at a MOI of 10 with either neurovirulent strain 03P37 or non-neurovirulent 
strain 97P70. After 1 hour of incubation at 37 °C, cells were washed thoroughly with 
RPMI and cultured in medium supplemented with 10 U/ml heparin (Leo). Cell smear 
samples were made 48 hours post inoculation (pi) and fixed in acetone for 20 minutes. 
 
(ii) In ex vivo nasal mucosal explants.  
The cultivation and infection of nasal mucosal explants was performed exactly as 
previously described (Vandekerckhove et al., 2010). In brief, immediately after slaughter, 
the head was removed from the carcass and longitudinally sawn into 2 equal sections. 
Tissue from the deep intranasal part of the septum of 3 different horses was collected. The 
tissues were transported on ice in phosphate buffered saline (PBS), supplemented with 1 
µg/ml gentamycin, 1 mg/ml streptomycin, 1000 U/ml penicillin, 1 mg/ml kanamycin and 
5 µg/ml amphotericin, to the laboratory. Mucosal explants were stripped from the surface 
of the different tissues by use of surgical blades (Swann-Morton). The stripped mucosa 
was divided into equal explants of 25 mm2 and placed epithelium upwards on fine-
meshed gauze for culture at an air-liquid interface. Only a thin film of serum-free medium 
DMEM (50%)/RPMI (50%) supplemented with 0.3 mg/ml glutamine (BHD 
Biochemical), 1 µg/ml gentamycin (Gibco), 0.1 mg/ml streptomycin (Certa) and 100 
U/ml penicillin (Continental Pharma)) covered the explants, thereby mimicking the 
air/liquid interface found in the respiratory tract of the living animal. Explants were 
maintained at 37°C in an atmosphere containing 5% CO2. Explants were inoculated after 
24 h of culture by immersion of the explant in 1 ml of inoculum, containing 106.5 TCID50 
of either EHV1 strain for 1 h at 37°C and 5% CO2. After incubation, explants were 
washed twice with warm medium and transferred back to their gauze. At 48 hours post 
inoculation (pi), explants were collected, embedded in methylcellulose medium 
(Methocel® MC, Sigma-Aldrich, St.Louis) and samples were frozen at -70 °C. 
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 (iii) In nasal mucosa of experimentally in vivo infected ponies. Six EHV-negative 
ponies (SN titer <2 and IPMA titer <10) were divided in two groups of three and 
inoculated either with strain 97P70 or 03P37 as described previously (Gryspeerdt et al., 
2010). In brief, ponies were inoculated oronasally with 20 ml of a virus suspension 
containing 106.5 tissue culture infectious dose 50 (TCID50). Ten ml of the virus suspension 
was administered intranasally (5 ml per nostril) using a thin probe and 10 ml was 
inoculated orally with a syringe. On two dpi, all ponies were euthanized with an overdose 
of Natriumpentobarbital® (Kela, Hoogstraten, Belgium), and the intermedial part of the 
nasal septum was collected. Tissue samples were immediately frozen with 
methylcellulose medium (Methocel®MC, Sigma-Aldrich, St. Louis, MO, USA) at -70°C. 
This experimental design was approved by the local ethical committee of the Faculty of 
Veterinary Medicine, Ghent University, Belgium. 
 
2.4 Double immunofluorescence stainings 
 
To visualise the presence of gB, gC, gD and gM in infected cells, the specific 
antibodies (mAbs) against these glycoproteins were used in a first step, followed by 
incubation with secondary Texas Red®-labelled goat anti-mouse antibodies (Molecular 
Probes, Eugene, OR, USA). For the identification of EHV1-infected cells, either the 
rabbit polyclonal antibodies against the IE protein (RK13 cells), or the biotinylated horse 
polyclonal anti-EHV1 antibodies (PBMC, nasal mucosa) were used. Subsequently, 
samples were incubated with secondary FITC®-labelled goat anti-rabbit antibodies 
(Molecular Probes, Eugene, OR, USA) for the polyclonal rabbit anti-IE antibody or 
streptavidin-FITC® (Molecular Probes, Eugene, OR, USA) for the biotinylated polyclonal 
anti-EHV1 antibody. Antibodies were incubated for 1 h at 37 °C and 5 % CO2 and 
washed thoroughly with phosphate buffered saline (PBS) in between staining steps. As 
negative controls, (i) stainings were performed on uninfected RK13, PBMC and nasal 
mucosa and (ii) isotype specific control antibodies on infected cells and tissues were 
included. All cryosections were analyzed using confocal microscopy (Leica TCS SP2 
Laser scanning spectral confocal system, Leica Microsystems GmbH, Wetzlar, Germany). 
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3 RESULTS 
 
3.1 Late proteins gB, gC, gD and gM are properly expressed in in vitro infected 
epithelial-like RK13 cells 
 
In a first experiment, RK13 cells were used to analyse the expression kinetics of the 
viral EHV1 glycoproteins gB, gC, gD and gM during an EHV1 infection. To this end, the 
immediate early protein (IE) was used to identify EHV1-infected cells and double 
immunofluorescent stainings were performed to detect the viral glycoproteins gB, gD, gC 
and gM. EHV1-infected cells were observed as early as 1 hpi and their number increased 
over time (data not shown). From 8 hpi, all late proteins tested started to be expressed in 
individual EHV1-infected cells irrespective of the strains used, with gB and gM being 
expressed in a larger percentage of the infected cells than gC and gD (Figure 1). 
Expression of these late proteins in infected cells further increased over time and finally 
at 24 hpi, the expression of gB, gC, gD and gM was found in all infected cells. This time 
point co-incided with the time point when the polyclonal anti-EHV1 antibodies recognise 
infected cells and therefore, this Ab was used in all further experimentation to identify 
late infected cells. 
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Figure 1. Kinetic study of the expression of late proteins gB, gC, gD and gM in EHV1-infected RK13 
cells inoculated with neurovirulent strain 03P37 (A) and non-neurovirulent strain 97P70 (B). All data 
represent means + SD of triplicate independent experiments. EHV1-infected cells were firstly incubated 
with mouse monoclonal antibodies against gB, gC, or gD and a monospecific mouse antiserum against gM, 
followed by Texas Red®-labelled goat anti-mouse antibodies. Secondly, they were incubated with a 
polyclonal rabbit anti-IE antibody, followed by FITC®-labelled goat anti-rabbit antibodies. 
 
3.2 Expression of the late proteins gC and gD is hampered in in vitro EHV1-infected 
PBMC 
 
Next, we wanted to evaluate the expression of the late proteins gB, gC, gD and gM in 
a cell type which is also relevant during the pathogenesis of EHV1 infection, namely 
peripheral blood mononuclear cells (PBMC). PBMC were isolated from the blood and 
infected in vitro with the neurovirulent or non-neurovirulent EHV1 strain. At 48 hpi, 
A
B
0
20
40
60
80
100
0 5 10 15 20 25
Hours post inoculation
Ex
pr
es
sio
n
o
f l
at
e 
pr
o
te
in
s
in
 
IE
-
po
sit
iv
e
R
K
13
 
ce
lls
(%
)
gB
gC
gD
gM
0
20
40
60
80
100
0 5 10 15 20 25
Hours post inoculation
gB
gC
gD
gM
Ex
pr
es
sio
n
o
f l
at
e 
pr
o
te
in
s
in
 
IE
-
po
sit
iv
e
R
K
13
 
ce
lls
(%
)
Ex
pr
es
sio
n
o
f l
at
e 
pr
o
te
in
s
in
 
IE
-
po
sit
iv
e
R
K
13
 
ce
lls
(%
)
Ex
pr
es
sio
n
o
f l
at
e 
pr
o
te
in
s
in
 
IE
-
po
sit
iv
e
R
K
13
 
ce
lls
(%
)
Expression of late proteins is hampered 
 
 98 
infected cells were identified using the polyclonal anti-EHV1 Ab and expression of the 
late proteins gB, gC, gD and gM was evaluated in these infected cells. For both strains, 
expression of the late proteins gB and gM was almost 100% in infected cells (Figure 2A). 
In contrast, expression of gC and gD was only seen in 15 to 25% of EHV1-infected 
PBMC (Figure 2A). These results indicate that expression of certain late proteins which 
are normally expressed in infected rabbit epithelial cells at 24 hpi, are impaired in their 
expression in leukocytes at 48 hpi.   
 
3.3 Expression of late proteins gC and gD is also hampered in EHV1-infected 
leukocytes but not epithelial cells from nasal mucosa in explants and experimentally 
infected ponies 
 
To assess the relevance of the observations which were made with the epithelial-like 
RK13 cells and PBMC, we repeated the double immunofluorescence stainings in 
cryosections of (i) infected nasal mucosal explants and (ii) nasal tissue of experimentally 
infected ponies. Previous work in our laboratory has shown that in both models, the nasal 
epithelial cells become infected with EHV1. In addition, single EHV1-infected cells are 
also observed, which are mainly present under the BM in connective tissue and which 
were identified as leukocytes (Gryspeerdt et al., 2010; Vandekerckhove et al., 2010). 
In nasal explants and in nasal tissues of in vivo inoculated horses, infected epithelial 
cells showed a full expression of late proteins tested (Figure 3), which is in line with what 
was observed in RK13 cells at 24 hpi. Individual infected leukocytes, located in the 
connective tissue below the BM showed the same tendency as in vitro infected PBMC. 
Hereby, around 80% to 90% of late infected cells showed expression of the late proteins 
gB and gM in nasal explants and in vivo harvested nasal tissues, whereas the expression 
of the late proteins gC and gD in these EHV1-infected leukocytes fluctuated around 10 to 
15% in in vivo harvested nasal tissues and nasal mucosal explants respectively (Figure 2B 
and 2C). No clear differences in expression levels were found in cells infected with either 
the neurovirulent 03P37 or the non-neurovirulent 97P70 (Figure 2B and 2C). 
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Figure 2. Expression of late proteins gB, gC, gD and gM in late infected leukocytes at 48 hours post 
inoculation with neurovirulent strain 03P37 and non-neurovirulent strain 97P70 in three different 
systems: (A) in vitro infected PBMC, (B) nasal mucosal explants and (C) nasal mucosa of experimentally 
infected ponies. All data represent means + SD of triplicate independent experiments. Firstly, samples were 
incubated with mouse monoclonal antibodies against gB, gC, gD or gM, followed by Texas Red®-labelled 
goat anti-mouse antibodies. Secondly, they were incubated with the polyclonal horse anti-EHV1 antibody, 
followed by streptavidin-FITC®. 
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Figure 3. Expression of late proteins gB, gC, gD and gM in  late infected epithelial cells. Since results were 
virtually identical for all three systems and both strains tested, only immunofluorescence pictures of plaques in 
in vitro infected nasal mucosal tissue is shown. First, a staining with the biotinylated equine polyclonal anti-
EHV1 IgG, followed by streptavidin-FITC® was performed (A). Second, a staining with specific mouse 
antibodies against gB, gC, gD or gM followed by secondary Texas Red®-labelled goat anti-mouse antibodies 
was performed (B). 
 
 
 
 
 
 
 
 
 
A
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4 DISCUSSION 
 
Equine herpesvirus 1 (EHV1) starts its pathogenesis in the upper respiratory tract 
where primary replication occurs and results in upper respiratory tract disease. After 
invasion through the basement membrane (BM) barrier, the virus enters blood vessels and 
rapidly disseminates in the body via a cell-associated viremia. Recent research has shown 
that EHV1 replicates in epithelial cells by means of plaque formation and in migrating 
individual cells, allowing EHV1 to cross the BM. The latter cells were identified as cells 
of the monocytic lineage, T-lymphocytes and a small amount of B-lymphocytes 
(Gryspeerdt et al., 2010; Kydd et al., 1994; Vandekerckhove et al., 2010). Hence, two 
main cell populations appear to play a crucial role in the early pathogenesis of EHV1, 
namely epithelial cells on the one hand and leukocytes on the other hand.  
In the present study, we studied the expression of the late envelope glycoproteins 
(g)B, gC, gD and gM in rabbit and horse epithelial cells as well as equine leukocytes, in 
three frequently used EHV1 infection models. Hereby, our salient findings were that in 
epithelial cells, a complete replication cycle of EHV1 was seen, with expression of all 
four tested glycoproteins, gB, gC, gD and gM in 100% of the infected cells. This, 
however, was in striking contrast to EHV1-infected leukocytes. In this cell type, 
expression of the late proteins gB and gM was observed in 60 to 90% of infected cells, 
whereas expression of the late proteins gC and gD never exceeded 20% of EHV1-infected 
cells. As these results were consistent in vitro as well as in vivo infected cells, we 
concluded that this phenomenon is truly cell-type dependent and not just merely a result 
of the experimental set-up used.  
A decreased expression of late proteins in certain cell types has already been 
described for another herpesvirus, the human cytomegalovirus (HCMV). For this human 
herpesvirus, viral gene expression in placental trophoblasts was shown to be restricted to 
immediate-early or early gene products during HCMV infection (Sinzger et al., 1993; 
Toth et al., 1995). In another study, where a human trophoblast continuous cell line was 
used, expression of immediate-early, early and late genes was only delayed when 
compared to expression in a fibroblastic continuous cell line (Halwachs-Baumann et al., 
1998). Hence, these studies indicate the importance of the cell type used when evaluating 
protein expression after viral infection. For EHV1, quantitative dot blot hybridization 
experiments revealed that expression of the late genes gD and gK was significantly lower 
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in placental trophoblast cells than in foetal epithelial lung tissue (Kimura et al., 2004). 
This low level of late gene transcription was linked with a limited production of viral 
progeny and the lack of immunoreactivity for viral antigen in trophoblasts infected with 
EHV1. However, all these studies have studied EHV1 protein expression in the later 
stages of pathogenesis at the secondary replication sites, and therefore, our study is the 
first to describe these events of decreased late protein expression in certain cell types 
during the early stages of pathogenesis at the upper respiratory tract. The underlying 
mechanism responsible for this decreased expression of EHV1 late proteins in certain cell 
types, however, remains unclear. These findings could be an explanation why no plaque 
formation in the connective tissue of the upper respiratory tract could be found in 
previous studies (Gryspeerdt et al., 2010; Vandekerckhove et al., 2010), as gD is an 
essential glycoprotein for virus spread and was found to be present in only very low 
amounts of individual infected PBMC in the present study. 
When combining our present results with data from previously performed studies in 
the authors’ laboratory (van der Meulen et al., 2006a; van der Meulen et al., 2003b), it 
could be hypothesized that EHV1-infected leukocytes which show a hampered expression 
of late proteins, are the cells reaching the blood stream and subsequently causing a cell-
associated viremia. This is supported by the results of van der Meulen et al. (2006), 
stating that 98% of EHV1-infected PBMC present in the blood during cell-associated 
viremia in experimentally inoculated ponies lacked expression of certain late viral 
envelope proteins on their cell surface. They did, however, show expression of the 
immediate early protein and at least one early protein, ICP22, indicating that these cells 
were truly infected (van der Meulen et al., 2006a). So one could hypothesize that these 
cells are in an early stage of infection and that some activation signals need to trigger the 
expression of envelope proteins on the cell surface to free the way for transmission of 
infectious virus at the secondary replication sites. Such hypothesis has already been put 
forward a long time ago by Scott et al. (1983). They described that although virus could 
be recovered after cocultivation of intact leukocytes with a permissive cell line, no 
infectious virus could be found after disruption of these cells (Scott et al., 1983). All this 
indicates that EHV1-infected leukocytes exist in a non-infective or subvirion form. 
Indeed, an in vitro study showed that activation of adhesion molecules in endothelial cells 
of the nasal mucosa, and the reproductive tract, is a key step in transferring virus from 
infected leukocytes to endothelial cells (Smith et al., 2002; Smith et al., 2001). 
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In conclusion, although this is only a basic study where cells in a later stage of 
infection were studied, these results indicate that the expression of certain viral proteins 
during the early pathogenesis of EHV1 depends upon the cell-type infected. Furthermore, 
this study underlines again the use of nasal mucosal explants as a valuable alternative to 
experimental in vivo studies in the horse. 
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SUMMARY 
 
Neurological disease in horses caused by neurovirulent strains of EHV1 has been reported 
with increasing frequency during the last decade. Therefore, concern has been voiced 
within the US horse industry that the neurologic form of EHV1 may be intensifying in 
prevalence and/or morbidity and mortality. Full protection against these severe signs 
cannot be obtained by vaccination with the currently available vaccines and effective 
antiviral therapies are not available. In Belgium, outbreaks of EHV1-induced abortions 
are a yearly recurrent phenomenon, but outbreaks of equine herpes myelitis (EHM) are 
extremely rare. This report describes an unusually large outbreak of EHV1-induced 
neurological disease in Antwerp, Belgium, which involved at least 13 different premises. 
Seven of them were characterized in more detail and were included in this research. A 
total of 212 horses were exposed to EHV1 and a morbidity of 26% was seen. The 
incidence of neurological disorders in the affected horses was 43%. Furthermore, the 
outbreak was characterized by the rapid occurrence of ataxia and paralysis immediately 
after disappearance of fever. EHV1 was diagnosed as the etiological agent by means of 
virus isolation and/or the detection of seroconversion. Isolated virus was classified as 
neurovirulent EHV1, with all isolates belonging to group 4 upon sequencing in the 
ORF30 and ORF68 region. The latter confirms the suspicion of the outbreak spreading 
from the first premise. The extent of this current outbreak and the high percentage of 
horses with neurological signs, along with the fact that EHM is only sporadically seen in 
Flanders, might indicate that the neurological form of EHV1 is possibly also emerging in 
Belgium. 
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1 INTRODUCTION 
 
Equine herpesvirus 1 (EHV1), a member of the Alphaherpesvirinae, is endemic in the 
horse population worldwide. After exposure, virus replicates in tissues of the upper 
respiratory tract. Primary replication is followed by a leukocyte-associated viremia which 
enables EHV1 to reach internal organs (Gryspeerdt et al., 2010; Kydd et al., 1994a; b). A 
second replication in endothelial cells at the site of the pregnant uterus or the nervous 
system may result in abortion and neonatal foal death or nervous system disorders 
respectively (Allen & Bryans, 1986; Gilkerson & Barrett, 2008). The latter, also 
designated equine herpes myelitis (EHM), is a severe condition which is still poorly 
understood despite the correlation between a single amino acid variation in the ORF30 
region of the viral DNA polymerase and neurological disease (Lunn et al., 2009; Nugent 
et al., 2006; Van de Walle et al., 2009).  
EHV1 is a ubiquitous pathogen with a worldwide distribution and yearly problems 
with respiratory disorders and abortion are common. In contrast, outbreaks of nervous 
system disorders caused by infection with EHV1 seem to be more rare. However, during 
the last decade, large outbreaks of EHM have been reported in the USA with enhancing 
frequency and the  fatal outcomes after substantial suffering appeared to increase (Lunn et 
al., 2009). In Belgium, EHV1 is also endemic in the horse population and EHV1-induced 
abortion is a yearly recurrent event. However, EHM is rare and mostly involves a limited 
number of horses on a single premise (van der Meulen et al., 2000). To date, only one 
description of EHV1-induced neurological disorders has been reported in Belgium. No 
extensive spread of EHM was seen during this episode and severe disease was limited to 
the affected premise. The signs in neurologically affected horses consisted mainly of 
ataxia and paralysis, but cerebral dysfunctions were also noticed (van der Meulen et al., 
2003). 
The current report describes a large outbreak of EHV1-induced neurological disease 
in Flanders in 2009, that started on a riding school and spread to at least 12 premises that 
had been in direct contact with the riding school. The extent of this outbreak, along with 
the higher percentage of horses with neurological signs, without the occurrence of 
cerebral dysfunctions, and the rapid occurrence of severe signs raises the intriguing 
question if EHM is also emerging in Belgium.  
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2 MATERIALS AND METHODS 
 
2.1 Description of the premises 
 
During an outbreak of EHV1-induced nervous system disorders in Antwerp, Flanders 
(June 2009), fever and neurological disease were observed on at least 13 premises. All 
these premises had attended a jumping contest on May 30th, 2009, at a riding school 
where the first cases of neurological signs occurred (premise n° 1). Although 13 premises 
reported neurological disease, only the data of 7 premises were included in this report. On 
these premises, EHV1 infection was confirmed by virus isolation and/or seroconversion 
(Table II). The other 6 affected premises had several horses with neurological problems, 
but refused to give any further information and were therefore not included in this 
research (Figure 1). Information about vaccination state, management and housing can be 
found in Figure 1 and Table I. Each premise was visited for evaluation of clinical signs 
and local veterinarians were asked to collect blood samples from horses suspected of 
infection with EHV1 for both virus isolation from leukocytes and detection of 
seroconversion in paired serum samples.  
 
2.2 Serological examination 
 
The presence of EHV-specific antibodies was determined with a complement-
dependent seroneutralization (SN)-test in acute serum samples and convalescent serum 
samples three weeks later. Two-fold dilution series of the sera were prepared in MEM. 
Fifty µl of these serial dilutions were incubated for 23 hours (h) at 37°C with a fixed 
number of infectious virus (300 TCID50 of EHV1 strain Arabica in 50 µl). Hereafter, 25 
µl of guinea pig complement was added. After 1 h of incubation, the mixture of serum, 
virus and complement was added to RK13 cells. Inoculated cultures were further 
incubated at 37°C in an atmosphere containing 5% CO2. After 7 days of incubation, the 
cultures were analyzed for the presence of cytopathic effect. The neutralization titre was 
calculated as the reciprocal of the highest dilution of serum that was able to completely 
block EHV1 infection in RK13 cells. Seroconversion was present when the antibody titre 
of the convalescent sample was at least four times higher than in the acute sample. 
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2.3 Virological examination 
 
Virus isolation from peripheral blood mononuclear cells (PBMC) was performed on 
RK13 cells. Unclotted blood samples (EDTA) were taken from horses with clinical signs 
(fever and/or neurological disorders). PBMC were isolated by means of density 
centrifugation on Ficoll-Paque (Pharmacia Biotech AB, Uppsala, Sweden) and 
subsequently inoculated on monolayers of RK13 cells. Monolayers were incubated at 
37°C in an atmosphere containing 5% CO2 and examined daily for 7 consecutive days for 
the presence of cytopathic effects. 
 
2.4 PCR amplification and sequencing of ORF30 and ORF68 
 
DNA was extracted from EHV1 isolates using a QiaAmp DNA extraction kit (Qiagen 
Benelux, Venlo, The Netherlands). Amplification of ORF30 was performed using the 
primers ORF30fw (gctacttctgaaaacggaggc) and ORF30rev (ctatcctcagacacggcaaca) and 
amplification of ORF68 with the primers ORF68atg1 (atgggtgtggtcttaattac) or ORF68fw 
(aagcattgccaaacagttcc) in combination with ORF68end1 (aacgtgtggatgtccggcc). PCR 
products were treated with Exonuclease I and Antarctic Phosphatase (New England 
Biolabs, Ipswich, USA) and used directly for cycle sequencing with a Big Dye 
Terminator Cycle sequencing kit V1.1 (Applied Biosystems, Foster City, USA). 
Additional internal oligonucleotides were used for sequencing of ORF68. Cycle 
sequencing reaction products were purified using ethanol precipitation and separated on 
an ABI Genetic Analyzer 310 (Applied Biosystems, Foster City, USA). The sequences 
were analyzed and compiled using Align, ClustalW and Sixframe in the workbench 
(workbench.sdsc.edu) and BlastN and BlastP at www.ncbi.nlm.nih.gov. To validate the 
sequencing, previously characterized strains 97P70 (Genbank accession number: 
GU271940), 03P37 (# GU271941) and Ab4 (# AY665713) were included (Garré et al., 
2007; Nugent et al., 2006). 
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2.5 Treatment 
 
All affected animals received supportive therapy consisting of anti-inflammatory 
drugs and antibiotics. Horses with severe ataxia and/or bladder paralysis were hung in 
slings and the bladder was emptied manually twice a day. Some animals received an 
antiviral therapy, consisting of 40 mg of valacyclovir/kg body weight, administered 3 
times daily for different consecutive days (Garré et al., 2009). The doses were prepared 
by mixing the calculated amount of valacyclovir with water and administered orally. 
Because of cost restraints and the limited amount of valacyclovir that was available, only 
four affected horses were treated for a different number of consecutive days. 
 
3 RESULTS 
 
3.1 Description of the number, age and sex of affected animals during the outbreak  
 
On the first premise, a morbidity (affected horses/total n° of horses present) of 21% 
was seen during the outbreak and this premise reported to vaccinate twice a year with two 
different inactivated vaccines (Figure 1). The animals on premise n° 4 had a variable 
vaccination status. The morbidity was only 9%. However, clear clinical disease was only 
seen in non-vaccinated animals and not all animals were checked for signs of EHV1. All 
other premises did not vaccinate against EHV1 and morbidity varied from 25% (premise 
n° 5) up to 100% (premise n° 2, 3, 6 and 7). Overall, a morbidity of around 23% was 
observed during this outbreak.  
The age of the affected animals varied from 3 to 21 years. No correlation between the 
severity of clinical signs and age could be noticed during the course of this outbreak. 
In total, 43% of the affected horses developed nervous system disorders. Of all 
infected females 55% (18/33) developed nervous system disorders. Only 24% (5/21) of 
all infected males developed nervous system disorders (Table I). Of the affected horses 
with neurological signs 30% (7/23) were eventually euthanized and these were mainly 
female (6/7 or 86%) (Table I).  
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Figure 1. Schematic overview of the course of the outbreak of EHV1-induced neurological disorders 
at the different premises. NSD: nervous system disorders; open management: public riding school with 
incoming and outgoing horses; half-open management: private premise, but where horses attend 
competitions at other premises; housing with direct contact: stables separated from each other by bars; 
housing with indirect contact: stables separated from each other by full walls. 
 
Table I. Description of the animals on the premises with EHV1 associated neurological disorders 
 
Total n° of horses present 
 
Total n° of affected horses 
 
N° of horses with neurological 
disorders 
Premise 
N° 
Male Female Total Male Female Total (%) Male Female Total (%) 
1 53 43 96 8 12 20 (21%) 2 6 8 (40%) 
2 1 2 3 1 2 3 (100%) 0 1 1 (33%) 
3 2 10 12 0 3 3 (25%) 0 3 3 (100%) 
4 42 38 80 2 5 7 (9%) 0 1 1 (14%) 
5 3 4 7 3 4 7 (100%) 1 4 5 (71%) 
6 2 1 3 2 1 3 (100%) 1 1 2 (67%) 
7 5 6 11 5 6 11 (100%) 1 2 3 (27%) 
 108 104 212 21 33 54 (26%) 5 18 23 (43%) 
Premise 1
First case: May 14th
Last case: June 16th
N°of horses present: 96
% morbidity: 21
% of horses with NSD: 40
Management: open
Housing: direct contact
Vaccination state: 2x/year
Premise 2
First case: June 5th
Last case: June 20th
N°of horses present: 3
% morbidity: 100
% of horses with NSD: 33
Management: half open
Housing: indirect contact
Vaccination state: none
Premise 3
First case: June 9th
Last case: June 10th
N°of horses present: 12
% morbidity: 25
% of horses with NSD: 100
Management: half open
Housing: direct, indirect contact
Vaccination state: none
Premise 4
First case: June 9th
Last case: June 19th
N°of horses present: 80
% morbidity: 9
% of horses with NSD: 14
Management: open
Housing: indirect contact
Vaccination state: variable
Premise 5
First case: June 9th
Last case: June 14th
N°of horses present: 7
% morbidity: 100
% of horses with NSD: 71
Management: half open
Housing: indirect contact
Vaccination state: none
Premise 6
First case: June 15th
Last case: June 28th
N°of horses present: 3
% morbidity: 100
% of horses with NSD: 67
Management: half open
Housing: direct, indirect contact
Vaccination state: none
Premise 7
First case: June 17th
Last case: June 17th
N°of horses present: 11
% morbidity: 100
% of horses with NSD: 27
Management: half open
Housing: direct, indirect contact
Vaccination state: none
6 additional premises
with reports of 
neurological disorders, 
but without any
addtional information, 
nor confirmation of 
EHV1
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3.2 Methodical description of clinical symptoms during the outbreak 
 
The most prominent clinical sign present, was fever (>39.5°C) that lasted for 2-5 days 
and swelling of lymph nodes. During pyrexia, most of the horses showed a temporary 
weakness of the tail. In the majority of the affected horses, a slight serous nasal discharge 
was noted. On premise n° 1 icterus and oedema of the hind legs were also reported. These 
symptoms were not regularly observed in the six other affected premises, as only three of 
them reported oedema of the hind legs in a few horses. In two horses, urticaria were seen 
during the pyretic period and two other horses suffered from muscle trembling after 
disappearance of fever. During the outbreak, 43% of the affected horses showed nervous 
system disorders (Table I). This occurred in most (65%) cases immediately after 
disappearance of pyrexia, but some horses (35%) developed ataxia and paralysis without 
preceding elevated body temperatures. Since body temperatures were not checked 
regularly in the beginning of the outbreak, a period of fever could have passed unnoticed. 
During this outbreak, moderate as well as severe ataxia were noticed. Severe ataxia was 
accompanied by bladder paralysis in approximately 50% of the cases. Several horses 
became quadriplegic shortly after developing ataxia, but quadriplegia also occurred 
without previous neurological symptoms. In total, seven horses were euthanized during 
this outbreak. Six of these horses (from premise n° 1) were presented with paralysis 
before an etiological diagnosis was made and were euthanized within 24 hours after the 
onset of neurological symptoms. The last horse (premise n° 4) was euthanized two weeks 
after the occurrence of paralysis since no improvement of the situation was seen. All other 
horses with neurological symptoms that survived were clinically normal 4 months later 
and regained normal performance levels, with the exception of one mare that is again 
suffering from urinary incontinence after a clinically normal period of four months. 
 
3.3 Evaluation of antiviral treatment during outbreak 
 
During the outbreak, four horses were treated orally with the antiviral drug 
valacyclovir (Table II). Horse A was a gelding of 4 years of age (premise n° 1). He was 
treated when the fever ceased after 5 days and the horse showed muscle tremors. As the 
muscle tremors stopped after one day and no other symptoms of EHV1 infection were 
observed, the therapy was stopped after 2 days. Horse B was a mare of 7 years (premise 
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n° 2), and the valacyclovir treatment started at the moment she became quadriplegic. This 
horse was unable to stand and was hung up in a sling. Two days later, she was not yet 
able to stand up on her own, but she could stand without the help of the sling and her 
condition improved rapidly. Treatment was stopped after 5 days. One week later, she was 
still slightly ataxic but was able to stand up and regained bladder control. Treatment of 
horse C (female, 5 years, premise n° 2) was started when she had difficulties standing up 
and was found severely ataxic. She was treated for 3 consecutive days. One week later, 
she was still obviously ataxic but this slowly improved over the next couple of weeks. 
Bladder paralysis lasted for almost three weeks. Finally, horse D (female, 7 years, 
premise n° 3) was treated after she became quadriplegic for more than 36 hours. She was 
lifted up in a sling and could barely stand on her own. The first two days after the 
treatment was initiated, the horse showed a significant improvement. She was able to 
stand on her own in the sling and even tried to walk. After three days, however, treatment 
was stopped due to a lack of available valacyclovir. The horse remained stable for several 
days, but no further improvement of clinical symptoms was observed. Two weeks after 
the onset of symptoms, the horse was able to stand in the sling and started to regain 
bladder control, but was not able to lay in sternal position or to stand up on her own. 
Because this caused severe anxiety for the horse, she was euthanized. 
 
Table II. Treatment of different animals with valacyclovir 
 
Horse Gender Age Symptoms Duration of treatment Improvement 
A ♂ 4 tremor 2 days +++ 
B ♀ 7 quadriplegia 5 days ++ 
C ♀ 5 severe ataxia 3 days + 
D ♀ 7 quadriplegia 3 days ± † 
 
†: euthanasia 
 
3.4 Diagnosis 
  
Blood samples were collected from seven horses with high fever, six horses with 
ataxia and two horses with quadriplegia at the moment of sampling (Table III). EHV1 
was isolated by means of PBMC co-cultivation from six of the seven horses with high 
fever (86%), from four of the six horses with ataxia (67%) and from the two horses with 
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quadriplegia (100%) (Table III). Seroconversion of EHV-specific antibodies was 
evaluated for thirteen of the fifteen horses, both at the time of clinical signs (acute 
sample) as well as three weeks later (convalescent sample). Twelve horses seroconverted 
for EHV1 (Table III). 
All EHV1 isolates were typed as neurovirulent by sequencing of the D752 allele in the 
ORF30 region (e.g. 09P240, # GU271939). In addition, all viruses were sequenced in 
their ORF68 region, a genetic marker for grouping isolates into six major geographically 
restricted groups (Nugent et al., 2006). All isolates in this outbreak of neurological 
disease belonged to group 4. These genetic analyses, along with a direct link between the 
confirmed premises and premise n° 1, further confirmed the assumption that all EHV1 
infections on the different premises were caused by the same virus spread from premise 
n° 1. 
 
Table III. Results from different diagnostic tools to confirm EHV1 infection in discussed horses 
 
Antibody titre in serum Premise Horse Signs 
at the  
moment of 
sampling 
Isolation of 
EHV1 from 
PBMC Acute sample Convalescent  
sample  
1 1 Fever + 128 1536 
 2 quadriplegia + 64 NA 
2 1 Fever + 48 512 
 2 Fever + 16 256 
3 1 Ataxia + 192 512 
 2 Ataxia + 96 1024 
 3 Ataxia - 16 256 
4 1 quadriplegia + 96 NA 
5 1 Fever + 4 1536 
 2 Fever + 12 768 
 3 Fever - 8 1024 
 4 Fever + 12 2048 
6 1 Ataxia + 32 1536 
7 1 Ataxia + 4 1536 
 2 Ataxia - 8 1536 
 
NA: not available due to euthanasia 
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4 DISCUSSION 
 
The present paper reports a large outbreak of EHV1-induced neurological disease in 
Antwerp, Flanders in June 2009. How the present epidemic started on this premise is not 
known, however two weeks before the first horse became recumbent and had to be 
euthanized, a 5-year old mare was presented with fever, lasting for 4 days. It might be 
hypothesized that this mare either reactivated latent EHV1 or got infected with EHV1 due 
to many contacts of visiting horses on the premise. Secondary outbreaks on other 
premises then occurred as a consequence of direct contact with infected horses from the 
first premise. Both the first premise as well as secondary infected premises were put 
under quarantine for three weeks and all horses without clinical symptoms in the 
neighbourhood were vaccinated. The outbreak was successfully controlled and one month 
after the onset of the outbreak, no more cases of EHV1 infection were reported. 
An interesting feature of the present outbreak was the rapid occurrence of ataxia and 
paralysis immediately after disappearance of fever. Previous reports mention an 
incubation period of 7 to 10 days for the development of nervous system disorders after 
experimental inoculation (Edington et al., 1986; Jackson et al., 1977). Interestingly, 
although sex and age did not seem to influence the incidence of becoming infected, mares 
appeared to be predisposed to develop severe ataxia and paralysis. Indeed, 55% of the 
infected mares developed nervous system disorders (18/33), whereas this was only 24% 
(5/21) for the infected male horses. The higher sensitivity of mares to develop severe 
symptoms after EHV1 infection has already been described, however, no explanation for 
this exists to date (Goehring et al., 2006; McCartan et al., 1995). 
Although the efficacy of current commercial vaccines to protect horses against EHV1-
related symptoms is highly variable and none of them can guarantee 100% protection, 
several vaccines have been shown to induce significant protection against either abortion 
or nervous system disorders under experimental and field conditions (Goodman et al., 
2006; van der Meulen et al., 2007). The premises which were mainly affected during this 
outbreak had an inadequate or no vaccination protocol at all. This observation has also 
been reported during other outbreaks of EHV1-induced neurological disease, where most 
outbreaks occurred on premises with unvaccinated horses (Goehring et al., 2006; van der 
Meulen et al., 2003). During this outbreak, morbidity rates were lower (7 to 21%) in 
vaccinated premises (n° 1 and 4) compared to the non-vaccinated premises (25 to 100%) 
Characteristics of a natural occurring outbreak of EHV1 
 
 119 
(Figure 1). On premise n° 4, where both vaccinated and unvaccinated horses were 
present, fever and neurological disease was only reported in their unvaccinated horses 
whereas the vaccinated horses showed no clinical signs of EHV1 infection. This could 
indicate that vaccinated horses have a clinical protection against severe symptoms of 
EHV1. Whether this protection is the result of a reduced spread of the virus or due to a 
virological effect is not clear. Interestingly, although lower morbidity rates were observed 
at the vaccinated premises n° 1 and 4, no difference could be seen in the number of horses 
that eventually developed nervous system disorders compared to the non-vaccinated 
premises (Table I). In Belgium, only inactivated vaccines are registered for use in horses 
which mainly stimulate humoral immunity, whereas it is suggested that cell-mediated 
immunity is of paramount importance to limit EHV1 infection (Kydd et al., 2006; Kydd 
et al., 2003). 
During this outbreak, four horses on three different premises were treated orally with 
the antiviral drug valacyclovir. Experimental in vivo studies to evaluate the efficacy of 
valacyclovir to reduce viral shedding and provide clinical recovery have recently been 
performed, but with contradictory results (Garré et al., 2009; Maxwell et al., 2008). 
During this outbreak, 8 horses showed paralysis. Two out of three treated horses (66%) 
regained normal prestations, while five out of five (100%) untreated horses had to be 
euthanized. Although the treated horses seemed to recover quite fast during treatment 
compared to untreated horses with the similar clinical features, it is difficult to evaluate 
the benefit of valacyclovir treatment during an outbreak, due to the limited amount of 
treated horses versus non-treated horses and the variable treatment periods. Still, 
extensive supportive care remains indispensable during an outbreak of EHV1-induced 
neurological disorders to increase the likelyhood of recovery. 
Both virus isolation from peripheral blood mononuclear cells (PBMC) as well as 
seroconversion were used to diagnose EHV1 during this outbreak. EHV1 was 
successfully isolated from PBMC during the present outbreak. This is in contrast to 
previous published studies, mentioning that virus isolation from PBMC in outbreak 
situations can be problematic (Lunn et al., 2009; van Maanen et al., 2001). In addition, 
seroconversion has also been reported to have limitations in confirming a diagnosis of 
EHV1, especially in horses with neurological signs (Lunn et al., 2009). Interestingly, 
during the current outbreak all horses with neurological disorders seroconverted, with the 
exception of one horse. An explanation for the successful diagnosis during this outbreak 
Characteristics of a natural occurring outbreak of EHV1 
 
 120 
could be the rapid occurrence of severe signs during the current outbreak which increased 
the chance of detecting infectious virus and seroconversion. Low initial EHV1 antibodies 
in a largely unvaccinated population could also have contributed to the easy detection of 
seroconversion. 
Although some interesting findings concerning risk factors, vaccination, treatment and 
diagnosis were observed during this outbreak, conclusions drawn from natural occurring 
outbreaks should be taken with care, owing to the small numbers involved and variability 
in both vaccination and anti-viral treatment. 
During the only other reported outbreak of EHV1-induced neurological disease in 
Belgium six years ago, a morbidity of 42% was seen with 15% of the horses showing 
neurological disorders. Ataxia and paralysis were observed, but also cerebral disorders 
such as blindness, torticollis and severe apathy were seen (van der Meulen et al., 2003). 
Cerebral disorders were not observed during this recent outbreak, but interestingly, this 
outbreak was characterized by the rapid onset of ataxia and paralysis immediately after 
the disappearance of fever. In addition, the incidence of neurological signs in the EHV1-
affected horses was much higher in the current outbreak (43%) compared to the outbreak 
in 2003 (15%) (van der Meulen et al., 2003). These observations might possibly point 
towards a change in neurovirulent potential of naturally circulating EHV1 strains. 
In summary, concern has been voiced within the U.S. horse industry that the 
neurologic form of EHV1 might be emerging, based on an increased number of EHM 
outbreaks with a larger number of seriously affected horses throughout the United States 
over the last decade (USDA, 2007). Until now, no such evolution was seen in Belgium 
and no reports of EHM outbreaks have been reported with the exception of one limited 
outbreak in 2003. The present report describes a recent large outbreak of EHV1 with a 
rapid spread and a remarkably high number of animals suffering of EHM. Together with 
the fact that also in 2010 two small outbreaks were reported, the question raises whether 
the neurological form of EHV1 is also emerging in Belgium and hence Europe. However, 
it is not clear if these observations are related to an evolving disease with a changed 
virulence and behaviour or if they are the consequence of a greater awareness and the 
development of better diagnostic methods (USDA, 2007). Many data gaps exist, and more 
investigations need to be conducted to better understand this evolving situation and to 
identify other possible factors playing a role. Therefore, a good surveillance system in 
Belgium and Europe would be of great importance to monitor outbreaks of EHM, to gain 
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better insights into the virulence of naturally circulating EHV1 strains and to determine if 
EHM is in fact an emerging disease.  
 
Acknowledgements 
This research was supported by the Institute for the promotion of Innovation 
through Science and Technology in Flanders (IWT-Vlaanderen). The authors like to 
thank C. Boone for the help with the processing of all samples and Ine Vanherpe for 
performing PCR and sequencing. We would also like to thank the veterinarians Marc 
Schelkens, Jacques Corstiens, Wim Vermeiren, Dries Vermeiren, Kamiel Warnants, Jef 
Nuytten and all horse owners for providing samples and detailed information. 
 
 
 
 
 
 
 
 
 
Characteristics of a natural occurring outbreak of EHV1 
 
 122 
REFERENCES 
 
Allen, G. P. & Bryans, J. T. (1986). Molecular epizootiology, pathogenesis, and 
prophylaxis of equine herpesvirus-1 infections. Prog Vet Microbiol Immunol 2, 
78-144. 
Edington, N., Bridges, C. G. & Patel, J. R. (1986). Endothelial cell infection and 
thrombosis in paralysis caused by equid herpesvirus-1: equine stroke. Arch Virol 
90, 111-124. 
Garré, B., Gryspeerdt, A., Croubels, S., De Backer, P. & Nauwynck, H. (2009). 
Evaluation of orally administered valacyclovir in experimentally EHV1-infected 
ponies. Vet Microbiol 135, 214-221. 
Garré, B., van der Meulen, K., Nugent, J., Neyts, J., Croubels, S., De Backer, P. & 
Nauwynck, H. (2007). In vitro susceptibility of six isolates of equine herpesvirus 
1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet. Vet 
Microbiol 122, 43-51. 
Gilkerson, J. R. & Barrett, E. J. (2008). Equine herpesvirus neurological disease. 
Equine Vet J 40, 102-103. 
Goehring, L. S., van Winden, S. C., van Maanen, C. & Sloet van Oldruitenborgh-
Oosterbaan, M. M. (2006). Equine herpesvirus type 1-associated 
myeloencephalopathy in The Netherlands: a four-year retrospective study (1999-
2003). J Vet Intern Med 20, 601-607. 
Goodman, L. B., Wagner, B., Flaminio, M. J., Sussman, K. H., Metzger, S. M., 
Holland, R. & Osterrieder, N. (2006). Comparison of the efficacy of inactivated 
combination and modified-live virus vaccines against challenge infection with 
neuropathogenic equine herpesvirus type 1 (EHV-1). Vaccine 24, 3636-3645. 
Gryspeerdt, A. C., Vandekerckhove, A. P., Garre, B., Barbe, F., Van de Walle, G. R. 
& Nauwynck, H. J. (2010). Differences in replication kinetics and cell tropism 
between neurovirulent and non-neurovirulent EHV1 strains during the acute phase 
of infection in horses. Vet Microbiol 142, 242-253. 
Jackson, T. A., Osburn, B. I., Cordy, D. R. & Kendrick, J. W. (1977). Equine 
herpesvirus 1 infection of horses: studies on the experimentally induced 
neurologic disease. Am J Vet Res 38, 709-719. 
Kydd, J. H., Smith, K. C., Hannant, D., Livesay, G. J. & Mumford, J. A. (1994a). 
Distribution of equid herpesvirus-1 (EHV-1) in respiratory tract associated 
lymphoid tissue: implications for cellular immunity. Equine Vet J 26, 470-473. 
Kydd, J. H., Smith, K. C., Hannant, D., Livesay, G. J. & Mumford, J. A. (1994b). 
Distribution of equid herpesvirus-1 (EHV-1) in the respiratory tract of ponies: 
implications for vaccination strategies. Equine Vet J 26, 466-469. 
Kydd, J. H., Townsend, H. G. & Hannant, D. (2006). The equine immune response to 
equine herpesvirus-1: the virus and its vaccines. Vet Immunol Immunopathol 111, 
15-30. 
Kydd, J. H., Wattrang, E. & Hannant, D. (2003). Pre-infection frequencies of equine 
herpesvirus-1 specific, cytotoxic T lymphocytes correlate with protection against 
abortion following experimental infection of pregnant mares. Vet Immunol 
Immunopathol 96, 207-217. 
Lunn, D. P., Davis-Pointer, N., Flaminio, M. J., Horohov, D. W., Osterrieder, K., 
Pusterla, N. & Townsend, H. G. (2009). Equine Herpesvirus-1 Consensus 
Statement. J Vet Intern Med 23, 450-461. 
Characteristics of a natural occurring outbreak of EHV1 
 
 123 
Maxwell, L. K., Bentz, B. G., Gilliam, L. L., Ritchey, J. W., Holbrook, T. C., 
McFarlane, D., Rezabek, G. B., MacAllister, C. G. & Allen, G. P. (2008). 
Efficacy of Valacyclovir Against Clinical Disease After EHV-1 Challenge in 
Aged Mares. Proceedings of the Annual Convention of the AAEP 54, 198-199. 
McCartan, C. G., Russell, M. M., Wood, J. L. & Mumford, J. A. (1995). Clinical, 
serological and virological characteristics of an outbreak of paresis and neonatal 
foal disease due to equine herpesvirus-1 on a stud farm. Vet Rec 136, 7-12. 
Nugent, J., Birch-Machin, I., Smith, K. C., Mumford, J. A., Swann, Z., Newton, J. 
R., Bowden, R. J., Allen, G. P. & Davis-Poynter, N. (2006). Analysis of equid 
herpesvirus 1 strain variation reveals a point mutation of the DNA polymerase 
strongly associated with neuropathogenic versus non-neuropathogenic disease 
outbreaks. J Virol 80, 4047-4060. 
USDA (2007). Equine herpesvirus myeloencephalopathy: A potentially emerging disease. 
Available at: http://wwwaphisusdagov/vs/nahss/equine/ehv. 
Van de Walle, G. R., Goupil, R., Wishon, C., Damiani, A., Perkins, G. A. & 
Osterrieder, N. (2009). A Single-Nucleotide Polymorphism in a Herpesvirus 
DNA Polymerase Is Sufficient to Cause Lethal Neurological disease. J Infect Dis 
200, 20-25. 
van der Meulen, K., Nauwynck, H. & Pensaert, M. (2000). Equine herpesvirus type 1 
abortion, neonatal foal death and nervous system disorders diagnosed in Belgium 
in 1999. Vlaams Diergenskund Tijds 69, 38-41. 
van der Meulen, K., Vercauteren, G., Nauwynck, H. & Pensaert, M. (2003). A local 
epidemic of equine herpesvirus 1-induced neurological disorders in Belgium. 
Vlaams Diergenskund Tijds 72, 366-372. 
van der Meulen, K. M., Gryspeerdt, A. C., Vandekerckhove, A. A., Garre, B. A. & 
Nauwynck, H. J. (2007). The protective properties of vaccination against equine 
herpesvirus 1-induced viremia, abortion and nervous system disorders. Vlaams 
Diergenskund Tijds 76, 186-194. 
van Maanen, C., Sloet van Oldruitenborgh-Oosterbaan, M. M., Damen, E. A. & 
Derksen, A. G. (2001). Neurological disease associated with EHV-1-infection in 
a riding school: clinical and virological characteristics. Equine Vet J 33, 191-196. 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
General discussion 
 
 125 
 
 
 
 
 
CHAPTER VI 
 
GENERAL DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General discussion 
 
 127 
 
GENERAL DISCUSSION 
 
Equine herpesvirus 1 (EHV1) is a ubiquitous equine alphaherpesvirus. After 
replication in tissues of the upper respiratory tract (URT), EHV1 spreads via a leukocyte-
associated viremia to internal organs such as the pregnant uterus and the nervous system 
where a second replication cycle is initiated in the endothelial cells of these organs. The 
viral replication can lead to upper respiratory tract disease, abortion or neonatal foal death 
and equine herpes myelitis (EHM) (Allen & Bryans, 1986; van Maanen, 2002). In 
veterinary medicine, vaccination is the most designated weapon against viral infections. 
Several vaccines attempting to prevent severe consequences of infection with EHV1 are 
currently on the market. Unfortunately, to date, none of these is able to fully prevent the 
EHV1-induced severe secondary symptoms (van der Meulen et al., 2007). Therefore, 
effective antiviral medicines could be of great importance to limit virus replication and 
clinical signs during acute and recurrent viral infections. To date, no antiviral drugs are 
registrated for the use in horses, neither are they efficient enough to battle EHV1 
infections. One of the major problems in developing efficient vaccines or antiviral drugs 
is that the pathogenesis and immune evasion strategies of EHV1 are not fully known, 
which necessitates further research on this matter.  
 
In vivo experiments are a necessary tool to study the pathogenesis of specific 
pathogens in animals. However, in the case of horses, such experiments are expensive, 
labour-intensive and are often a sensitive matter from an ethical point of view. Therefore, 
attempts have been made to find appropriate models to replace those horse experiments. 
Laboratory animals may be convenient and valuable tools for use in experimental systems 
of disease in large animals. However, they are often criticized because of their failure to 
provide relevance to the disease in the target species. The most frequently used in vivo 
model for the assessment of virological and histological characteristics of EHV1-induced 
disease in horses has been the murine model. The extent to which valid comparisons and 
extrapolations about pathogenesis can be made from mouse to horse remains highly 
questionable (Walker et al., 1999). For example, the EHV1 strain RacL11 causes only 
mild disease in horses (Van de Walle et al., personal communication), while in mice, 
inoculation with RacL11 results in severe symptoms and even death (von Einem et al., 
2007). Even though the mouse model is suggested to provide a valid method for 
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investigation into several aspects of EHV1-induced disease (Walker et al., 1999), 
investigating the pathogenesis of EHV1 in its natural host, the horse, remains inevitable. 
Therefore, EHV1 pathogenesis studies in the horse were performed in this thesis, which 
provides relevant and unambiguous new insights. It was found that EHV1 replicates in a 
plaquewise manner in the epithelium of the upper respiratory tract. Plaques were not able 
to penetrate the basement membrane, but individual infected cells could be found in the 
connective tissue from 1 dpi. These cells were mainly CD172a+ cells and CD5+ 
lymphocytes. Viremia was detected from 1 dpi, with again CD172a+ cells as main carrier 
cells. Infected epithelial cells and mucosal leukocytes were examined more thoroughly 
and expression of viral late glycoproteins gB, gC, gD and gM was evaluated. It was found 
that although a complete replication cycle with formation of plaques was seen in 
epithelial cells, individual infected cells showed a low expression of late glycoproteins gC 
and gD. The latter indicates that the protein expression in EHV1-infected immune cells is 
hampered. Interestingly, the results obtained in this thesis were virtually identical as the 
results obtained in the recently established in vitro model of equine nasal mucosa 
(Vandekerckhove et al., 2010). Therefore, the latter model could be a valuable tool for the 
study of EHV1 pathogenesis in vitro. 
Based on the observations above, several new insights in the pathogenesis of EHV1 
were obtained and some missing links were elucidated. Therefore, an improved model on 
the pathogenesis of EHV1 in the upper respiratory tract is put forward in this thesis 
(Figure 1). Upon infection, EHV1 replicates in epithelial cells of the nasal septum and 
nasopharynx, which results in a productive infection with plaque formation and nasal 
virus shedding (2). This nasal shedding allows transmission of virus to susceptible contact 
animals and ensures that EHV1 can persist in the equine population. This productive 
infection in epithelial cells, however, is self-limiting, most likely due to IFN-α 
production. In addition, EHV1 seems to cross the basement membrane through the help of 
CD172a+ carrier cells, probably mucosal dendritic cells (3). We postulate that these 
infected carrier cells can transport the virus across the basement membranes and through 
connective tissues in the direction of vascular endothelial cells (4a) on the one hand and 
lymphatic epithelium (4b) on the other hand. As a result, a cell-associated viremia is 
originated (5), together with migration of infected immune cells to local lymph nodes, 
hereby initiating the start of a specific immune response. During viremia, also CD172a+ 
cells were the main carrier cells, suggesting that these cells indeed originate during the 
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early stages of infection in the upper respiratory tract. Although epithelial cells undergo a 
complete replication cycle with the progeny of new infectious virus particles, infected 
leukocytes seem to have a hampered expression of some late proteins. The same 
observation has been previously demonstrated, as it was seen that during viremia, 98% of 
EHV1-infected PBMC present in the blood stream lacked expression of certain late 
proteins (van der Meulen et al., 2003b). When we combine the latter results with our 
findings, we can conclude that infected leukocytes in the upper respiratory tract could be 
the source of the cell-associated viremia. These cells undergo an incomplete replication 
cycle even in the early steps of pathogenesis, which might be a mechanism to protect 
these cells from destruction by the immune system. Interestingly, the latter could explain 
why despite high antibody levels, viremia is still observed in immune animals. Transfer of 
EHV1 from viremic cells to endothelial cells of target organs (6) causes infection, 
followed by replication of EHV1 and subsequent damage to these organs (7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Adapted schematic overview of the pathogenesis of EHV1. 1) Attachment/penetration of virus in 
epithelial cells of the upper respiratory tract; 2) replication of virus in epithelial cells by means of plaque 
formation; 3) spread of virus through the BM by means of individual infected leukocytes; 4) spread of 
infected leukocytes to vascular endothelial cells (4a) and draining lymph nodes (4b); 5) leukocyte 
associated viremia in CD172a+ carrier cells; 6) transfer of virus from infected leukocytes to endothelial cells 
of target organs; 7) replication and spread of virus in target organs. Full arrow: known mechanism; striped 
arrow: unknown mechanism. 
1
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New insights in the pathogenesis and the natural occurrence of EHV1, may provide 
new directions in the amelioration of vaccines and the development of new drugs for 
treatment. Indeed, at present, the two most important tools in the battle against EHV1 are 
vaccination and antiviral therapy.  
An efficient vaccine against EHV1 is of great importance to control outbreaks of 
EHV1 and prevent the development of serious problems such as abortion and nervous 
system disorders. Firstly, during this research, we have observed that the first steps in the 
pathogenesis of EHV1 occur very rapidly. During primary replication in tissues of the 
upper respiratory tract, single infected cells are already seen at 1 day pi (dpi) and plaque 
formation was seen from 2 dpi. Already after 1 or 2 dpi, single infected cells were present 
beneath the basement membrane and viremia could be detected. The latter implies that 
vaccines can only prevent viremia and subsequent spread to internal organs if an effective 
local immunity can be established at the level of the upper respiratory tract, preventing 
the origin of individual infected cells beneath the basement membrane and the subsequent 
viremia. Because horses have been shown to be protected against viremia up to 6 months 
after a natural infection with EHV1 (Breathnach et al., 2001; Edington & Bridges, 1990), 
local immunity can prevent viremia at least for some time. This makes a modified life 
vaccine (MLV) a good candidate in vaccine development and a suitable recombinant 
EHV1 MLV could be a virus which is able to replicate in the epithelium of the upper 
respiratory tract but unable to penetrate the basement membrane by the use of individual 
infected cells. As it has been shown that the mucosal nasal explant model is an accurate 
alternative for in vivo testing, this model can be used to rapidly screen several potential 
MLV candidates before starting expensive and labour-intensive in vivo experiments 
(Vandekerckhove et al., 2009; Vandekerckhove et al., 2010). Hereby, suitable 
recombinant viruses could be selected for the use in in vivo experiments based on their 
inability to penetrate the basement membrane by using individual infected immune cells. 
Secondly, during viremia, carrier cells of EHV1 are present in a blocked stage as certain 
late glycoproteins are not expressed (van der Meulen et al., 2006). In fact, we could 
demonstrate that this immune evasion strategy already took place in the early stages of 
infection, as soon as individual infected cells appeared in the connective tissues following 
penetration of the basement membrane (Gryspeerdt et al., 2011). Such immune evasion 
strategy could supposedly protect them against antibody-dependent destruction, 
suggesting that humoral antibodies are of no use during this phase of infection (van der 
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Meulen et al., 2003b). However, a humoral protection could be of importance in the last 
step of the pathogenesis, when virus is transferred from its carrier cells to the endothelium 
of the target organs. Here, antibodies can play a role in either (i) preventing virus to be 
transmitted from carrier cells to endothelial cells, or (ii) limiting the extent of plaque 
formation in target organs. Unfortunately, a recent study demonstrated that virus could be 
transferred in vitro to endothelial cells despite the presence of neutralizing antibodies 
(Goehring et al., 2010), meaning that humoral immunity will probably be of limited use 
in this step of the pathogenesis. However, antibodies may still play an important role in 
limiting replication in target organs and thus limiting the damage and the occurrence of 
severe symptoms. The latter could be of interest for future research, where the effect of 
neutralizing antibodies on plaque formation and virus spread in endothelial cells of target 
organs should be evaluated. 
A thorough knowledge on the pathogenesis of the virus is of paramount importance 
for the development of antivirals. Based on the results of this thesis, we are now able to 
predict where an antiviral could exert its action. When we look at the rapid invasion of 
EHV1 into the connective tissue, combined with the fact that carrier cells are already in a 
blocked stage during early pathogenesis, there are only three places where antivirals could 
have an effect on the replication of EHV1 in the horse: (i) the entry and primary 
replication of the virus in the mucosa of the URT, (ii) the transmission of virus from 
infected PBMC to endothelial cells, and (iii) the secondary replication of the virus in 
endothelial cells at the target organs. To have a rapid effect on the primary replication in 
the epithelium of the URT, an antiviral with a metaphylactic use, applied locally in the 
nose to protect horses from getting a productive infection, would be the most suitable. An 
antiviral with an effect on the amount and duration of viremia will be difficult since 
during viremia the infected leukocyte seems to be blocked, which limits the possible 
targets of antivirals (van der Meulen et al., 2003b). Due to the rapid course of an EHV1 
infection, most animals during an outbreak will already be in a late stage of infection, 
namely the secondary replication in endothelial cells of the target organs, before a therapy 
can be initiated. An antiviral which either inhibits and/or limits the extent of this 
secondary replication seems to have great potential in limiting damage at secondary target 
organs and therefore severe symptoms. However, until now, the latter is difficult to 
evaluate since there is no appropriate in vitro or in vivo model to study the possible effect 
of an antiviral at secondary replication sites. Given the fact that after oral valacyclovir 
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treatment no influence on nasal shedding or viremia was observed (Garré et al., 2009), 
but that a clinical effect and a more rapid recovery is suspected (Maxwell et al., 2008), it 
seems that an effect of valacyclovir on the secondary replication of EHV1 cannot be 
excluded. Interestingly, during the outbreak of neurological disease studied in this thesis, 
a rapid spread of the virus was seen followed by a rapid appearance of neurological 
disorders. Some horses did not show previous signs such as nasal discharge, fever or 
ataxia and were merely found paralyzed, necessitating euthanasia. As treatment should 
preferentially be initiated before severe symptoms such as paralysis become apparent 
(Maxwell et al., 2008), any antiviral treatment would have been initiated too late in the 
course of disease. As there is no way to predict in which stage of infection the horse is 
during a natural outbreak of EHV1, an efficient antiviral drug should have both a 
metaphylactic and a curative action. The best way to achieve this goal would be a local 
treatment via aerosol, to prevent primary replication in tissues of the upper respiratory 
tract. Horses with (severe) symptoms however, should be treated in a way to prevent or 
inhibit further extension of endothelial damage and should be treated orally or 
intravenously with a curative antiviral drug. Future research should be focussed on how 
EHV1 penetrates through the basement membrane and gets into the blood stream. Also 
the mechanism of transmission of the virus from infected PBMC to endothelial cells 
should be studied. These are two phenomena where future antivirals could possibly 
interfere with the pathogenesis of the virus, hereby limiting severe consequences after 
infection with EHV1. 
 
In 2009, several outbreaks of abortion and neonatal death were seen during the first 
period of the year. Exceptionally, a large outbreak of EHV1-induced neurological disease 
was seen in Antwerp. Concern has been voiced within the U.S. horse industry that the 
neurologic form of EHV1 is emerging. The latter is based on the detection of an increased 
number of EHM outbreaks throughout the United States over the last decade (USDA, 
2007). Until now, no such evolution was seen in Belgium and no reports of large EHM 
outbreaks have been observed with the exception of one limited outbreak in 2003 (van der 
Meulen et al., 2003a). The recent large outbreak of EHM showed a rapid spread and a 
remarkably high number of animals with severe neurological symptoms. The latter, 
together with the report of two novel outbreaks in 2010, raises the question whether the 
neurological form of EHV1 is also emerging in Belgium, and hence, Europe. In 2009, one 
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outbreak of EHM was reported in the UK, one in France and three in Ireland. In 2010, 
five outbreaks were reported in France, two in the UK and one in Italy. Until now, three 
outbreaks of EHM have been reported in France in 2011. Unfortunately, most European 
countries do not report outbreaks of EHM, providing insufficient data to decide if EHM is 
possibly emerging in Europe. Additionally, it is not clear if the reported observations are 
related to an evolving disease with a changed virulence and behaviour or if they are the 
consequence of a greater awareness and the development of better diagnostic methods 
(USDA, 2007). Many data gaps exist, and more investigations need to be conducted to 
better understand this evolving situation and to identify other possible factors playing a 
role. Therefore, a good surveillance system in Belgium and Europe would be of great 
importance to monitor outbreaks of EHM and to get better insights into the virulence of 
naturally circulating EHV1 strains. An efficient communication system and a centralized 
diagnostic centre would be of paramount importance to achieve this goal. Diagnostical 
methods should be quick and efficient to have a rapid diagnosis during suspected 
outbreaks of EHV1 (Lunn et al., 2009). Although virus isolation proved to be a reliable 
method to confirm infection within two days, PCR techniques could be of importance as 
results can be achieved within a few hours and information could be given about the 
neurovirulence of the isolated EHV1 strain and the quantity of virus present (Allen, 2007; 
Pusterla et al., 2008; Pusterla et al., 2009b). 
Worldwide, several guidelines are available of what needs to be done during an 
outbreak of EHV1. These guidelines vary widely both within and between countries. A 
protocol on how to manage an EHV1 outbreak, from being prepared to collect samples 
appropriately and how to contain the situation would be of great importance (USDA, 
2007). Some guidelines found in literature, formed the basis of our approach during the 
outbreak of EHM and were checked for their efficiency (Allen, 2002; Lunn et al., 2009; 
Pusterla et al., 2009a). Based on our observations, we would like to discuss some of these 
guidelines. 
In the case of a suspected outbreak of EHV1, immediate measures should be taken to 
prevent any possible spread of the virus within the affected premise or to other premises 
(Lunn et al., 2009). Affected horses should be put in isolation and contact with other 
horses or care takers should be completely avoided. Other horses should be monitored for 
the appearance of fever or other symptoms suggesting an early infection (van Maanen, 
2002). If possible, all horse movement in affected regions should be avoided until three 
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weeks after the last reported case. During the outbreak of EHM in Antwerp, isolation and 
quarantine measures proved to be of great importance to prevent further spread of the 
virus. Suspected premises were closed until EHV1 infection was either confirmed or 
excluded. Quarantine measures in confirmed premises were only lifted three weeks after 
the last observed clinical case. Major horse events were cancelled and all horse 
movements in affected regions were discouraged. 
An early and accurate diagnosis of the cause of the observed symptoms, with virus 
culture and isolation as the gold standard test, is of paramount importance to further 
determine the strategies to be followed in managing the outbreak (Lunn et al., 2009). 
Several samples were collected during the outbreak: unclotted blood samples for isolation 
of PBMC, nasal swabs and paired serum samples. Isolation of EHV1 by means of 
cocultivation of PBMC proved to be an important and efficient diagnostic tool. Within 
two days, virus could be isolated from affected horses with fever, ataxia or paralysis. 
Although nasal swabbing could be a good alternative in an even earlier stage of infection, 
during this outbreak, no virus could be isolated from collected swabs. An explanation for 
this observation could be inappropriate conservation techniques or the long transport 
period under non-ideal circumstances. A seroconversion could be noticed in almost all 
infected horses, but such methodology takes about 4 weeks before the final results are 
known. Therefore, the best samples to collect in an acute stage of infection, at least in our 
hands, seemed to be unclotted blood samples. All samples should be immediately put at 
4°C and sent as soon as possible to the laboratory.  
EHV1 infections in horses are very difficult to treat. The virus has a peculiar 
pathogenesis which makes it hard to interfere. Until now, no antivirals have been licensed 
in Belgium for the use in horses, limiting treatment to intensive supportive therapy only 
(van Maanen, 2002), along with supportive antibiotics and anti-inflammatory drugs. 
During several naturally occurring outbreaks of EHV1-induced neurological disease, 
attempts were made to prevent infection or treat horses with severe symptoms using 
antiviral drugs (Friday et al., 2000; Henninger et al., 2007; van der Meulen et al., 2003a). 
Acyclovir and its prodrug valacyclovir are the most popular drugs in this matter. During 
the outbreak in Antwerp, a limited number of animals were treated orally with 
valacyclovir. Treated horses received an oral dose of valacyclovir of 40 mg/kg body 
weight, three times a day. This treatment was initiated as soon as possible. Preferentially a 
treatment should be started before paralysis occurs in order to stop this process. However, 
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evaluation of a drug in clinical cases will always remain difficult as animals are mostly 
not treated under identical conditions and EHV1-negative animals need to be present as 
controls to exclude any influence of the immune system. Despite these limitations, it was 
observed in this outbreak that valacyclovir-treated animals seemed to recover more 
rapidly from clinical symptoms during treatment than non-treated animals. Treatments 
with anti-inflammatory drugs and antibiotics to prevent secondary bacterial infections 
seemed to contribute to a better recovery. Finally, intensive care greatly improved the 
chance of recovery in the severely affected horses, emphasizing the benefit of such 
treatment. 
The development of a fully protective vaccine against EHV1 would be the most 
efficient way to eradicate EHV1-induced problems from the horse population. Until an 
efficient vaccine has been found, management procedures are still the most important 
measures to prevent or control an outbreak of EHV1 (Lunn et al., 2009; van Maanen, 
2002). During the present outbreak, vaccination of horses against EHV1 was highly 
recommended. Within an affected premise, horses without clinical symptoms were 
vaccinated. Further, owners of large premises and organisers of competitions were 
advised to prohibit contact between their horses and visiting horses, and to allow only 
horses on their premises which were vaccinated. To date, only inactivated vaccines are 
commercially available in Belgium. Although they can not completely prevent abortion or 
nervous system disorders, they seemed to protect horses partially from abortion or 
nervous system disorders during the outbreak of EHM. It was observed that morbidity 
rates during the outbreak of 2009 were the lowest on the first affected premise where a 
correct vaccination protocol was used. Moreover, and as far as we know, virus only 
spread to premises where horses were not vaccinated against EHV1, suggesting some 
clinical protection of vaccinated horses against severe symptoms (Henninger et al., 2007; 
Studdert et al., 2003).  
 
In conclusion, given the peculiar and rapid pathogenesis of EHV1, the development of 
a curative antiviral will be a very difficult task, as the points of action of such antiviral are 
rather limited. Therefore, the best way to protect horses from severe complications due to 
an EHV1 infection, is to prevent them from getting infected. This goal can be achieved in 
two ways: i) the development of a fully protective vaccine and/or ii) the development of 
an antiviral with a metaphylactic action to protect in-contact horses during the course of 
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an outbreak. Until further research is able to fulfil the above mentioned goals, 
management procedures are still very important measures. 
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SUMMARY 
 
Equine herpesvirus 1 (EHV1) is the most important infectious cause of abortion 
worldwide. Infection can also result in severe nervous system disorders with frequent 
fatal outcome. Horses are infected via the respiratory system. After local replication in the 
upper respiratory tract, virus spreads via a cell-associated viremia to the uterus and/or the 
nervous system. Replication in endothelial cells of these organs can result in abortion or 
nervous system disorders. Vaccination with current available vaccines against EHV1 can 
not offer full protection against these severe symptoms. Therefore there’s an urgent need 
for improvement of existing vaccines or the development of alternative strategies for 
prevention or treatment of EHV1 infections. However, the lack of knowledge about the 
invasion strategies of EHV1 is an important obstacle. A thorough knowledge about the 
pathogenesis of EHV1 is crucial for vaccine development or efficient therapy. 
 
In Chapter 1, an overview of the current knowledge of EHV1 was given. First a short 
overview of the common characteristics of EHV1 was given. Further, interactions of the 
virus with the cell and with the horse as host were reviewed. 
 
In Chapter 2, the aims of the studies described in the thesis are put forward. The first 
aim was to gain a more detailed insight in the invasion strategies of EHV1 strains from 
the upper respiratory tract until the origin of a cell-associated viremia. The second aim 
was to examine how individual EHV1-infected cells escape from immune effector 
mechanisms at the primary site of replication. The third and last aim was to gain more 
information about naturally occurring outbreaks in Belgium in terms of risk factors, 
protective properties of vaccination, the effect of experimental therapies and diagnosis. 
 
The first aim was addressed in Chapter 3. An experimental inoculation study in 
ponies was performed with both a neurovirulent and a non-neurovirulent strain. Two 
groups of six ponies were inoculated intranasally with either strain. Clinical signs, nasal 
shedding and viremia were evaluated. At early time points post inoculation, one pony of 
each group was euthanized. Tissues were collected for titration and immunostainings. 
Number and size of EHV1-induced plaques were calculated, and individual EHV1-
infected cells were quantified and characterized. Inoculation with either strain resulted in 
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nasal shedding and replication in several tissues of the upper respiratory tract. Both 
strains replicated in a plaquewise manner in epithelium of the nasal mucosa, but 
replication in epithelium of the nasopharynx was largely limited to non-neurovirulent 
EHV1. Plaques were never able to cross the basement membrane, but individual infected 
cells were noticed in the connective tissue of all examined tissues for both strains. The 
total number of these cells however, was 3-7 times lower with non-neurovirulent EHV1 
compared to neurovirulent EHV1. CD172a+ cells and CD5+ lymphocytes were important 
target cells for both strains. Interestingly, in lymph nodes, B-lymphocytes were also 
important target cells for EHV1, irrespective of the strain. Viremia was detected very 
early post inoculation and carrier cells were mainly CD172a+ for both strains. 
 
 The second aim was addressed in Chapter 4. Since both epithelial and mononucleair 
cells appeared to be crucial cell types during the pathogenesis of EHV1, we studied if 
EHV1 uses immuno-evasive techniques in these cell types during the early stages of 
pathogenesis. Therefore, the expression of viral late proteins gB, gC, gD and gM in these 
target cells was studied in different experimental models. Firstly, RK13 cells and 
peripheral blood mononuclear cells were infected with EHV1 in vitro. Secondly, the 
recently established equine nasal mucosal explant system was used and thirdly, nasal 
mucosal tissues of experimentally EHV1-infected ponies were analyzed. Our salient 
findings were that for all three systems tested, the late proteins gB, gC, gD and gM were 
expressed on EHV1-infected epithelial cells. On the contrary, gB and gM expression was 
observed in 60 to 90% of infected mononuclear cells, whereas expression of gC and gD 
on these cells was hampered, because only 20% of EHV1-infeced mononuclear cells 
showed gC and gD expression. These results indicate that the expression of certain viral 
proteins depends upon the cell type infected and that a hampered expression could be a 
mean of EHV1 to stay invisible for the immune system during the early pathogenesis of 
EHV1. 
 
The third aim was addressed in Chapter 5. To gain more information about EHV1 
problematics in Belgium, a recent outbreak of EHV1-induced neurologic disease in 
Flanders which involved at least 13 premises, was both clinically as genetic analyzed. A 
total of 212 horses was exposed to EHV1 and a morbidity of 26% was seen. The 
incidence of neurological disorders in the affected horses was 43%. Furthermore, the 
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outbreak was characterized by the rapid occurrence of ataxia and paralysis immediately 
after disappearance of fever. Morbidity and virus spread was remarkably higher at 
premises were no or an incorrect vaccination schedule was used. Mares seemed to be 
more sensible for the development of nervous system disorders with fatal outcome. A 
positive influence of valacyclovir treatment during the course of disease was seen if 
treatment was initiated immediately after appearance of nervous system disorders. EHV1 
was diagnosed in each case by means of virus isolation and/or the detection of 
seroconversion. Isolated virus was classified as neurovirulent EHV1, with al isolates 
belonging to group 4 upon sequencing in the ORF30 and ORF68 region. The latter 
confirms the suspicion of the outbreak spreading from the first premise.  
 
Following general conclusions can be made from the studies performed in the 
present thesis: 
 
1. EHV1 has a rapid course after infection and replicates in the epithelium of the 
upper respiratory tract in a plaquewise manner. These plaques do not penetrate the 
basement membrane, but individual infected cells can be observed in the 
connective tissue. These cells are mainly CD172a+ cells and CD5+ lymphocytes. 
At the time point of appearance of these individual infected cells, a cell-associated 
viremia could be noticed, harbouring the virus mainly in CD172a+ cells. 
2. In the beginning of infection individual infected cells are already in a blocked 
stage, allowing them to elope the immune system. Contrary to infected epithelial 
cells who expressed al tested glycoproteins, individual infected cells only express 
gC and gD in only 20% of the cases. 
3. As observed in America, equine herpes myelitis caused by infection with EHV1 
seems to be emerging in Belgium. After the large outbreak in 2009, also in 2010 
two small outbreaks of EHM were observed, showing a larger number of horses 
with nervous system disorders and a fast spread of the virus. Again, this points out 
the necessity of a thorough research into the pathogenesis of EHV1, in order to 
develop efficient vaccines and antiviral therapy. Vaccinated horses seem to have a 
certain clinical protection against the appearance of severe symptoms. Diagnosis 
is possible by means of virus isolation and seroconversion. If treatment with 
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valacyclovir is started at an early time point in infection, horses seem to have a 
quicker and more complete recovery. 
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SAMENVATTING 
 
Infectie met het equiene herpesvirus 1 (EHV1) is wereldwijd de belangrijkste 
infectieuze oorzaak van abortus bij paarden. Infectie kan ook resulteren in ernstige 
zenuwstoornissen met veelal fatale afloop. Paarden worden geïnfecteerd via het 
ademhalingsstelsel. Na lokale vermeerdering in de bovenste luchtwegen verspreidt het 
virus zich via een celgeassocieerde viremie naar baarmoeder en/of zenuwstelsel. Daar kan 
vermeerdering van EHV1 ter hoogte van endotheelcellen resulteren in abortus of 
zenuwstoornissen. Vaccinatie met de huidig beschikbare vaccins tegen EHV1 kan geen 
volledige bescherming bieden tegen deze ernstige symptomen. Er is dus nood aan 
verbetering van vaccins of en het ontwikkelen van alternatieve strategieën voor preventie 
of behandeling van EHV1 infecties. Een belangrijke hinderpaal hierbij is het gebrek aan 
kennis over de invasie van EHV1. Een grondige kennis van de pathogenese van EHV1 is 
onontbeerlijk voor de ontwikkeling van efficiënte vaccins of een doelgerichte therapie.  
 
In Hoofdstuk 1 werd een overzicht gegeven van de huidige kennis over EHV1. Eerst 
werd een beknopte uitleg gegeven over de algemene eigenschappen van het virus. 
Vervolgens werden de interacties van het virus met de cel en met het paard als gastheer 
besproken. 
 
In Hoofdstuk 2 werden de doelstellingen van de verschillende studies uiteengezet. De 
eerste doelstelling bestond erin om een meer gedetailleerd inzicht te verkrijgen in de 
invasie van EHV1 stammen van de bovenste ademhalingswegen tot aan de 
celgeassocieerde viremie. De tweede doelstelling was na te gaan hoe individuele EHV1-
geïnfecteerde cellen er in slagen te ontsnappen aan de immuun effector mechanismen op 
de plaats van primaire vermeerdering. De derde en laatste doelstelling was om het verloop 
van natuurlijke infecties met EHV1 beter in kaart te brengen wat betreft risicofactoren, 
mogelijke bescherming door middel van vaccinatie, het effect van experimentele 
therapieën en diagnostische middelen. 
 
In Hoofdstuk 3 kwam de eerste doelstelling aan bod. Een experimentele inoculatie 
met zowel een neurovirulente als een niet-neurovirulente stam van EHV1 werd 
uitgevoerd bij pony’s. Twee groepen van 6 pony’s werden intranasaal geïnoculeerd met 
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één van beide stammen. Klinische tekenen, uitscheiding via de neus en viremie werden 
geëvalueerd. Tijdens de eerste dagen na infectie werd telkens 1 pony van elke groep 
geëuthanaseerd. Er werden weefsels verzameld voor titratie en immunofluorescentie 
kleuringen. Het aantal en de grootte van EHV1-geïnduceerde plaques werd bepaald en 
EHV1-geïnfecteerde individuele cellen werden gekwantificeerd en gekarakteriseerd. 
Inoculatie met elke stam resulteerde in virusuitscheiding via de neus en een replicatie in 
verschillende weefsels van de bovenste ademhalingswegen. Beide stammen 
vermeerderden door middel van plaque formatie in de mucosa van de neus, maar 
replicatie in het epitheel van de nasopharynx was grotendeels gelimiteerd tot niet-
neurovirulent virus. Plaques doorbraken op geen enkel moment de basaalmembraan, maar 
voor beide stammen werden individueel geïnfecteerde cellen gevonden in het 
bindweefsel. Het aantal individuele cellen was echter 3-7 maal lager voor niet-
neurovirulent EHV1 vergeleken met neurovirulent EHV1. CD172a+ cellen en CD5+ 
lymfocyten waren de belangrijkste doelwitcellen voor beide stammen. In lymfeknopen 
bleken B-lymfocyten ook belangrijke dragercellen te zijn voor EHV1, onafhankelijk van 
welke stam gebruikt werd. Viremie werd reeds vroeg na infectie vastgesteld en de 
geïnfecteerde cellen bleken voor beide stammen vooral CD172a+ te zijn.  
 
In Hoofdstuk 4 kwam de tweede doelstelling aan bod. Gezien het feit dat zowel 
epitheliale als mononucleaire cellen cruciale celtypes bleken te zijn gedurende de 
pathogenese van EHV1, werd in dit hoofdstuk nagegaan of EHV1 in deze cellen reeds 
vroeg in de pathogenese gebruik maakt van immuno-evasieve technieken. Daarom werd 
de expressie van de late virale proteïnen gB, gC, gD en gM in deze doelwitcellen 
nagegaan in verschillende experimentele modellen. Ten eerste werden RK13 cellen en 
perifere bloed mononucleaire cellen in vitro geïnfecteerd met EHV1. Ten tweede werd 
het onlangs gerealiseerde equiene nasale explant systeem gebruikt. Ten derde werd de 
expressie nagegaan in nasale mucosa van experimenteel geïnfecteerde pony’s. In elk van 
de drie geteste systemen bleken de late eiwitten gB, gC, gD en gM volledig tot expressie 
te komen in EHV1-geïnfecteerde epitheliale cellen. Dit was in tegenstelling tot 
mononucleaire cellen, waar gB en gM expressie werd gezien bij 60 tot 90% van de 
geïnfecteerde cellen, terwijl gC en gD expressie enkel werd gezien bij 20% van de 
geïnfecteerde cellen. De expressie van bepaalde virale proteïnen lijkt dus afhankelijk te 
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zijn van het celtype dat geïnfecteerd wordt en het lijkt er op dat EHV1 op deze manier 
kan verborgen blijven voor het immuun systeem in vroege stadia van infectie. 
In Hoofdstuk 5 kwam de derde doelstelling aan bod. Om meer informatie te 
verkrijgen over de EHV1 problematiek in België, werd een recente uitbraak van EHV1-
geïnduceerde neurologische stoornissen in Vlaanderen, waarbij minstens 13 bedrijven 
werden getroffen, zowel klinisch als genetisch grondig onderzocht. In totaal werden 212 
paarden blootgesteld aan EHV1 en werd een morbiditeit van 26% gezien. De incidentie 
van neurologische stoornissen bij aangetaste paarden bedroeg 43%. Verder werd deze 
uitbraak gekarakteriseerd door het snelle optreden van ataxie en paralyse na een korte 
periode van koorts. De morbiditeit en spreiding van het virus was merkelijk hoger op 
bedrijven waar niet of niet correct werd gevaccineerd. Merries leken gevoeliger voor het 
ontwikkelen van zenuwstoornissen met fatale afloop. Indien onmiddellijk na het 
verschijnen van zenuwstoornissen gestart werd met een valacyclovir behandeling, werd 
een positief effect gezien op het ziekteverloop. Diagnose was in alle gevallen mogelijk 
door ofwel virusisolatie uit perifere bloed mononucleaire cellen ofwel bepaling van 
seroconversie bij gepaarde serum stalen. Het geïsoleerde virus werd geclassificeerd als 
neuropathogeen, behorende tot groep 4 na sequenering in de ORF30 en ORF68 regio. Dit 
laatste bevestigt het vermoeden dat de uitbraak verspreid werd vanuit het eerste 
aangetaste bedrijf. 
 
Op basis van de studies uitgevoerd in deze thesis kunnen de volgende algemene 
conclusies naar voor gebracht worden: 
 
1. EHV1 kent een snel verloop na infectie en vermeerdert in het epitheel van de 
bovenste ademhalingswegen door middel van plaque formatie. Deze plaques zijn 
niet in staat om de basaalmembraan te doorbreken, maar individueel geïnfecteerde 
cellen kunnen worden teruggevonden in het bindweefsel. Deze cellen zijn vooral 
CD172a+ cellen en CD5+ lymfocyten. Op het moment van het verschijnen van 
deze individueel geïnfecteerde cellen kon een celgeassocieerde viremie 
waargenomen worden, waarbij het virus zich vooral in CD172a+ cellen bevindt. 
2. Reeds in het begin van de infectie bevinden individueel geïnfecteerde cellen zich 
in een geblokkeerde staat, waarbij ze kunnen ontsnappen aan het immuun 
mechanisme. In tegenstelling tot geïnfecteerde epitheelcellen die alle geteste 
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glycoproteines tot expressie brachten, werden in de individueel geïnfecteerde 
leukocyten enkel in 20% van de gevallen gC en gD tot expressie gebracht. 
3. Naar analogie met gebeurtenissen in Amerika, lijkt ook in België equiene herpes 
myelitis door EHV1 in opmars. Na een grote uitbraak in 2009, waren er ook twee 
kleine uitbraken in 2010, waarbij het voorkomen van zenuwstoornissen in een 
groter percentage van de gevallen optrad en de spreiding sneller verliep. Dit 
benadrukt nogmaals het belang van grondig onderzoek naar de pathogenese van 
EHV1, voor gerichte vaccin- en therapie ontwikkeling. Gevaccineerde paarden 
lijken een bepaalde graad van klinische bescherming te bezitten tegenover het 
optreden van ernstige symptomen. Diagnose is mogelijk door middel van 
virusisolatie en seroconversie. Bij het tijdig starten van een behandeling met 
valacyclovir lijken paarden sneller en vollediger te herstellen. 
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DANKWOORD 
 
Na ettelijke jaren van hard werken, bloed, zweet, tranen, maar ook veel memorabele 
momenten, ligt het hier dan eindelijk: mijn doctoraat. Het is moeilijk te vatten wat een 
grote waarde dit kleine boekje heeft. Na al die jaren verdienen heel wat mensen een 
woord van dank en dat in het ongetwijfeld meest gelezen hoofdstuk van elk doctoraat… 
 
Eerst en vooral wil ik hier graag mijn promotoren danken. Hans, jou wil ik graag 
bedanken om me de kans te geven in jouw laboratorium te werken. Ik denk dat er weinig 
werkplaatsen zijn waar de sfeer tussen de werknemers zo goed zit. Ik denk ook dat er 
maar weinig manieren zijn om jou te beschrijven. Zelden heb ik zo een gedreven en 
hyper-enthousiaste wetenschapper meegemaakt. Je bent echt een uniek persoon! Ik hoop 
dat het labo virologie nog lang zo mag groeien en bloeien. Karen, jij was de persoon die 
me geïntroduceerd heeft in de wondere wereld van de rhinopneumonie. Met jouw hulp is 
de IWT-beurs binnengehaald en kon mijn onderzoek echt starten. Je hebt het werk niet 
kunnen afmaken, maar je hebt het startschot gegeven zodat ik op eigen benen kon staan. 
Mijn schrijfsels zijn nog steeds niet top, maar ik zal me altijd de verbeterde versies met 
kleurcodes herinneren die ik in het begin van jou terugkreeg. Gerlinde, jou ben ik heel 
veel dankbaarheid verschuldigd. We werden gewaarschuwd dat er een felle madam in 
aantocht was, die de tucht in onze paardengroep moest herstellen. Die felle madam bleek 
echter een heel aangename en gedreven onderzoeker te zijn, die er als eerste in slaagde 
om een artikel van mij gepubliceerd te krijgen. Honderden schrijfsels heb je verbeterd en 
hoewel ik nog steeds geen bestseller auteur kan genoemd worden, is er toch enige 
verbetering merkbaar. Verder stond je altijd voor me klaar toen het weer eens moeilijk 
ging met mijn doctoraat. Dankzij jouw motivering ligt dit boekje hier vandaag! En ik 
denk dat ik zeker mag zeggen dat je goed bezig bent, Professor Van de Walle! Ik ben er 
zeker van dat je een prachtig labo zal uitbouwen! Herman, ik wil je graag bedanken voor 
je geloof in mijn onderzoek en praktijkgerichte aanpak. Bedankt voor je luisterend oor 
tijdens moeilijke momenten en voor de aangename congressen wanneer je van de partij 
was! 
Ook de overige leden van de begeleidings- en examencommissie zou ik hartelijk 
willen bedanken voor de tijd die ze vrijgemaakt hebben en voor hun waardevolle en 
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opbouwende kritieken: Prof. dr. P. Deprez, Prof. dr. J. Kydd, dr. K. van Maanen, mevr. B. 
Caij, dr. K. van der Meulen, dr. J. Nuytten en dr. T. Picavet. 
Het agentschap voor Innovatie door Wetenschap en Technologie wil ik bedanken voor 
de financiële steun die het mogelijk heeft gemaakt om dit doctoraat tot een goed einde te 
brengen. 
 
Eerst wil ik even de moeite nemen om de fantastische laboranten en technische 
krachten van het labo te bedanken. Zij zijn het hart en ziel van de dienst en zorgen er 
dagelijks voor dat alles op wieltjes loopt, wat met al dat volk geen evidente taak kan 
genoemd worden. Chris, ondertussen ben je op pensioen, maar ik zal al het werk dat je 
voor mij gedaan hebt nooit vergeten. Je was de onbetwiste kampioen wat betreft het 
isoleren van paardenleukocyten! Bovendien was je een zeer aangename persoon en 
hebben we samen ook veel plezier gehad. Ik hoop dat je geniet van je pensioen! 
Vervolgens hebben we Lieve. Ondanks het feit dat we nooit echt rechtstreeks hebben 
samengewerkt, kan ik me nog goed herinneren dat je me in het begin ogenblikkelijk hebt 
duidelijk gemaakt dat het een slecht idee was om mijn voorraden slechts op de dag van 
mijn experiment te checken. Geregeld ben ik met rode kaken tot bij jou gekomen om te 
zeggen dat mijn medium weer eens op was of beschimmeld was. Ik heb dankzij je strenge 
aanpak echter zeer snel geleerd om me wat beter te organiseren, waarvoor dank! Chantal, 
jou moet ik bedanken voor het opgroeien van ontelbare virusstocks, want zonder virus 
geen experimenten! Vervolgens hebben we Carine. Wij hebben heel veel samengewerkt 
en het is altijd met het grootste plezier geweest. Je bent een zeer aangename en 
hardwerkende vrouw en niets was ooit te veel voor jou. Ik kan zelfs al niet meer tellen 
hoeveel weefsels je vakkundig getitreerd hebt. Het enthousiasme waarmee we de 
zoveelste diagnose verwerkten was legendarisch! En het plezier dat we hadden als we 
weer iets geïsoleerd hadden na veel problemen maakte het de moeite waard ☺. Ik hoop 
dat de diagnostiek even goed blijft draaien en ik hoop dat we daar in de toekomst nog veel 
contact over hebben. Nele en Melanie hebben me ook geregeld uit de brand geholpen. 
Nele door het biotinyleren van ontelbare antistoffen en Melanie met het ingeven van 
diagnose uitslagen en het inspringen als het praktische werk mij weer eens boven het 
hoofd groeide. Dries heeft de ondankbare taak gekregen om me af en toe moleculair te 
begeleiden. Helaas voor hem ben ik er zeker van dat ik op dat vlak vervloekt ben. 
Bedankt voor de moeite die je er toch telkens weer instak ondanks de hardnekkige 
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tegenvallende resultaten. Jan Van Doorsselaere wil ik bedanken voor alle sequeneringen 
die hij voor mij heeft uitgevoerd. Verder hebben we de technische krachten nog, waarvan 
vooral Geert een eervolle vermelding verdient. Je hebt me op hele vroege uren geholpen 
met de paardjes en zulke goede hulp heb ik nooit meer gehad. Ik hoop dat je gelukkig 
bent op je nieuwe werk! Fernand is ondertussen ook al aan zijn pensioen begonnen, maar 
heeft ook dikwijls zijn steentje bijgedragen bij diverse experimenten, waarvoor mijn 
dank! Bart en Zeger, jullie hebben de moeilijke taak gekregen dit duo op te volgen. Ik 
hoop dat jullie je draai vinden en genieten van jullie job! Marijke mag ook zeker niet 
vergeten worden, de persoon die als moeilijke taak heeft om het labo netjes te houden. 
Bedankt voor het onderhouden van mijn bureautje en de vele leuke gesprekken! Mieke, 
Ann, Gert en Louise, bedankt voor alle praktische dingen die jullie dag na dag moeten 
zien te regelen. Jullie zijn echt de duizendpoten van het labo! Dirk, bedankt voor het 
oplossen van vele computergerelateerde problemen, maar toch ben ik nog steeds heel erg 
blij met mijn PC’tje ☺. Mocht ik mij in de verre toekomst ooit eens een Mac aanschaffen, 
dan zal ik eens aan jou terug denken!  
 
En dan hebben we de collega’s. Er zijn er in die 6 jaar zoveel gekomen en gegaan dat 
ik echt hoop dat ik niemand vergeten ben!  
Ik ben mijn tijd op het labo gestart in de paardenbureau. Annelies, jij was mijn collega 
van het eerste uur, eerst als laatstejaars, vervolgens als Phd student. Ik herinner me vooral 
onze vreugdedans in het bureau van Hans toen we vernamen dat we beide onze IWT-
beurs gehaald hadden. Verder heb je me ontelbare keren geholpen met 
paardenexperimenten. Ik wil je bedanken voor alle leuke jaren. Ik hoop dat je als “the last 
one standing” de eer van de paardengroep hoog kunt houden en dat je het EHV onderzoek 
nieuw leven kan inblazen. Ik wens je een prachtig leven toe met je allerliefste Lieven en 
hoop dat jullie heel gelukkig worden samen! Filip had de ondankbare taak om als enige 
man ons bureautje te bevolken. Ik moet zeggen, ik ken niemand waarbij de spreuk “stille 
waters, diepe gronden” zo goed van toepassing was! Je kon je mannetje heel goed staan 
tussen al dat vrouwengeweld! Zelfs de Flair werd op de duur opgenomen in je 
literatuurlijst ☺. Hartelijk dank voor alle gezellige etentjes, gesprekjes en je hulp met de 
paardjes. Ik hoop dat we elkaar in de toekomst nog geregeld eens zien en ik wens je veel 
geluk toe met de bouw van je droomhuis! 
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Na vier jaar werd het tijd voor een nieuw onderkomen, wat werd gevonden in de 
beroemde “eerste bureau”. Sarah G., als ancien van deze bureau heb je de nieuwelingen 
hartelijk ontvangen! Ik wil je bedanken voor de talloze gezellige etentjes en het 
onvergetelijke congres dat we samen in Portugal hebben mogen meemaken. Ik hoop dat 
alles vlot loopt met je onderzoek en dat je heel gelukkig mag worden met je toekomstige 
man! Amy, you arrived a bit later, but you are really the sweetest girl in the office! I am 
really glad that your husband finally arrived in Belgium and I hope you will enjoy your 
time here in Belgium. I want to thank you for all the nice Chinese gifts I received from 
you and I wish you all the best with your research! Hossein, you got the very difficult task 
to find our well-hidden equine dendritic cells. I hope you will find them eventually! Keep 
practising with your bike and then you will avoid becoming as fat as I once was ☺. 
Sabrina! You are the most energetic person I ever met! It is really a delight to have such 
person in the office! With you, nothing will ever be boring! I hope you will succeed in 
your Phd, you really deserve it after all the work you’ve put in to it. Enjoy your beautiful 
daughter and always remain your cheerful self! Mieke, jij bent stiekem binnengeglipt toen 
ik op zwangerschapsverlof was, maar ik heb de indruk dat je je plaatsje al goed veroverd 
hebt! Ik wens je veel geluk toe in je onderzoek! Lennert, tja, er zijn zoveel woorden 
waarmee jij beschreven kunt worden, maar saai is er in elk geval niet één van! Je brengt 
altijd plezier in het bureau en bent altijd in voor een grapje. Ik ben blij dat er nog een 
echte veearts in het labo aanwezig is! Veel succes in Amerika en ik ben zeker dat jij er op 
professioneel vlak wel zal geraken!  
Verder heb ik nog een heel tijdelijk onderkomen gevonden in mijn oude bureau 
tijdens het “pimpen” van ons nieuw bureau (kunnen jullie nog volgen?), waar ik hartelijk 
werd ontvangen door Sjouke en Annebel. Bedankt voor alle leuke en serieuze gesprekken 
en Sjouke, bedankt voor de hulp met het streepje aan de bovenkant van mijn pagina’s! Je 
bent een ferme madam en je zal er zeker komen in het leven! 
Marc, jij verdient ook zeker een eervolle vermelding! Met jou is er altijd tijd voor 
plezier en dat al sinds ons eerste jaar in Gent. Ik vond het super dat je onze ploeg op het 
labo kwam vergezellen. De sfeer op het labo is er enkel maar op vooruit gegaan! Bedankt 
voor alle amusante gesprekken, maar ook voor de steun die ik altijd van jou heb gekregen. 
Werp je maar op het schrijven en haal dat doctoraat binnen! Merijn en Wander, jullie wil 
ik bedanken voor de talloze vragen die jullie beantwoord hebben naar aanleiding van mijn 
moleculaire problemen! Niettegenstaande het feit dat mijn moleculaire vervloeking overal 
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stokken in de wielen stak, heb ik wel veel nuttige tips gekregen! Wander, het was fijn om 
een compagnon te hebben bij de finishing touch van onze doctoraten. Ik hoop dat je in de 
toekomst iets meer relax je deadlines zal halen! 
Ik denk dat ons labo ondertussen wel gekend is als één van de grootste van de 
faculteit diergeneeskunde. Volgens mij is het ook één van die uitzonderlijke plekken waar 
de sfeer tussen de werknemers echt super is. Daarom wil ik graag iedereen bedanken die 
nog niet aan bod is gekomen, zowel onze inheemse (Matthias, Tim, Veerle, Ytse, Hannah, 
Annelike, Dominique, Ben, Lowiese, Sebastiaan, Hanne, Inge, Karen, Miet, Céline, 
Thary en Nina) als uitheemse mensen (Sabine, Ilias, Eva, Dipu, Joao, Tù, Uladzimir, 
Xiaoyun, Jun, Lang, Liping, Wenfeng, Yu, Zhongfang and Maria) en natuurlijk iedereen 
die zijn/haar carrière op het labo nog maar net gestart is! Elk van jullie draagt zijn steentje 
bij tot de tweede thuis die het labo voor veel mensen geworden is. 
Nog een woordje voor de collega’s die het labo reeds verlaten hebben, maar die zeker 
ook een plaatsje in dit dankwoord verdienen. Barbara, ik weet niet zo goed wat ik hier 
moet neerschrijven. Ik herinner me nog de eerste keer dat je me moest wegwijs maken in 
het labo en je me heel vreemd aankeek omdat je me maar “raar en luid” vond. Maar heel 
snel hebben we een gezamenlijke passie ontdekt, die ons tot heel goede vriendinnen heeft 
gemaakt. Je hebt me door de moeilijke periode in het labo geholpen en hebt me zowel 
privé als werkgerelateerd heel veel plezier bezorgd. We hebben van in de vroege tot de 
late uurtjes samen gewerkt en om het met je eigen woorden te zeggen “bedankt voor heel 
veel en nog zoveel meer”… Hopelijk vinden jij en Eric jullie droomhuis en kunnen jullie 
een prachtig leven uitbouwen! Sarah C., jij was ook één van de meest opmerkelijke 
personen in het labo. Ik vind het super dat we nog af en toe contact hebben en hoop dat 
het je op alle vlakken voor de wind blijft gaan! Leslie, ik heb grote bewondering voor het 
feit dat je zo goed weet wat je wil in het leven en daar ook helemaal voor gaat. Veel 
succes met je nieuwe job en bedankt voor alle leuke gesprekken! 
Hoewel het minder gebruikelijk is, wil ik ook alle paarden en pony’s bedanken die 
een bijdrage geleverd hebben aan dit doctoraat. Ze hebben me veel plezier bezorgd en een 
aantal van hen hebben ondertussen een super thuis gevonden! Een speciale vermelding 
wilde ik graag geven aan Cointreau, het veulen dat ons bloed, zweet en tranen gekost 
heeft omwille van zijn speelse karakter. Ik denk dat de jacht op Cointreau het meest 
memorabele moment was in die 6 jaar. Ik vergeet nooit de hulp van Prof. dr. Gasthuys, 
die in volledige jacht outfit, verrekijker en laarzen inclusief, er in slaagde onze ontsnapte 
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dwarsligger na twee dolle dagen van zijn touw te verlossen… Helaas bleek onze 
ontsnapkampioen twee weken later nog steeds niet bereid om in zijn lekker warme 
stalletje te komen staan, waardoor er weer een paar dolle jachturen moesten gespendeerd 
worden, deze keer met dank aan de sterke mannen van verloskunde. Ondertussen is 
Cointreau een flinke vijfjarige geworden en doet hij zijn uiterste best voor zijn nieuwe 
baasje! Ik hoop dat hij een lang en gelukkig leven tegemoet gaat! 
In de loop van mijn doctoraatsjaren heb ik ook enorm veel steun mogen ontvangen 
van mijn collega dierenartsen in de praktijk. Ik wil hen graag bedanken voor alle hulp en 
suggesties die ze mij geboden hebben. Ze hielden me met mijn voeten op de grond en 
zorgden ervoor dat ik niet vergat waarom virologisch onderzoek voor paarden zo 
belangrijk is. Hierbij moet zeker een speciale plaats gegeven worden aan mijn ”mentor” 
Jef. Het is door jou dat ik 6 jaar geleden de stap genomen heb om in het onderzoek te 
beginnen. Jij was het spreekwoordelijke duwtje in de rug dat ik toen nodig had om er 
helemaal in te vliegen. Gedurende al die jaren heb je echter mijn interesse in de praktijk 
levendig gehouden en heb je er op gehamerd dat de virologie voor paarden dringend 
verder moest onderzocht worden. Ook ons eigen onderzoekje met de honderden swabs en 
bloedjes mag daarbij zeker niet vergeten worden. Evenals het ongeduld waarmee je belde 
om de uitslag van de zoveelste diagnose. Hierbij wil ik je nog eens uitgebreid danken 
voor alles wat je me bijgebracht hebt aan ervaring en “West-Vlaamse levenswijsheden” 
en voor de vele uren ontspanning en plezier als het onderzoek mij weer eens te zwaar 
werd. Ik hoop dat we in de toekomst nog evenveel praktijkplezier mogen meemaken en 
dat er af en toe nog eens een glas champagne geleegd mag worden ☺. 
 
Ook buiten het labo zijn er zoveel vrienden die me geholpen en gesteund hebben. 
Lieve Leen, je woont misschien wel ver weg, maar het contact is er na meer dan tien jaar 
nog steeds en onze schaarse ontspannende uitstapjes en de deugddoende gesprekken zal 
ik nooit vergeten! Julie, in al die jaren zijn er honderden en honderden mails over en weer 
gevlogen! Super dat we nog altijd zo een leuk contact hebben en ik hoop dat dat nog jaren 
mag blijven duren. Bedankt voor al je steun en begrip! Je bent een super meid en 
supermama! Sophie, jij bent er maar later bijgekomen, maar op die korte tijd ben je echt 
een goede vriendin geworden. Bedankt voor je altijd luisterende oor en voor alle leuke 
etentjes die er al geweest zijn. Veel geluk met je prachtige gezinnetje! En last, but not 
least: de familie Demeyer en hun bonte beestenboel. Ik kan mij al lang niet meer 
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herinneren wanneer ik bij jullie ben binnen gewaaid. Ik weet enkel nog dat het begon met 
een brommertje zonder benzine en 100 frank. Zoals jullie het zelf zeggen ben ik bij jullie 
ontvangen als vijfde dochter en ik denk dat jullie maar al te goed beseffen wat jullie 
daarmee in huis gehaald hebben ☺. Jullie staan stuk voor stuk altijd voor me klaar en 
hebben gezorgd voor jaren ontspanning, plezier en serieuze momenten. Dank vanuit de 
grond van mijn hart! Miss Domino moet ik nog danken voor de hersenschudding die ze 
me bezorgde vlak voor ik mijn project moest indienen… Gelukkig heeft haar zoon dat 
ruimschoots goed gemaakt met de ontspannen momenten gedurende de laatste loodjes 
van mijn doctoraat! 
 
Wie hier zeker niet mogen ontbreken zijn mijn allerliefste ouders. Zonder jullie steun, 
of het nu op financieel vlak was, of door jullie rotsvaste geloof dat ik er wel zou komen in 
mijn leven, zou ik nooit staan waar ik nu sta. Jullie hebben me altijd gemotiveerd om 
datgene te doen wat ik wilde en hebben ervoor gezorgd dat ik mijn grote droom als 
veearts kon waarmaken. Ik ben jullie oneindig dankbaar hiervoor en besef dat er velen 
zijn die die steun moeten missen. Mijn zus Charlotte en broertjes Filip en Frederic moet 
ik natuurlijk ook danken, want ze hebben heel wat geklaag mogen aanhoren! Ook de 
aanhangsels zijn hier vandaag aanwezig en wil ik danken omdat ze onze familie nog 
groter en gezelliger gemaakt hebben! 
Liefste Jan-Bart,  jij hebt het gedurende al die jaren het zwaarst te verduren gekregen. 
Je moest het regelmatig ontgelden als de stress weer eens te hoog opflakkerde. Gelukkig 
kan je wel tegen een stootje. Ons leven is op korte tijd grondig omgegooid met ons eigen 
huisje op een ver afgelegen plaats en onze prachtige, lieve dochter. Nu komt er weer een 
verandering met een nieuwe werkuitdaging bij. Ik wil je danken voor al de steun die ik al 
gekregen heb en die ik nog steeds krijg, want jij begrijpt wat een carrière vrouw is en 
vooral wat een gestresseerde carrièrevrouw betekent! Lieve Aline, sinds jij er bent, weet 
ik wat belangrijk is in het leven, weet ik waarom ik het doe en kan ik alles wat beter 
relativeren. Met je stralende glimlach kon je me altijd weer doen smelten. Ik hoop dat je 
mag opgroeien tot een gelukkige vrouw en dat je evenveel passies mag kennen als je 
mama en papa. 
 
Dit dankwoord is zeer uitgebreid geworden en dat maakt me blij, want het betekent 
dat er veel mensen zijn die het de moeite waard vonden om me te steunen. Ik hoop vanuit 
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de grond van mijn hart dat ik niemand ben vergeten, daarom nogmaals: dank aan 
iedereen, dit is jullie doctoraat! 
